var title_f26_25_27024="Femoral nerve block";
var content_f26_25_27024=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F75244&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F75244&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 516px\">",
"   <div class=\"ttl\">",
"    Femoral nerve block",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 496px; height: 541px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The patient is placed in a supine position. The common femoral artery is palpated. The needle is inserted just below the inguinal ligament and 1.5 cm lateral to the artery. When stimulation of the femoral nerve produces twitches of the quadriceps muscle, (ie, the \"patellar snap\"), the local anesthetic is injected.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_25_27024=[""].join("\n");
var outline_f26_25_27024=null;
var title_f26_25_27025="Patient information: Porphyrias (The Basics)";
var content_f26_25_27025=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"14\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Porphyrias (The Basics)",
"    </div>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H632285681\">",
"      <span class=\"h1\">",
"       What are porphyrias?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Porphyrias are a group of disorders that affect how the body makes a red pigment called &ldquo;heme.&rdquo; Heme is what makes blood red. It helps the blood carry oxygen. Heme also has other important roles in the body.",
"     </p>",
"     <p>",
"      There are about 8 different kinds of porphyrias. Most of these are caused by abnormal genes that are passed on in families, but it is possible be the first person in a family to have porphyria. The most common porphyria is called &ldquo;porphyria cutanea tarda,&rdquo; or &ldquo;PCT.&rdquo; It can be caused by abnormal genes or by some chemicals, alcohol, or infections.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H632285699\">",
"      <span class=\"h1\">",
"       What are the symptoms of porphyrias?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Each of the porphyrias causes different symptoms. In general, they can be divided into 2 main types, &ldquo;acute&rdquo; and &ldquo;cutaneous,&rdquo; which are described below.",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <strong>",
"         Acute porphyrias",
"        </strong>",
"        &ndash; Acute porphyrias cause &ldquo;attacks&rdquo; that last a few days to 2 weeks. These attacks can cause:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Belly pain (this is the most common symptom)",
"       </li>",
"       <li>",
"        Vomiting",
"       </li>",
"       <li>",
"        Constipation",
"       </li>",
"       <li>",
"        Seizures (convulsions)",
"       </li>",
"       <li>",
"        Weakness, numbness, tingling, or problems with sensation (caused by nerve damage)",
"       </li>",
"       <li>",
"        Paralysis of the muscles that control breathing",
"       </li>",
"       <li>",
"        Tiredness",
"       </li>",
"       <li>",
"        Red or dark colored urine",
"       </li>",
"       <li>",
"        Anxiety, confusion, or depression",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <strong>",
"         Cutaneous porphyrias",
"        </strong>",
"        &ndash; Cutaneous porphyrias affect the skin when it is exposed to sunlight. These porphyrias can cause:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Skin that tears or bleeds easily",
"       </li>",
"       <li>",
"        Blisters on the skin (especially on the face and backs of the hands)",
"       </li>",
"       <li>",
"        Skin pain, itching, and swelling",
"       </li>",
"       <li>",
"        Tiredness (caused by having too few red blood cells)",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Some porphyrias cause symptoms of both acute and cutaneous porphyrias.",
"     </p>",
"     <p>",
"      Some people have symptoms of porphyria when they are children. Some do not have symptoms until they are adults.",
"     </p>",
"     <p>",
"      The symptoms of the different porphyrias can also get better or worse depending on a lot of factors. Some examples of things that can make porphyria symptoms worse in some people include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Certain medicines",
"       </li>",
"       <li>",
"        Certain hormones (which can change during a woman&rsquo;s monthly cycle)",
"       </li>",
"       <li>",
"        Not eating enough or not drinking enough fluids",
"       </li>",
"       <li>",
"        Cigarettes and alcohol",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H632285714\">",
"      <span class=\"h1\">",
"       Will I need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If your doctor suspects that you have a porphyria, you will need tests done on your blood, urine, and sometimes a sample of bowel movement.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H632285731\">",
"      <span class=\"h1\">",
"       How are the porphyrias treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you have a porphyria, make sure the doctor treating you knows a lot about the condition. Porphyrias are not very common, so many doctors do not have a lot of experience treating them.",
"     </p>",
"     <p>",
"      Each of the porphyrias is treated differently. Treatment is also different depending on whether you are in the middle of having an attack or trying to avoid an attack. In general, people being treated for a porphyria might:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Get fluids through a tube (called an &ldquo;IV&rdquo;) that goes into a vein, to treat dehydration",
"       </li>",
"       <li>",
"        Get a medicine called",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?18/20/18755?source=see_link\">",
"         hemin",
"        </a>",
"        (also through an IV), which replaces the heme the body would normally make",
"       </li>",
"       <li>",
"        Need to wear special clothes and sunblock to protect their skin from the sun",
"       </li>",
"       <li>",
"        Need to avoid some medicines (if this applies to you, your doctor will give you a list), cigarettes, alcohol, or anything that makes the porphyria worse",
"       </li>",
"       <li>",
"        Have blood removed (this is a lot like donating blood)",
"       </li>",
"       <li>",
"        Need to make sure to eat at regular times, because going without food for too long can make symptoms worse",
"       </li>",
"       <li>",
"        Need to take a vitamin called",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?37/32/38403?source=see_link\">",
"         beta-carotene",
"        </a>",
"        , which can make the skin less sensitive to the sun",
"       </li>",
"       <li>",
"        Take pain medicines",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H632285746\">",
"      <span class=\"h1\">",
"       What if I want to have children?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You can have children if you have a porphyria. If you want to have children, ask your doctor or nurse whether you might pass your condition on to your child.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H632285761\">",
"      <span class=\"h1\">",
"       What will my life be like?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Having a porphyria can be very hard for some people. The symptoms can be painful, scary, and confusing. If you are having trouble coping with your condition, talk to your doctor or nurse. Many people with a porphyria find it helpful to speak to a counselor. Some need treatment for depression or anxiety.",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?26/25/27025?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 87579 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-83.177.194.223-F706DDF602-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_25_27025=[""].join("\n");
var outline_f26_25_27025=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H632285681\">",
"      What are porphyrias?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H632285699\">",
"      What are the symptoms of porphyrias?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H632285714\">",
"      Will I need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H632285731\">",
"      How are the porphyrias treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H632285746\">",
"      What if I want to have children?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H632285761\">",
"      What will my life be like?",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_25_27026="Scimitar syndrome I";
var content_f26_25_27026=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F60621&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F60621&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Scimitar syndrome with partial anomalous pulmonary venous return to the inferior vena cava",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 343px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFXAWgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5Zht5Zj+7jZq0rbRJ5D+8IA9q7y10IYwFGc4ziuksPDm7AWPOAC3GcfWgDzaz8OoSONxzjn6VsWvh/EgHlYJ7da9Dt9AaKVWMOVf8hWmdGVHZyUIx1HXjtQBxmneHC5BELYxjIHSuh0vw1Fs3vhNnA45JFdPpgQvmAFeNv0P+c/nVy1t4o4sFmZuT0ySB0AoAxJNM24jCgROi+mfXJxVzT9ANy6tboCSwyMnJ9fxret9Kk1E+dMm2PPyAHFeh+C9AQyR3kybvLX5I+xPrQB5x/wAIuI4jH5DeaWzhh2zVm18OpaS+YWi3KOBjIOPWvS9Zig+1KkAUqgKsy9Nx61j3NkZiVI+THBH9KAOasrNGjaeZVUlwx2jp7VsafpLzzB40GzqxI4FbmneHBDH52oOYUPIiH3nH+16VsIgdfs9uipEvChf880AVtPso7ZVxy4xjNaCIzS5xyT3PWrtvY7FDSkABQMtxgVS1XxBoOlRM17qVuhPYMGYn2xQBd2gFcnAzjioXti7lo9v0JxVGTXtMKIyNKpfH3hjr6ir0V7YP/wAtHB6HNABDbSDcdvTsBxUyRFiAnDfTk1dj8uQAwuCvqDUYV0nIzvXHQigCW3jZAcnmpmGQQehqOLuORT9wUE5AAoAxdPiKXzlmDAZwD61LaPK1w5f5lZfm46ViX+qx2d1uYf7XXk81BD4yjnj2LbFJi3OCMNQB2RT5gS3HbFS5GQorNguy9pE+05YcjFXo3LbSOARQAGFW5Yk4/Wm/eO1Y1AHc1KcOSp6CmyusS8jPoBQAhQf8tAoX3rO1rVrHSbczzgMwGQiDJNUdTvXXc0kmXByqgfKv+JrzfxNqFxePlM+W7YJbjIoAva18W/JVo9MtIy5+71Y9PyrlR8UPEtxKrGWFORujUAFR9K4jW/FOkaXeyw2ludQdD8xU7Ig3cZ6nHtXFal461h5ZVsksbEMpDNbxZY/8COaAPaYviT4p+2YiilmjwTjYTkeoIHFdBo3xF1DUJVgvLWa3nONrAfI3596+WrzxD4gnYibWb/DDoJSBisNr7V7mfYt5dPIOBmQ0Afcf/CR3EYV54JWVujBTg11OjoNRRZZ90YPIiIwf/wBVfKnwah17UNRW2N9dzNFgljM3lxj3B6kda+nbO6uNGt/Jmu5buTGS780AdQLO2Dq4gj3L0O3pRLbJIrAAKW6nFY9jr/mybZUXB7rwR+FaS6rYtMsQuohKwyFLYzQBS1NItNsHlZS6gdMd68Y8Upe6rdfaZ5N+wtiI9FHYAV7feCeMEtiRP4gwyCPpXN6joNleITagW055Kg/I3+FAHzpd6Yz3A8+MKvAHPzfgKzptNWCRm2blz8rE8n+tev67o9tHKqXkHk3Knv1I9q5xtF/esYELLzksP0FAFvwFdwQ2EEcq7U3EZPUZ9a7hxpFhKly8k1ztHywIMKD6k15vYxTWN5vkUCJwTg9B/nmuji1SG2iSRopSMHB7t7YoA0tW1c6k5dLZQ3VQDmqpTa0XlAFs8qo74ra0m3t7208+3U+cRkRMMMB60wWrW7NcyCTKDaCemfpQBt6OFnt0Url8fPjrj0oqr4Xt5I5ZZnYlS3eigDzW1+FuurtU2KqxG4OHyoOa2U8Fa/aJ8tj8w4yjDkZr2Zo9QHzRyKAxzg4OKkj89GxK5bOcYoA8Cu9L1K1yJ7OeE7hglCcDv0ph0lHh/cFyD1GOSQetfQasrnbIu8HpvAqpeaVpk6lZrVEyD8yjH6igDw2LQJlQMpkK5JIHStLSdMC7VWLbtyQG75NepJ4dt1j/ANBnBQ9m+b9ajXQWj++g3A8MozmgDnbDTgcrIEWPtt5rt4IvsGkbVwshXr6E1V0vRDBcedclWIORjuferGoy+aGHAQcA560AYi2zO+2MbgegHc1t2enR2sAkGGmHQkZ2/SptNtPKUyHlm6c9BU87rCRl8sfuqepoAo/ZfO3y3BCoB8zMeMeteb+Ovi7pPh0SWmgRpe34+Xf/AAKf61rfE7Vo006W0nmxG0ZZkV9u5fTivny81a2M3l6dZoFZfvBMnHrmgC/feLvGXih3kmuJ1gZtuM+Wgz2HpV3RtLksJo7vULqCabAaNFfcFHTJJrJWTUmjaTY8YA2kyYHUY4z2q9Ett9nQ3eq20T4wImmG/vx3GPagDo4tXubHU1lMpeMFS4ZvyP8AKvTdDv4dQiUsPnA5boSeteGaj4zs4Y0tUhF88YVPN+705OD1Nbvh/wAeizeON9P2RPjDeYevPWgD2+0BDgpLtbr83Ga0oNQuYmPmgPGe/pXnui+NtIvHVGka3OctvUlQfqK7G11O2PzCZWUjII5zQB1EMqSqDEw+lSFMqVbkHisy0KTSK6Fdx+bI4/OtN8eWd2OlAHP6hp1pk7txHTAqvFo2m20kUiLhgoYHGetWb5JDKADuBPAp80GJgWkyANoUdOnINAGtapGYlYDP1qYoD9MYxVezGIgduO2BVqgBmNrfKPTj0qjqLMYmES5YdTmr0kgVcnp1riPFWo3kkMsNm7IXHzMpx8voDQBjeKtch0s5aRXbdtO84AP9a8Q8ZeLrvV2eOJRHGG5yOg9q67WvDs7ROZHjVwDgs+5iSc5P+FeT641w07wWyHzUyXwMBRQBg61OkJaNWzyCSO9YrXsUpwPl/wBojpT7yIi7UXQeXvtQ4NaOiaS9+BFZ2DS3Emfk2k4FAGQ9wvl7Nwz6nkiu68EeA9W1iRLi6tZbbTCNzSuhDSL6jPaut8L+AbHSvKvdaZTeBh5cCoCp47jHWu6lurq9h8uN2t0UlV56Dtk9vWgC1oEkWjxx2ujWyQ2iD5pVwWJ/xNd1Db3Fzbo4UuuMEdc8da868udZXWItnYp3d296NW8VX8FpNpelRTNNsbNwOgGOcY6n3oAu+OPGa6PF/Z9jk3pX5pSuVXr+ZryNfF1/BuMtzIz+d5wkLEnPfHsfSl+3ajbSs0kM08ak5dhnJ7A/zrH1a/DNJut05XGWXAFAHtHhn4tXkCxecy3EAADRuRkj1Br1vSb/AE7xJZm60yQh/wCKJuCD6V8baHfWJVYpjLA443g5/MGvUfBXiaTTr9Wt76KTyyMqeA4z1oA9zu7OC8VrbUIyUXkPnDofY/0rkL/SZ9NvFR/3lvJkpIejf/XrvdMvrLxFZLNAds+0FkPUf4057APE0FyVMT+vY+ooA87uLMOc+WNvHvV+w0+GQCWaBdnZMcZ9RXRjRbe0kLXl0GAGQqqfmHbJqxssNu9t/lL/ABY2j6UAY1rZBpA8X7pUOd69hW0Y0vkDXUQSNOjHqf8A69VJtaiWErbRIqr045NYt1qNxcSiSVvlHIU9PyoA6KS8it9qRQKsScDHU0VR0y/gnhVXwSei45WigBmn+IL7O115HIwMj3rVTXTJI0c0CvjA3Dg1pW9nFb4WKNVQDgL1P1NU9TsEMhnC4bocccetAEkN9bSBgrtHj+8ucVZj2zEBJkYk561jW6STSSRwxlycEsB0rQitIbNg902ZO0anp9TQBsRQog+4me5AxmpRWXFqhkf7g2n8K0o3EiBhnBoAdTGijZssik+pFPqGa4jizuILeg60ASMDsIQgHHGRwK5zUy1p+9vJhgnqvJFacuo4JXAGQcYzWZdPZTsrSjDEfePUUAfO/wAQ/G1pZ69fwW+lmefIBku87cY6hfxryTUPFOq3M7eRNHbRAEBbdQmAeoz1r6p8ZeDbDVpzMrLKxXAV8HGO/NeVaz8ILkXMn2VLJY8feYkE/hQB4w15c3EpMtxNNjjDMWJqdYb2RAYrSZwnX5cAV7Fp/wAO7zSGCQWkLF/9Y+eTx2OPlrIuvB+qLNJJPBKUbO3YxIPPtQBwOl29zLMhXbjrnPI9s11+kW8gv4Ybg5gPzM6fMAOtVrjT7m2jMUEcqBMgjZ971zW58PGvJNZ3KVYMhXAGM+4oA7TTjFYqscCRm3fLdB82MfrXZ6HeqHZZl++QCCvA9/Sq+nWlnewqXjXzgDkjj5v89qu22meVJEPObYwJAfkfn9aAO5sRHiI5JY88Gr8l15apgZwTkZHSsTQXaO4IdM5TBOeK1dQshNEvkk5xnHrQBGkwS+G8YUnjJ6VLLP5CP5u0B2JGf51WjtDPCCr7pE4ODTBp1zLOWkYEdwRmgDVs5v3O7IKdsDqadLc4ZdvT3p0EJSDY+FAPGKQW4aYtuyB2oAhvpSIVYDJ7gelcvqqPdJKYQT8vyr1rr7rHklQOM9Kyr8/Z7aVowqhRyR3oA8X8V2OoPHIyv5KEgMwP48e1eT+MVklvmSzUsCMblzulPYtXtl8t9qt1cx8xIv3ZJOAPoD1rkprXT9KupJ1k8y6jbdJKcEgjsM8fSgDzzwz4Fv72SS51UNZwRcfMuXP0Feg6TPoXhG3dI7yC2nJyVZfMkP0A/ma57XvE2p61JNbWhEELnBZR87fVuoH0rlJY7exaSORQZScMxOST65oA9HufFmmG7ja10m4uH35aad9gx6gCo9a8dzWnmG3sbGO2GWMmCfl9TnrXn0+ofuDdX8wit4lA+voB61yHiDXpNXuBbw7ls+qIT19zQB2Gr/EXXdUjnisbxoopMB3jjA347A44FYcXiDXbZIl/tC5iO7oDwBVAqlrp1tFG25z1x2qKa4YEbiSAc5NAGraeKtds71/s19IS7A/MAd1JrXjTUp0MV5BZyjGMeUFPHuKz4s+bFcSBVjVeM+v9awdQkw0jyYIzxg0AbWneIdIa5P26znt2z9+F9wx3+U/412Ojvoupsw0vVoDIchI5/wByw9ODx+teNyv++JjGMVNZTYk24wCBk+nvQB9S/D/Vtf8ACutQ212W8g8eWfu4PcEda+hrK/g1aGNkbZIQDz3r4Y8G+OtY0B40t7gz20ZB8ib50PsM9Pwr6f8AAnimw1pY5CDYzhQzITlMnkYNAHps9orxkTjgH5R3z/hXP6nNuTYScR8bOgrftr5LsmKQgSY45+8PUVgeIYGgmWUDKvwPc0AYc8/lq21Pl9uKx7mVhExyADnB71pyoGOCFUsec1RvV/csCp8tR0BoAr6ZqZt7g+cNwUADFFUI4MgsCdxxyTjj3ooA93EbF8k8DjkUXPlLAxm+4OtNublYSFHLH36VlahdNPGFPAzyBxQArakDmK2QQxgjkdaoOhJPzMMHGPWoUQgjOeTn1NaWnW7TzfOD5Y+Y+9AE+mWY8tZZFGMcL/e9611zjng+lIvPbAHQVg+Ktcj0+0lihkX7SVPAPK0AZHjjxrbaPutopis+M7lGefQV5qnxPnW+kF7AxiHVkcZbB6gGuW1O11DWtSnu5k8iP1lfGQKzLm304mIQO8twMP8AMQAp/pQB7fo/iu01WOKW1nKMwJCyjb7H61tAxrGWuJgzDug4xXg+mW2oawyEypGitsYN0JHsK6qDV4NAEUVxrKzSjhoh+8HHbPagD0bz7e4ZRbodg4BPHFYlzpt407TW5bcpJYs35D2rhbv4r+Xc+T/ZnlxpIE89Tv8Al9duOKtR+JZ9Ys7iRLn5EJBERzj3xQB1F3rMemW8huZYhIR8x3btoHoK4y7+IN+9vcCxihkJBjhlkXPTviuam1fUriGS2S3+0DIIkWMlwPf2pbTSr27WMJZ3EMkWXBIAV89cZ4zQBRm8ceK0l/e3cMyKfuTW6Mh7dMdK6C08aWUTD7V4fsYrwsrymBSin1Iwe9YsnhzVpJVNrp8twgcFghBOfwrJ1q1uYtSElzbyw+UQuGU56cfjQB7Dp3jPSSUL6YVi27meNjkEnjjvXZWFzp99GkkYwmMjJzjPtXjujWUr6dbCTMTsS5O3O0noa67SbS5snjkScsqtlvce4oA9V0yNAWaFwwByRjBrbCtsQqcHv71gaDcJMWdTgsuD9fet3bshVCe+CaAMiByt44BGGPb1rVhUbSUYDJ6VUkiVZMjAJbNX0j2qFyT3oAcy/uiM4+lIobjkd808cKBS0ANdQy4NYHi/WLbRdIklaMyM3Coozk9a2bpmUptGfb1rh/iFE1xFDEhcAA/LH1ye9AHhfjbxTquuTJGFFrGQf9WT8x6jP4Vzl3O0cPlzyM6kBgpGcnFek3Xg5bmSWZUMDfdLOeO/P1rMj02y063eDZG80i4E0wyVPqPx70AcF5dzGq3KxskbNj94Nmc9jWTqdg0Mk0+pzhY2OUiU5L8ZGK0td1SW0vRFdL5xjfAU/MHx7+nvWZr0txqM8d1KN4A+VUz8o9MUAcxqC/bLcC5dmIyFReAo9KnsNPFpCsjQqjkDYG+bj1rofDulHVblmFs245C5OBx1zmumXQ4Eule8vtMjtlUFi0qr+HFAHOS2NxawqslrEu5N21k2kD1zWaCYhJ5pXrjaVycGuu168sry/KrqNjLsUIGSf5SPbvWNCmklxHc38DoMkyRtnJHSgDI1VFureFHB2xj7oHArHuNLge3ZnT5QuR2PNddcNpjwKLW+t5ZnPIaTG2smS3nvLvy4IYpxyFVHA49aAONl0CQ5MEqnHVXOD+feqKW01pcYuInVB1OK7OS3uLQFJrZowDk7lIzUVtcFp9jDII4DAHj0oAybCEPPGiAnew5r2iBjpnh+HyZCDLNschsbtoGB+ZrkvC+maTda+vnbrSOCPzGkznn0A757Cu58SaGy+HIJLGZpYY5mIU9ecf5xQBs+DPiFcaPJDBqm6e2JO1wcsnPY+le+wz2ut6SlxFIJbeUA5U9PevjOd5IphkkbD0b0+h967/4OfEKbRtfXTbyTzdMlOHz0QnnI9KAPZ9RsWtn2suQBuD+orLlG6Nht3V3V3bpdxLHGUKSrvhkU9QRXITxGGZkKlQpPegDEFtmUblG5Tjb2+tFXxEpkc4K9s+tFAHcSyZcNMxySd3NIo3rubdgDn0pDFyC2cqSc4qaOElc4AHXigB1tFuPONhFbFrD5cCgcE8n3qnBGCV+UcgZ5rTZgiFm4AoAiuZDGny4z0yT0ryrxLfR6Y140g825AY7mXPPoK7vUp57pSIgoTuSeAPc1498V/FWn6JpUTWMaapdzMYixGIkI7kj738qAOJWzutVume4n8pMEuGbCoPUk9AKz7/XdJ0ZNkLtqlyowTHlFHPXd1P0FcZf61qmqT51C6YxZz5K/Kg9sDisxXMMmUOzBxx1oA3b/AMS6pqkjxC5S3iAJEMQ8tQPT3P171mCaNYlMrMz43bgfeoGt5pBHNuWNJPlbJ/HIrV07RLZYzHdO/wBoYjyxkBWGP/1UAGlvNLdpHAGkZ8ADqRn1rqpNAuLWJJ5LgWyycuwPIHTAA7965y5kNrtS1Kx9AxXgCul0m3S8swjXTkjht3f2zQBueH9eu7aKWO4dbiBVAG9efrkVBf6tDd3+Le4eGLZsZJGJA9SGHQZqnPqOm6DeW7AW9xIF5ghYsQOpLHt9K4q88ZX9/eOLe2s4g7/KqRD9fwoA9K0fUF0i4RbN3mZeZGhfIJ7E8810MGpTTSST36iOIsrCTHQd+PWvBr7xNrenasWjNsJQQf3cYGPfivQPDnxGWfThFe6fGzrguyvwR9DQB7BZolzcJKGQgc/LwH9sVo2NgGZQWw56HHTmsLwjq2kX0atFK8RX5nLLwDj1Fdrp8TNMrKFZXPy5x09aANbSbF7YBnZTKePl6VuyIdpY5z7VRgGxsbec1o5XYBkkN070AZ5QyEE9jxg1pLjAOeMVTGzBUk5z1/pVmDGwBTkCgCWiiigCOVCxGMYHUGsLXYkjcHaCSN30H+FdDVLVYfMt920MV/lQBwerQLdwzJGNqqQvH15NeS/ESCa2YPHNBHaqp3Tu+FU9Me/0Fd5498WQ2cx0vT5RHOygmXZlSf7ue1fPHjgaxc33laq0jRxEsuTlfqO1AGZqfiLTjCYY911cL8omddqH+tY+lazqs1w8IlFvAD88iIPl9MHvWTewpFIfmAbuBW7YXFg2nsfLk+0KuEwflP1/WgDVFjevtW1lmdBkgq+Bj+LPv3rJ1BI/shtkPGe7Z+vNSxa88CqLeRlMa8h+47ioLmSC501mh2l9+4cY4oApSrDBboePN7ewrPchi0exAC2773Sn3Rbfuf8A1cYywasppp2VykYZSccKeKAG3EmZgiNjacE1GxktmDRylXY5BU4IqdLK5toWle2kJIIGVPA7mmWscUbiW9yQCDs7t7UAXLDXdXtlf7PdSsg6o3zg/nW/oPiBLnUFTV9Mjk3EjzYgYynv6cViPIt1ckWVuFDAZXPK1olIYgkIdhO/Ltj+VAHfafZWizxS6VqsErA7nimOxi38vavTbSFW0HypnkjnhcTElfT+dfN16BHcnyC5AHDDg12PhH4gXNjay6ff/wCnWw67wd6qRzg0Adbq6WlzFMbgqJwCEkQfePqfbmue/sa80Z0mKAxZ+WVeQffNaNvNa6ujS6ROGhTl4WPzf/qrp9Au7W8tvsFy+9GGdsgyFPQCgD2D4QeIDrXhpbG4P+l2vzRknJK1v69BvVblS3IKyY7H1rzDwJYXXhfxBbTQhnspH27mPIz2avY7yJJfOjX7ko4weCe1AHHRFQ8gB7cYPWinmFllZWXAU4PNFAHYRpyN5BGecc1ajjDScHqMc0RkAZGencVbs4yeW5x36ZoAktoivzMTn0rL8Wara6Rp5ub+YpED8sacvI3YD/Gta7nW2gaV+QOg9a8K+IettcG4munZ1U4CgdBnt9KAJPEnjDUb6byTC1tZEgpBEfvDplm7/wAq858dqYvssAjBhVize4brkVpaRqXmW8SyFZIypChzkN04Hp2rLvreS+1aaW5Z7eHcFRAcsSP896AOMvLB1uljs/3kAOA237oP941r2Phu3jha7uZAcpujkIwrEHHyg9xXpNhp1lMHjgiRoFbdgDHPfNZ+paHa2aGe/uPLsYcsElfHB7KOp/CgDzq4S1j3x20TzO5wrt69uO1Vra2u3hP2qRLdA2EeQ459Mmp9Z8XWFhesPDdjk/w3FyN2fovT864jVr251ac3dzPJPMrchjj8gOBQBt3+s2FhctHbwtdTjHzM2E/+vWTe+KNRuJyol8lOgjhGwEH1x1qnepL9mWURgBR8zBc5qK0tHuZfMUFEH8RHSgDodPvUtkaUoFaVShHfH1q1Fbwx2dxdtFhMbUz8vzVS0FLKN9t35syBsK33Qa2Gjt57lFdW8gtgKWztoA5r7OWiNymH28GrWjJKjgiSLc/HJ5A+neu31vT9NttEtxaWpImyC27nA9ayNK07S5ruFHM8Qxy4+bB+lAHd+GYWh0uFLa/jVQ5TJyRk17NouoT2MEKu0ToEBZuuT615H4N8M+RelhceZaygsjqcAgd2HavSl+0y26R3GxEQ4i28gj0oA7m11RZ8hNoLDrmt9WUQJuOGCgiuB0WJhcHcDkYAHHFd4yFo1U4LDoQKAIJBuViucmrdmD5XNQMoxwScHg1bgXEYyc0AOJ49qdRRQAUHpz0opkoLIQuc0AfPfx5so9JuYZrHIgmO10zwD1zmvFb7UJpLZoJnLRSH5VznA9vSvq34qeFJNe0U28D/ADvjtyMEcg9q+dPEunQeF7u4hjkhuJFLLG4G4+mfb8KAPMLu0uJy6pAWCnO7HBpLHS5UQMHHmhj+7HOa7bWXmSztTdQqqzL1XGcdj7fjVTQQWu/LhhaTbnDJ1xQBnXXhxJ7eNow/mtn75259fxqrDDY2CLm13nkAFjwcda19TS/nn37JtoJK7zjOKw4rHULq8VJE+ZTnB7UAVL2+e+YRJsVYxyqqAD9fWjQVlk1e2VX2rGd7EjPT+dTvpFwHM6+WCPlKlsE/Sr1nIumWDGUwi4k7nBK+1AFuWd7vUJnupN0Jfbgr09fesmbTYrm9IS33sCSM9MVGk6zXKr56biMBs4Vfqa14p38hYI4t8QOHZT8xPsfSgDMXRrdWUxhomByWUZ5qhfaZMLoPb/vADyV6/XFdrZ27xo1xJE6BVyAeAT71Se8h+5HbqGZcyOW5z6D0oA4u4zHqASXeg6MGHWs+SYx3gaJ/lc43A+tdneTR3cIjlSPcA3UdPcmsiPQGbfcW8iwqBkq/R/pQA20km04G4tZWimz2bGR7ivUPAuv6drrxxXMkdtrCAY3HCSkep9a80vYH8rftKKwx8wrIG+0kjMTYkVsiQetAH2D4Vu2kuIbe7IILbWUjJGDwa9VCbYBxwp+XnqK+cfgp4tTxDLHYai+zUbcecsnTzQP5mvovSWa5tXidgXxxQBlahGqzy7t21+Rgevainaiu2UbxkqMY9aKAOigUliAvJ/WtRFCKFHQVVtEPmbj0Aq1I21GPoKAOa8V3hMWxGO0ZBx614p4s06+1WR47FW8oEbn3YH41654gtp72Ty045y7Z6L61wuuFo5fsGmR7493Jxksfp3oA4KwtIdBjleIPLJHgyb0+6Sf4fStDw+kWo2z3s8ccNsjESSO2FHOQSScCr3iSOx8JWjvr8zfbro5S0jOZJBzjP9wZ7mvFPEGtatqdwY7p/LtlYbLKL5Y1XPp/Efc0Aevaz44trKGS38PWcMq7cm+dc8/7AP8AM153eXV1fyyXtzetczKMHzWJOD2X0rOtbua5ilgggIzgZzgJ+NdH4P0Mi1uru5KyGAgsGwyr+dAHKX+izXim5srcqvcNxg1gtprxOVmaQMOCqL19cGva/CE8U2pG3njikidWLOxHAPb6e1c74r0zytVmaMKItxCr6e49BQByHh+wVGeU25a3I2sJGyc9jWVqEM0t95MQYqxwuB+VdAJjA1zAZAsSEsu0ZOfQ1T1DxFFp5A0y1MFw6jdKzb9p7496AI77Q7yCASSgRxD5toIBPqQKt6FA1yrwNLCpA+TLDnPv2rjdRjvdSuR5V3NNM5+6WPJNWtY8Paj4egiluwweZMg+n1oA9gn0GaGwW1MlpuSMFh56lj3yOelaOgeE30KFr2+thPFcDaCAXEZYcHIzxXjeiXU88MSM7Mw4Yg84rtPB3iHVtMumhN1J9lHG12JAB9BQB3WlS3Wk30EM4KxyNtTbkj34Few6fai6t1kx8rqFIAz+NeIR+LbiS9gh1OFY0cfupkXkD1HrXsnw81CSa0SF3WWMcoR3B7/WgDo9N0t0uMqR5Y4GOPzro5CYyNufxqvGNsv/AAIE+5q+SOc9BQBWK7weDnOevSrEYwoHWkyrDinLwMUALRRRQAUUUUAZfiH9zpVzcKGZoY3ZVXuSpH9a+PrDR5LiC5Wdha7XLNPMQFX1ySa+nfix4uHhbwzdTRRCSdo22bhlQcfqa+Eta13UNYk87UZ5JWPzBS3A9OKAOk1XVNEs96yXlxezocKsKfu/zP8AhUmg67fSkLolgkZlB2uSSyYHJzXn1xKoUn5c/wAjXS+ENfn0u2ktbdkXcctJj5sY5HtQBi65d6xLqUi393KJAeMvgDNZKSSw7nd3LH5fvVqam32nUWkIZg53B27AVWlMVzKAmQsI+8B1P0oAuxRYgW5lbbIcgKrcGq16huHMr/KwGBnkfX61Wu3ZwiRl2I/hxWg1pcNDASrKygY4z+FAEECxmMRzEKmQc9d3/wBerm91jaTLImcIpbrzVKFvMuVjZG+Q4cnoMHmtK6v7Q3LSKu3yumRlR7+9AE7eJdb0+2W0gupvJ3ZMch3A/gaRPFUFy+NRtfLY4y9tjA9TtP8AjXOzySXskhDk5bI3HGSf0FRW9q8kyoQfw9KAPQrHT4NThR9CvEupifmj+7Io91P9M1aDhIzZSQlHQ45HzH6V59Orxyr9mZ4mTkMvH8u9dXofiW9ijEWr2v8AadrgBZSdsqD1Df40AdFZ2iz2s1uU3qhPy5z161yetaJLYK91GvmwKcED+E/1rs9L+zODd6TO11aj/XK/yvET/eA9K6uDRIL1YnkAW3blxjIYdQB9eaAPMvCM01lLb3VnIYp2kyrdwAf619peAdWj1rSLe7hP73ZtmX+61fNT+GGt7iTULC2xAy7vI6sgB6/SvQPgDr0i+M57B2JtryJsA9Ay8jH6igD2fV4yblZcggjBOOhoq1doTFMhB3DkfhRQBtwjaCOOuadIu+NlzjIpU6UPnadvXtQBzerGWV/slimWYfOw7159428U2/hkyWmkpFca0q5aY8x2+eMgfxN/Kux8f6pLoOnldNjH2q7Jj809I8/1rwi/tM3c6S2/73kqzuSWJ6nH60AcX4z1O91HU4zqM6zzgcyY5P19arWGkvrGNh8uQDarMwUvg9BXQ6j4OlW5l1G5dJ4QcpEjZJOcc+2etT2OkXU1ykzYiWNflxhVXAPzfh1yaAMLVNKm0tPKUgO4wVQ5wcck+5qxaRXUWjmS6cWdrIeS7YLY9upro/F3iXSLTQlfQY49R1naI5Lp1IiVx95kXv8AWvGbvUL7UNRe6v7iS4kbli54/KgDsH1uytdNuxYrNLck7BMeAF+nvXPLqd1MoluJWnBb7pJAB9MVnyTERyxoNsbHPB46UW0scIVyGdemPQ0AakMkU8yOWZWySynjipbrRmivkVmiZnUbecrj/GsaeZGbciBnPJBPAqzNPOLWGWCQvIh5zk49BQBGlpPomvebIvnLG27b0B/Guv8AEuvXHi2wt5dkUcMIMSxqASF/rVCKO416CMOC1zINoAHzD3+lUEtNV8PStY3MAyHy2ecg0AVtF0i6OqQ2drIrPOcKTwFPoa2bFJV1ma2kQ+eh2qVGRkcHnvWxpmh6jqF0k1l9nXsZGfap9/8A9VbA8FalB4ggktkDKw4xKPvDGSPagDhdR+0DXrYnzMb+D/PAr3r4eTX9s6z796FQWQHgAfyryO+0rW9M1ZRc20hQS5yMHAzjj25r2HQ4ZUt4I7S3aMnCtk85/wAKAPbNMuVvY4pF+uPStIgHrWP4UtWtdJjSTBfqT3NbBGc80AMCYIx0qQdKQDH1paACiiigAprttGT0p1NkXcuOnv6UAeHftN7W8HfaImkMkTkEDsCK+NFy7biFB9ScACv0B8ceGP7etZ7KZt0EowRjA+ufWvlD4g/CLU/CVw9zZp9r03JJaMbjGfRv8aAPIn2M+HVmY85Arc0TTriUmRIiQV4B6mrelWE19MEjBiYNglgBiuqjtbmyv4orjiUFeOx/AUAcjeaXcxwjzEVX5BXPI9qr6bot0Zt6AKOp+bPHvX0NN4a0vWbnzJpoLW1syjzksAHbA+XH86wPFEvhXS45bTRf9I3tmR1XKoPQZ60AeOpYS28kjqsYZRydwOTS2h1ESn7QCVVsAAg81r6s0V5q+LCHFkME7hjJ7nNbWkaLHa2f2iWPP7wHc3Ud+B6UAY+teENV0/SRd/Yp/wB+NwZF3fL2HHQ1xLW05iVZEdTzjcCMfWvf7TVZ7m3upJJmWBFwNh79B+lcf4rvcWyPbWgkR3J+ZckHpQB5f9k8o5nkEaj06/SrNsjqjlcorrkSN1rqLjSbXULhZLq2NuqAbthxurP1HRZJGLWchMYGEjYAHFAGY/lpAHikeRh94MOp9qdBLcOziMnaq4wvQUxLSW3yLuNo1xjAH8qsRqyqDEvlo5O31/KgA097201JJ9PuGiuRyXHpjp71774B8Taf4is4LC+SG21eJdgBG1Jj9exNeOR4SCJAgVtuXapdNY211HMhYuxwCDjBzQB74DNpczQujHkqQDjaP68VF4Xs/wCyPiFp97ZIRbu3TPCk8ms/wh4kh1xRpur7TqMC4t5yPvj0JrvvDVjm8jEwG4ng4xj3AoA9WmK/aSw6Nz+dFRSsfKiJBBAwTnpRQBtjOOahvbhba3ZyQD0GfWp653Vbo3FwYgDgHaB/WgDl9aYXrSQ3O6QSHBGMkE9xXI2fhyTTzJLeD7TedYz/AAoOoxXpElusIBkAMzHnOPl+lZ+v3Nh4b0OW/wBRVhvJ2QKfmYn69BQB5dLYJbvc6rrl19itIGbyh955j3VV7k81wHjLxXLrwNnYQy6ZoyH/AI91PL/7chHLE+nSpPG97qev6la3s86yYjxFBAfkgU/wAfz7muct9wuXsVGzzQSR0wccdaAKllMLSRrZgGgfk/7J7GquoWSLMxiOYmA6j9RUrabeStJtR2LD5uMAn/Gr2nabDIQL272AcmMDn0ABoA5K9jMbbCCMnpjvVeCCeW4znYhXJ7Yr1u60fR9RFzb24EE0KLtk27sv/tHtXLHwnqVoZ3njJVM4OOvrQBjaXFbKgNxlyccHjP8A+utZLh5k3JDFbwJkDbgDpjmsa4iuJHIktXJzhVXr+Fb40jUP7LWS7eO1VCGxKcFge5FAEnhi8lTVodt1sUblJK5IHsK9K08WGrW0sGouBdynbHOeDtx6151bQaYJ7BG1FZZpj86QLuZQD612mreI/D+laDh11FSjgGaCPGM+5/KgCx4r1O48Cy2cMNrHcROoCyBMqfX8au+HvGia/q6Pe2sQ807RsX7ox0I/DmuPsfE/hi8sp9PuL+6lg3K0bTISwB64Pbmuq8H+DrJLaXUrTVP3T/KtuqHcuOjE9qALniZPK1tBHBIxDhtqtnjPHX+VeqeBbIM0EnRQPmDdc1wNlDBqOtWf2i9hNxbS5VAcFvQe9e36bp8dvsyV34yMcUAaKtgEjG3tikEyHHP/ANelK7VCg4HTmoHDAKFA2dOlAFhWDCnd6hjJA6YPapaAFooooAKCMjFFFAFeaIOArgbT09j61D/Zlq6MJIllRwQyuuQQfarvBHrS0AfPPxH+F8/9vC6so7ZLAAsm0CMD1U9s+9ULDRfCdvHJdarfpPJAh2Wyt5mH9SRXsvxP0I6z4TvUhZhcIPMRtxyuOuK+b90OkPdWDzIysNhmI65//X+lAEWoa74Su9Pmt7qe+NzJcfchg2bVAwDk9TVHRpvDbXDPJeXiPErB96KVcdgPf1rnNT1LTrWa62IspDMUkByB1wa5BLgSyAmN5e7AHbxQB2+pTadI8ywPvbftUbcHBNJqeoJZ6MkchLSj72z+H24rlNXul+wL9lTypG+abbzn0xVI305skBk8tHBLq/8Adz6e9AFyPWSLN0iuSvmMO/X0zXdaeyanpFnbTSq0MQM0xQg4JwP8K8rWRlT5QJGPJHAAHqK6rw/qFtaaS4v0YgkjfG2MewxQB1Oty2s1ywSBxYjgt3/E+vWstbCASXEkRkkiCZR3AG1a51PFGrW0OxJzdWQbiGRA1XB4o0y7hS3vUksZz96RBuQenHUCgDVnurI2UdsyGcg7vMYevUCor7RLSa1860yk+c4Pp60610SZ7SS9tWju7BPvSxNuUg+3Y1qXFr9lihnkjUJMg2bW+59fegDlp9GvLZUe4TERPyvngfWpfNtYbSNYR+8V9zSE5B9MCuma5a+hIkiWR2IT73X3+tYeq6G3kzCyDmYMQ8RAGMenvQBAlzKt3BLC7LPncrIfu19P/DXUYNe0S0uFUC7i+SUZyd1fMGlHYrQBdrjg88j8K9h+B872HiFMOXtJk2P83GR0NAH0TKxNqrDI/hOaKV0zEyfe4yuKKANts7Tjr2rm7+EWkr3SgPcHgLngD3rpT0rM1B4ra2kupxvC52of4jQBz99ew6Vbrd3X7y6k+aCAn73ufavLvHsj6mFfUWJmny+8nC4XpgenPStzUr+5k1Jrm6j8wORnnAjA6ADpXJa86avqCxOspUJlUA3bm7A+goA4fWLRtPtobqOXfLgYVchgSeoqTw5Y2d7eibxPJiV0KwoBh93vWzPposrjCySPdod0YQZGeDtPp1rMvIpdY1ATIiQkna0RyNrAc0AXr6Ce2L6dEcRyFSr7MYXvx3rD+xaaZGlVZS0Y4CDkkHrivQNItE1CzhGp7I5oY96zyNsBUHgDpxxzXM+I/GmipG6eHrWKTVFY+ZIU2oPde7UAchDNeW8hezSRVc8luFyPWtnUvGGn3dgiapdPLdW/VbccHHv61yuq2WsanLHNOzOkhLBU6fXArDtrdLO5mEqLJ2xjOSKAOk1vxXcagIl06GKxVRhHiXMx+rGuK1O5u7ViZZJbiQnLNK24n61PZPIpnXc21SSuecCp1X7X8gCu6nJyegoAp6DrclvqkUyhU2NnapwT9PSuxn1nUZYro3Ng1xYzAlQckLjnPviuLubDE5kgZAD82MdDXd+GNRu7i3fSINpNyMYxkjjjHtQBgxa1pyXEbG1RmZdpyO/+cV7d4f1AS+D4Z4dqXjsVZE+XaM4AH868Ov8AwVqeizNLq8LCQtujQnOa6/wGt5ez3BjlP7ohtue+eB6UAek+HYLlNVtY5IlWS5kWRYwuduOCfavdrS6b7QBLjCnafY1454R1GDV9at3lnMLQAKUwAQem0GvZNkbTRtkeYR1A60Aa0jblIQgZ5zSqPkA6+1NAwg3YJHGcYoDDJHQ9gKAJU5HSlzSDpTScHjk0ASUU1M45oJJ6frQA6mS/d5xilJypx+vFVZZQrEEbvqaALKMp4Tn2p+eM1Vt3Bb5WGD1Bq0aAK2oQm5sp4VbaXUjcOa+U/iZ4bv01SVvJZTGPnYH7wA5YV9a14J8S/FB0fxBeWMKC4nm5ZHXcEU8nAoA+UWsJ7/VZYBJ9ntIwTJM5wAAP51Rm1OO22xWihocbSS3LCtnxzPLq2oXE0cItwGZvJiHygewrmrEC1KXEsIkI5VG6N6UAdNp88S2zyywneRhR1wKwL0hZCYgPLY9XOTU4ubkQOzuwlmO7PoPQVctdPSS33bMAYJOM0AVbS3KzPKyAMVwoA6//AFqnmcQ2h83oD+BJq/HbTSfIud7ENk8cexpusabc3hAjUsy87EOT0oA5iWaZApUkR4yMdM5//VTfMW4baygSH+LFabafPAQswZiw+4w5qT7DHEPPiUs6jlcUAVrC81DTZg2lzyxBOWKNgP7EdDXc2PjOx1C1W31q2W0uHYN9qjzsyB/EvrXDbEsleSc8sflVe9UnmmnIkkjLR+mOKAPUJ7K8Aiu4tr2srbkmibKH2GK1tOk2yKULCReCG6c+lebaD4q1HRpVW2KT2YxvtnGUYehFen6IbfxBaPfaIxSRfmlsj99PUj1H8qAJLzSvtFwTaRJ9pQAsV48wYyc+/vXb+ArSS1sUnfO5yCpPG0A1keHbW5a4hlKt5ikZKjGPUflXpN7bwRRR3lnFthY4dA33XoA9M06cXGl2kwyzMoB46YorO8IylvC6/McxyEZJ/SigDsyARzXK+ILn7Q7KCfKTjA/wrqJSBG2TjjGfSuWmsmubw9Qq/eOcCgDjp9NbUbiKBHKw7vnZhwB6n8K5W9VrG7lTTcyMCUVnztbGcgn09DXqeqqiacRCANmc478dM/rXDvbxwwSarq9xHa6WBtlLj5pCOyDqTQByOhzXWtaqUgtnDbcuVONvYnn1qLWfE/hfw1fuLC2OraycpKEf91Djrk9z9K5P4g+OtQ8RR3Fh4dR9L0KP5cR/JLMBx8568+grzyOf7HOHMDugbkng/U0AdB4j1jWtb1K3uL6TEMT7olRdkUQzwgHpVfU9N82QXdoQijG8KeVJ6ihEkvICIZALZgQqpzg1YS1mJALGKB1Cl3O35hQBk2+rX8F4iREmGPkox6n1q9p8KalqsNsxiSWRtpIPBzWdcmS0ZhJHko3DAZ/yDWh4Y0WPU76SWFmyFDD2Pce1AGx4q8F2mh3U6jUFecwbx5YBXPYda4u1Sz/f7spNjajAHNd/o3gHxNqWsgjTbi6t1PzzFcRoT05PWtjXfhze2duzvLGXxuVET5j6g59PagDx+G2MRVJpNwJ3ZA7V7X8EtH0k6xa3Ms6NMTnynyOfT8RWB4c8GRXR8yeNmjBztJ2lW+ldpp+gjS74XFkuyYMHyxzx7YoA9x1rw/pet2pivraF4tu08DIyO3vXiUHgSHQby+Gl3DMhDAq/0r1Cz1+4nWFJIwwI2HCjg/Wqeu2TSo7siQoeCT/Ev1oA8q8E6PqSeLLYyFdkTh3AI468179bQzLLH5z7zjA5xXnmhWbi886EKIEJ2bScnPUn/CvRNFMklwglO4Yxz/SgDbcvGUHYDkZ6mpl+Zckn/PapJIw3bmm4woGc4oAVGzxzx0NKSMnnFIAQxz0pNnJ7igCRTyec4p3emgdscUooAQjJ+lZ94AkoUAAE9fStKq9zF5nXAHGaAKyjyVypDEngjp9atWsvmKcjke9MMKgYxkU63jIYktke1AFg9K8c+KXh03upz34sGlQ2+wOnGOTzXsdUNYE0lo0MEe8yAqfYUAfM/hnwd4eSWSW+jWaQHAjLgknPTNZfiH4ZWdhqn9pxIn2Q5JsVyWQexPY+leo3vhJLG6urm40wsw+dWT5Q3uB2NYP9r28mHvVCyJkZlHzD6UAeKX2mRtqMqJaBlz8kYTDEevoK6abw9Y22jaalnCjS3BwSwwNzdBzVnxvC9utndBhuDkBI0/h6gk1nWviC3/sm5huElkuEIMEaY2x+/oKAMHxFpQ0y8eAorSxYVyp3AH29qr2UMK3MM5uJLZWG1mIP3jxkD0qa0vxeXLbiAgO53/nml1bVRczpG7IYzyABnaB70AY+o2d0zzTQ3Ed2S5G70H9K5q6nlsZv3sYz0IXkV3dpNB+9ErRpCFySeCfSsuK3tfnlRFdjlzuwOPpQBw05a9/eSL5ZB5Pbb9KdL5nkRpb/ADhePlHWu+xYzWb209jGHmPyyjqPYVz+raJe6W7CzYGM87SOv0oAxRDexqkkkflLjcpYYJH+FbWia7e6Rew3+myFJlPJAxWPc3NxI6xXrSKcYAc9B/hV2wsWkbeSohb5TQB9G+BLyLXtNXUYGUTN/wAfMHQE+o9Aa73QQssEsDqqpIMj0Gf6183+BNbk8OazDNE5MRbbKh6MtfSNgyTPFPbMDBMu9celAHXeGIHg0ie3f+F85NFXrBl+xmRMneAPyooA37os2I06tVG/UPAYYpAhAwSeM1pN8m5twyemaq3Cpbo882GwCQPU0AcjrupQeG9O+1aifNLn93CBneff2rwv4keKI/EUn2i8gYyw5EKRMfLAIGcD16V2Hj2O51W5kvo3kLBz5kbg/Ivt7V5b4i0y80+yjnuMjzSQMDIjz2OPWgDm7qdlk86BklJ5eAdNueh96j3WU7q06sN2VIJ6H0rPaC4nuGS3ViSCcYyTW5baLCn2Q6vL9n3kMy7eTzwaAMIg2cqtaykODgAH09q7fwrYT+JraRdWmEfzggN1f/D610Ws6DoD6dC9pptzZXEmESUDekmTyx/Csx9NXS52hzNEiruSZz94/hQBZuvDukXOkzW0UwTUIZGaMZPzgfwn/wCtV3w9HpuhLYB4HaSeQIxU7EGe2T1rznU725a9W9sppJZlYnKnGK6LR7PWvEP2fcmUGGV5mARSD1x3NAH1H4fQHTjJYyhd44QOO3X/APXXPa9c2WpahDpqXSPqijPkKQ5K55wR0P1rnNH0dptOlRdbkNyBnzo23bWA7KOgrjPDfivRfCusTXIspbh0GJpmIVgc84zyee1AHdeMPBtx4b0tNSspZbhgwEsR5PzH7ox2BxWXpk1+b+AyWc0OVG9pVycgegpJ/j0mqX/2PTdLU22zcs8y7juHQbfWpD8RNYuIpbe5MEM8o25iUKVH978BQBo20N3J9skmjaDcu5d2QMD0rNb+3tWMdosb/Zt4Xeh+Yr3qnreqyWPhW4vTqV5NcE7POLE/TjoBUfgKO6Glyahe30jwSDKSA8H160AepaPY2tlbLbRuFYKM5IJ+p966HSbULcI4+ZcZBPXNef6Bc2iO0iTM7tzvPQ/lXoGlXG3YDg579KANykPXpxTc5IwaUZwOKAFIH50mVzSA5J68U04Jz19KAJMcUuMU0Hn60MQvJ+lAC8UvtTWJAOAar5O9iDk+9AFjaD/+unYquoYkNuOB1qQuSDtHI/WgCSuf8T3VwkZitJjDJjqDW1PLst2PIYggfWubWJ7yUI8bO2d249/Y0AcZ4iu9Q+zNBNqUgEgwkgf5h9PWvD9Tj1nRPEt5HrF28kKAEMzZ8zPTPt0r234gX0Oh2yJexgAybUKckGvBPHWujVryefyGltUXy2K53Be2fTmgDRv9UF3buNUa0uIVXICuFYjHGPWuKngWCWRoZHgt5VzgjcMeme9VWsDd6NPf2MokNuQJImYB1XpkDuK5tr7UfMQ7i0KtgknAUUAddY6a2oXkdrpk5lL4baq4b8ao6rKLG6dJEYTrlGAxwR3PrVPTPF95ZTbbGFQyNnzY+G/OqWoarb6peSTmRlmbJbd60AbNvNZrZhpVZiSCyn+I+lRloJUBG4SM3zEdh6Vh3NuXtoFhchSSeeCT9aYuozWyqnzR4AXL9z/WgDs0gWNhl4pCuORyM1b1pJmYNNPuBAKH39646w1lPmExKMeAT61uWFwsjt5khe1XG5uuaACXTYL4bZ8tgZJC/d96pnSbqwGUV57bJxJjkfh2rZEiLIPswCwA4AHX8TXR6FeRRRPGqLK75Uq3Q5Pc/wBaAOMWMbImVCyMeWPb617t8F9ZTUNLl0q5lLzQkiME87Pb6f4V5B4i06eyjaSL5LckFgo5Gf6e9Xfg34gNp8RtLmY/unYQNkYBDHAz+OKAPsPT4tuk+UuSVGfrRV2MoszoAAM8AUUAaLje5DAhQOT6+1cd4j1ZZpXi3EwAYQL13etdD4lvBZ6VKQcSONq4ryVdRjuJzbylxOCcDufpQBJqF1NFZyzIqywj5WjfqR71w194VvdTmldnFrZTrkhwWKnsR7e9ejWumskouLqPbt+7GDnPuatXd1DKHWSPG4bdqnt6GgDzK8srfwhYx28doJbZ2JWVgPMLdCd39K57UNGguljY3Ku7t8qoBuUH616zdaHY6vZMy3EivEMNERkhD3GeuKzbPSdD0qNbiScXYiJ8t9vA9RQBq+E9HmOhW9jOiuyDjdwSMcHP61n6/oGkQ3C/bblJPLUqSB0P4Vxvj34k3ksptNLuBb2oXy2aHhyPr/hXnZ8S6gjJC125i3csGw34+tAHofhPQ9D1LUbnTpNVh0+4V28l5SoAHbPrnNZ2u+BdX0vS7i5N2bjT0JxLE2ARn09OK86RbjVdX8iyR5iSXJ4ywzjj1+lfReja1baJ8O00fWIJrqLKwRmQZIJHT2A7ZoA+e7rxVq2nW0trpVzLaLIDuaNsfr1rAF6DaD7TcOGZgCWbOa7D4maPcQaat5Z2L20BbYR3X2z9K8xXAt/MmAUM2Ap/xoA9P8Faro2m6fO8kxlv5V8lSV4j6ENXpPh7RRPZzBYj9sJJDFsEr1DZzwfpXnfws8Gy32o2t1eQ5t5SdqtyH96n8ZeNX0S8k0LRJtkkW5JJl5c57A9qAPZ9Oh0+Wzn0u7tWuJHADuFyCfStyx8OrDZtE6CC2PCovCEduK5j4JWN/eeG7e5u5i9yoLPvPJGeCc16DfTsColfESqQigAZ+tAGbp/hnToI9hl2Fjk7W9/SutsEgiaJFm3hSAPcVyepQ3xmiFuybXXLZAB+lW9JV7ZwzFi4/vd/pQB6BtUZI4PSlzkVWhZjF8wJOeoNTo4bJ9KAH/Sgj8aUUhPagAHvQAMCjqKWgBDx16VDwXbaOffipj0qEAM2ABn16UAIh+fb29KlwA+QOaZt+ZsAHil2ksM8D+VAGfq9yEicBcgd/esey1kRSOCVGfmyeenatvUbM3IdY2UFlxg9DWH/AGR9mRQ6LvBI470Act8RtEm1rSxPCSZCwkVf0rx3VvDV3DpFyI7WRpnQxspX73PGK+mIM/ZWS4QoFPyvjIxisrVrGyvdOdbW1keRVySp/X3oA+HzHcaZM81wjW8jkqUJwCPStW8W0n0WCCFA80o3vgfdXt+NekftEeHYo/D+n3NtYMPKY73C45I4yO/414ZoWoy2Csp3l2IJDcj6UAUb/TpbS42BiABkEcZFUVtpRPuZQF688ZFdfcSxXtsSwAkJO1u341zau0ExWcEIrZORQApmnM6wqQY0TABPap0H9pW0aZIkjyVQ96SOe3lu08pXLucAEdPrWxfRWOm3EZm4mKA7UPPNAHLi1maZoWA8wfeyeT9KmW/ktJDHE2YV42E8H1/Gup8aazp2uixbRtMi01YYRG5QgvIR3LdzXFXKkMT1X+tAHe6HqUGoxZO2GbOAB0Pauj06dInVMs4zkADhvxrxuKV4mVo3ZWHIIPSvQPBviKKYLBdSiO+BCws33WP+NAHpc0NxqlrNAEzC42ybfve4/SuS8M6bPpPiwCdSGspFkXPGecg5/Wur8GSzpdukuSjty7Z+U9etdH4s0NY9Oj1FV3XCEeay90JwCfof50AfRcMivBaTKciaJXz+FFUNLk/4p3R5BnH2ZO/sKKAIfHcxxBAoyzg7Qeh9q5RNEjshHdXTB7rGAqj7gNeh6tZrLJ9qkGfJBCiuUvlZtzdCeMsBg+g96AKUt0YYID5kcpcYVFOSfr74qpqTpBC9zd7rRFHCMfv/AE96z/E1/Z+FNOa8u41a5JJt7ccF2Pf2X3rz/TNd1PxNNJe645WBTlPmxGMHhfpQBf8AEWuXwhUW8cluhGEaJsu3bk44zxise8sr220aSa4ukhWVflj3Hbk9dwPQjrVt2vPNjv3iWUy5XyMZQDqGHvWOj3Gqi5M8g2o24Kc5bHBUe9AHIyaAbyygNneq0zBndJDtxjPc9R9KoR6bHbSbrqRSdoZcn5SfrWjNdSNIllEpcK7BU27tg9ARWVcW8yzSItpK75K/MM4PpigDV8L3NjYanHOHV2X51weVb1+lbWrePPI1WJ4GiljuADIkuSqsO4Fc14f8N6nfXMzLaCEKApZuAo9TSWnhGa7vbmGeXaluQSx+XBzQB67f6/Z+KPDEtq0Yd2j2NFs4Y46rXkujfDbUbrWzc31lMukRvv34HIHYe9e1fDzQfD2k2rtMsskhTKzKc/MewFN+JOrrpeirHDKyy8sFAwD7f40AeUeMPF2rTzJp2kxrp8MJKQRxjBCgfeOKxPCOm2b+I4bnUi8yK/mNtXJkYduexPrV+3nlgdtQZkE79Fblue1dT4KvbATR2UlkxvZ7gN5kYBz9fbv6UAe++CzGLO4iWJoUMI2omBgY45pgiUXTtI0jhFGQRnJ7YFXLKwbEZtmZoAMEk9Tjv7VJYwSvciR8eUCenNADGiSedHcMU2jGTgg+grSt4Nm1nUHH97mi2tZFGBHkN8wIGfxq/DAYtofksDn0FAGtCBIgYKV9iKVAE/iyaS0OIgp6ipfUAdKADPOP6UjnB7/lmkVssc+uKk5z1/CgBoPB7mlBo79qQgsPr1oAU55Pb2qBm2ysOn4VKRkfLgYqJ8Bx83NAEkXIOTzSSLuBXkD0FRq67/lJ4pXmRiMsevbtQA0xnepHIXgZ7Uk6LIAZARjoQelSZBcNtbA70/zExjHB55FAGBd3DRXBif5YyCDkdRRoM4XYkG3aGIf2Fat9Bb3Q/eblYdG6fhWAlrKLtTBINmSAQev1oAyPiPpcWtaLewXEe+1kA2BRypHOa+PvFukR6RdyxSSfLvKb2Tkc19sSSTNuhlw655754xivBPjf4dtLK7gKw77aQZUsfu885/GgDxbTmtUcW7RxyIRy5XH4itDX9AtLi08y0yVxySMYqQaC93ewQ2MIWMvs3DO0e9exeHvA8dwY4YroXcccS/aCGAXfj07igDwbwp4avL66kNsiytACS3QqPoaxdcg3X8zaiXWfJGWXgivfvFenWdjr8UarFb2qAOzwOFY47VyevBNblRmtorldu1WSPkAf560AeP2IiSOZVjkcZ606RBcsVCKABwBxiu+udAtoUKwxeTITllb09vWuN1S1mtJ3iVS0YJw6dM0AY8ttGsYzKofp7fjULI0Uu6J87DkOOma1jYbo2L4D4zgE81WjTbCY5NmwN0xyB60AexfBvVm8R3KW16XkvIBvkwcmaMd/94enpXvstgt7uiaMBLiIxbcflXyP4ZkuPDWqW99p1yfMRhISvp/d/wAa+z/Dk8GraTpWo2QJhnCt15Ukcj8KAOjeMwaVpsDDDJEEIHbAoq3qp2yxhemMiigDWuQCmDnHoK47xPc2/h+0kuLn9/O+TDAo6n1PsK7O4cRQvIwyAM49a858RWx1JXnuHJfcdpPbvge1AHkGoQXev6xNLqYea4Z+CDmMKegA9qj12ykAjtIImt7S3JHXAkbua7aw26TFPdalCrouV2jgkcf5FY7adFfzG7abNqx8woCCfoaAOT0u8uztjv8AzHTzPL8yLJOO4+mK276OysdQk028jeJZl8y3MJyQp7nvmpRY3E2pkafGII49oMrDA/AGr3h+zkuPFBuL7bNtYo0x9Oy+lAHCw+Gb+zuHu9ywFnO0S/eIzx7ZqzeTrYOkk0SicHzHkh5bJ6cevrXbeNWWYzmyk3MjYkOPuY5H4/SuO0rTDql2Y4EkYjkl/uigDR0PWrZkui8PlyygMZBIF6dc+9cbqOo3rmc29vtt2Zt8vXHbk/Su+tNDsPDtqb/Ubi3aEZLK+ME+n19q898aeKbK8uxHoUOVOcArhM/SgDqfCuvSDQ7eGxhG6ByAJDySSOQe4FT+ObaK8t4m1e5hjuMM5G/IK59BzXm2h3N9rTxQNerAI32AoNq5P09a7u68Ovd6fHCqt9rUhHLcgqO+fr2oA4HUtd0i382KGC4vX3cNjbwBxiuz+Eepeal3dx6faJc2/KtKzSEZ6ECuStdAutQ1lrGKDZdCTaxIxtGeeK9M8G6aPCWpmwuYYpLy+cNGoYEqo4yR2oA9mt9elg8Px+YIoZ5VO0KmOvT86fp9zK8bmbeoGMDjArmLmebVb3y2hMTLjaduNw6VvQtLC8YyzRhdoC854oA3hdzOQInZExgg9Dir9pNKz7pcMuO461QsEFyiSbSBjqR1rUhXDEbeF4wO1AGgmARtGN1OOVU88dc+lV4N/BPQ1YLZGO1ADCcnkDPt/WnB/lIOc0EEsSCRTSM9ec+tACjkjPSnew7etNHyEBmHXggUrZxnOPTNAAepw2Oc1Wl4fHAOO1WRyCO1VLp8MeMUAMBAbIPI7UA/PwO/NRoxZwNp3Hk5pGc5YHtxnFAFtZFyo6rjmnSJkLtJIUetZ+/YxJIq0jYQ89TQBKYWmhZSecjBqlPZvbshVvMDHkdMVZW7KbgORjIOKqXl9nbnkZ9KAKLWplnaS3HyjjBOD9a534haAdd0N1MAedfnjIOAre9dRBcxqjMJDy3ORU0FxBKjlHTC5yDQB8mXttqekW94Vj2DeUMQXLKfXFN0zxTJ4d0+CewLNcgFbnBwHDHgEe1fQnxB0+O6s2nttPW4dEywVMlgPbvXzTruo6GsV1Ba20kF23yNG54j5/n/ACoA6S+vbLxBGl/dusaDCyRg859hU1pqy6TaHT9IWDdKGMs8iZynPHtgV5lZ6xc2qKnmCUE58vuPT8a6Y68ktkqXxDJMOGQYI9KAKVxPCbqNLkB1XONg4b86s2aaeNTU26FEYcI/POOnoaWW0eMxwPHHKSu5ZMZAB6Y/rUcVlJFciO7BD4LeWo5X3zQBBq3hmxuGM9qDBdOfmIIK/l2rlv8AhG7q2vXW8gdAp64yH9wa9L0SCK7vYYx5okU4ZQegHU59K7saZZ6rpQjmQrHG20B1yQOm7igDwcWJgKggfdyzE5xmvqD9m28F74IltWYt9kmJTPUKefy614VrvhW60q8kZ1Y2hPyzdFI9K9k/ZlJVNSQfLDIoCKOnB/woA9k1VCfIdeBjFFT3uPsu5hgRHJz2ooATWnPkCNWAJyea5GaPci7cnaTnnH5V1XiCIvbq6jLA4rl4POuGm8tCGUYbA4H0oA5HxXazXdgLeBC8xfiNxneB2OKn0HRl0/T/APTFjeRwCI+oQ+ldSbJImieMbnAwzEYqpqkavHPNBhfKXOAOv/16AOXugsW77vBO7dztY9CfaqOoH7PpUsshMcqjG4ZAHpgDr1qxHIHaSeRjkqcZXt71la7e79PtovO8oO55ZsMw/pQBUtiFuZYHLu0hDcgAO2OCTUWra3ZeG9Ky7h9QkZiXRcKx7g/SuF17WLiSZ3jcQhflQKcZx/FVjxJKL/SLS4jUzLMAzcc8DnA/OgDnPF2qzanGkJd38ttwC/dOfb1rDuzHb2flsB57c5HOAfSppt1lD5ih2ckMEJ+6tUpZ/tNwNhKtJgbPSgDpfhfZG41NookJZzgqB90ete6z2z2YhitLQXUgwRtfG8+ntivJfhffJaeL7e2KArIgCsOimvb0tZre9e/nuAHMpMJReIxjoaAOO/sObwzqeoeJTL5lzIoAtWQkbj/Dx/OvP7K81fUPG0Gtywuspk2NGwIIXkAZ9Ole3+I7fU5rS9vLEeWqKWiMo3bmIPzV5SusakLs3V25+0QxDzElXuOQfQZODQB674Oe7u7cnUgIpkJ2buCPbNdDaQ7VBZcpnHJwOtYvgPV11Dwvbag8kbCbhzjq/Oa6azeGUBS+RkkMfWgCwjsZAsZKAdgf51etY5DKcP8AIvUepqvEiRkupyCCSanglGG28/SgDTBG/bH07n0qTAzyc+tQ27FidoHrmpX4JPOaAEZgvA601SOM5z1pH+6WwRz1NMb5hgZB78UASb+MHk98U7PPJJB7GokwMjHfjml4yAM/lQBLkBumTVK7UM524ABq0SN/BOP5VVnfqADnntQAxQNu7OCPahgpVhmo0k3ttbnj6UshIfHJ+lAFcghQM5OeTip13JFnIPOMUrlVAC896jWUnOTgD1oAIX2yguuOeuetPngBcbW+UjGKhkYZUggAdQDVxApjAJyR696AKN7CbeJkVVwRjkc5rm9s0byLChBPUjvXY31v58HGRt5rEktfLLtKDyegoAhk1D7NapHKctIn/fI96+U/jLokdn4mluYo8RXPzllPG7PX8a+ob+FbqNC58sj3xxXj3xn0SF9Ja7t2IlhGCvXIJ/KgDwS1nt96Mud7NtOeoNaVwTJ+8tpoVEY2uhOPasqK2zKoAO1ic4PIpkfmIRBKr5P3Qe9AHWWt0lna5k87LcxyZO3I7Cux0HXodQ00RzQRJK52G724b2BNefXzO5hhum2pCoKouQDWmksKaQsas0fnSAyYPANAHon2B7TL2bQSDbukdCG/D6cV1fh5goe5kd4g2AI8/KxPcivHdIvXtJSizu2MgEDoO/XtXeeGPEFrIq2958kpOIXfo/oPrQB29/aW+s2cljcAeROCrY/hIPVfxra+FWktoOppYPguqMWdVwHz0P5Yqn4eCS3AilQNIrbvpXdaLCp1ITgEOikH6GgDY1BsWl0AOtFRXp/dTjGQQTRQBevR5sTwDOWGKxFjWw4AJkb7x657V0Em1X3N1PGfSsjWIwcSE45xg0AZmsBIrdSoZXY5IHPFZMULTRNJwI8YJY9O4+tW9RuBH5kt2y+Uijj1+lctqWvSf2e5i3eXI20Kg6D19qAMfxZqcMcRhsyqTqSWJXKsenP+NeR+IJ7mVVW7dS+cKHzkexrtfEMon52skW0u46kkdc/WsKzsZ9QZrYQ73Zt3JyyjHHJ6CgDlnxK+yQiNkUDLc7hXoHw48NtrOl3QvGWGGNg0TOcEZ64rlG0X+ztQaaeSOaeIFzEOcYPp3qwt1qup3cnkTC0jlAEuTgYA9aAJPFOhW0US4vLWQF9nmJg/Tj0xXOaJoEV9c4QvvWQIsmMLkn1rpv8AhG206xMlw5cmQOu8Zyewx2q3YyRw6jZW3mkklmB6Kp9cY7UAb3w/8CJp3ihn1BfMnh+aMocAsex9a9X1bVbezuRpojiQqoMgC5b8q8a13xfeaP4qsLi2Hni0XJ+bhie7V2Om+JdH1i7uNU1fUre1u5EBCpIDgemfxoAm8ReJbi6iitdLZSI3G4bT09sVx91a6hqc2sXCwQwxTKI8SH+IdxntW3/awtL9o9M+zwxy7t0rgO755+UetcfqNveT6TdS3F3cSCMM2cEDPYfXnmgDtPhTfaba2B0STULNr2ORpFRZc7sj06V6NYtbhXZbiNBnjnOa+M/CEsll4kjMoDbZvN37sbgDytfU3h+WC4cMxLD74Zz1B7CgDukkieH5p1IzwAKv2sW5gY2DLjr0rLsVjlZSvQDI2ity0XJxg8ZPWgCzFmPjn8utKSXBoBAbGOvenYyffpxQBGQTncQe1RqcY5J/Gp2U4IqF12nGcn6UADZ68fj1pWbO3nGe/pTCDuyMccjvRsbvwvWgB+SM84z3qG4cBd20fTNP2Ng+oxUE6sN6+g4AoAgWUEB8YzzyKSWZBtKjknp0qKRf3RAbGagUgdcenNAFlbhGcrtIAGcUwyIHfBZSRj2qupaOccnAOQKRmSRy2eR2FAEkpTzDtYHucGrQk4Qg/h6VmXcTIyuO47VLaSOE2sAR6Z/rQBtrKSq9elNeFZWO4e/0qmsi5weMHJ54q0khMa7Twe+KAMzULNHQ7VwRxzyBXB+MNGNzpl3ay+WXkTCFuAWzxn8hXot2QSRsbcRwcVzWsRu0TsCWCgnaR39KAPkDWdPvdM1Xd5W2eFyTu4AA60yTUFnkjXCiUHqFB9+teg+MZIZ9duYrhlMbLgoVLMhOOh+tcpa+HZLy9D6UQZVOTG5APHrQBQ12OfULlJPvMV2hlGPpVuaJLOzgtJQGnfDFzzz7VLHK1vNd2upQyRTMeNv3V9MdqbqDfZpTHkFcAqP4ue//ANagDTgtbcWtwL2Z4pdoKlk5aotOwb1Im3kgYQnqOOPpVOEXOoKq3LHzC2UduM+xNbfhOO5m1JrSSON3lyAsh6D1z+FAHrnwpvTc2Msd2yedv2RHPLeoPvmvVtF+QysVwGIXPevDQosyHtQ58tP3bDgZHbHrXt3huZp9EtriYbJWQF/r3oAu3JyJh3wRiii6AQOw6FTmigDVm4QnsOazruULCDKyhM52+tX7plVcucCuX1O4Ly5bcAOFB7CgDjPGF673bFEB3IQi54x7+9c1dF7cebePsXymDoB8p9PpXVXduJXljJHIyjA8E1g6rCZbWGCRfL2t8xDYx3NAHHC+K3AFvmP5AjK3IPp16cd6Za6Pc28zXDzEzzZ8sQAnA7sT6VL4mk03Zb2lmzyXMZKv5anKJ6k1KNRkt7GOBTIPmEXmp156qc0ASaZ4bisL+S5u3Wd5I9yO38B9D6motYvIJL3yJ4gyjAVlOMcfe44xTr7UhNYwwSu4MCFVYNkE57mue1K/tpDGLcgvkA4Jxjp82PfHFAEviRrzUrsx21wrbtu5D2PQH0//AF1HPbx+H5I7nUhIZgCdqkcDr8v+NZI15Ib9FsQJJlPyhUPLdyBS2ekeIPEl5eHybiR9m8iUbRjOBjNAHF+KfEV54g1eckmK3YhNiHkj3I707Q5Qji2Z9pQlQBwa7/w38HdY1Zr5riaOweNC8e5d25vT8s10ll+z5LZ+TPqOstyOfKixnPXqaAOesbySO9s9qyGRFGd4wCvpVnUL9rtGs1Ztsj7llLHbjuG+vrXe2PwigaUzNql80PG1NwHTt71r3nwispNghvLqNoz8xGGBHpigDwa/8KTtfSzeQY7dWDM2cAZr2fwck1nFCLt42iSJYkZF46YGTW1L4Lhj0oIXadYfurIOvHU1e8P6TP8AZ9tyqKqED03fhQBvaLH3RlKHAyD1NdNAcYIABxxk9awdPtikyCIfuuSQvXNdBCgZxkAdgaALCqSSxP0GKkzknPUCgbcdc4GOaVe2KAGkgkDP51Eeef6VMwx2zTDu5AGTj8qAGBTx056jHSlwcZBLepppQ4yMkk596cNygkdT39qAE4PBBx1qvd5AOCc461LnaTwc5xTLpSBnJyR1oAzIy7E8A4/SkmRVU4G3PrUvlkAkFc9cjjNQ3W6SMJjnrmgCNBlizAn6c1FLGBMSgwtNjYrKVXqOKnDhnIJAb3oAieQyRshAwvX3pgUh12n8KkQASgk4HSldNkm715ANACMzAgA5HTPSpbUyZClnyecdsU1SGQKqj61KSEADEq/v0oAvNGrBGZl6gjNY3iR4nspEUKZGBwR6VeUI7AAlQRhgD3rK1eKOCMCWQAYwpY8fSgD5d1livii5uJN/ls2WJX5uvarVpd/YtZ862P8ApEyHII45HIz3OKq/F6OWw8TqlmfkHzF1PAJOeayNN1MXjLNI+7ZgM5G3GDzigD0yTRobzS1F1bYuFAbaV4II4rzDW9EuPtUkwkEjsxPyHJX2Fdp9uvDfWl1ZTGaCQNmOVhnjv1602/fz5prlgqSbeI9m0nOBz+FAHD293IlzH9oO4xEAYGAR3H1r0vw1a22xb+VsTSsURif4QPXp14z7VmWnhyx8QLELY+Q6DdLJJkg//WNa+kzPpssltcxhk/1axYzgDuPb6UAaE/nS67BCzIsTEE+XzgH2+teyeHJjHttid2FHU85rzbw/YGO5lupxkhcqM+vt2rutFYxXUBcjI4Zh3zQB1F6cQMTyQCM0U69INvMBwV54ooAm1x2a1YRfeQ5PGRXNyu01vhcEkHI966W9Zd5HOHyPrXKXhFmW3H7pOQw5IPSgDNuQYkkkcbCrZxWJqVoNVT/RmEcoQbix4/LrXQODeWbJGUGDuXjJI7iqcNlNNGYbBVaQdTjqT6mgDzZvsOmIwViZi371mGSWbI59sVg6xqKlVttPgmlcSbx1YsenSvZ/+FfR3xhe/lY4bcyLwr+xPWuksvC+l6XCqWtrFGF6MEGT9TQB4hpvg/xDqtrFJJEtikpLZIyR/wAB610tl8LIBGDcTFpWQ5dBxnHp2r18W3mwquAFz09amht1TCYDA0AcF4Z8A6fpbCWK2j80L/rSoJJ+tdVpeixW8rSbQVbuB3zW+YVSMhQFXAz71IFVYcE7RnpQBkvpYY74gPKyflzjNaTW5lRBICcADB5GamjwMAEY6AZqQrk5H86AK0djBEBtTbtOeDgVOsQ+Y4wx9qkxzk9aWgCtNZwyph13HHr1qCWyiI5iUdO1aFBAPWgCpBAg+6MYGMetSNGADnk9AB2qYD04paAIVBAJYHipPcChuKQ5I7YPY0AITgY7Uzk+lPb5sjIx/KjaNuDkZFADB93nkmg52kYz9KVRt+926H0pCcnOeMdqAGlhg7hjn8aZeZZRj0qUd+lQ3bBV+bHXtQBQR0wQfr16VGpHmthARjPSqa3SR3P3c4JyT2qT7Q6zNtQ7CM59qAJzbIZTKuB7mqzQkyk4GT0Pej+0F8tlIJUDJI60xWBXckmDx1oASRZImJI4PQUkzExAoOfSla4c5Zh9KfFcAKzEDGMdOlAFVZ5Ag4xuPTFPklNwoRX/AHgHIFQMjNG0iHDD3qmpaCUXHR0GWyO9AE82ptYcyvtVeuRxiuV8eair6FLI0xZHGA6nGPf6CpPFE6XtgHiZkIYZwcgE+ue1eEfFjxZJYwy6ZBcI0eAhiH60Acpda8b3VrkXk8lxaqxx83GBnFP3mdz9ijjEBIQAgZJNck0KFVMcjIWQkjGMH6VY0rUpdKjS4Ul+clW5BbtQB1Go3IttQFsrv+7QHcOMHHIrfk1iRrexmgk+dztfPOenA9BXFtrEF00cskJS6Z+WB4JPt2FdpDIg063jmEESRFmymC2DwKAPS/D7QS6Qktk0Ynkci4UHGBWzZWqX4uLSfbkKAkqD5gfX1/CuA0eeFbaOTTZ13BtjjBO0/wD169I8OrLGm+QAuoCqV6k4oAmjtJLS5itd294wpdmJz14rrdO2hoRjJLAk4rOgtxcKWkJ81OQ2eSe4NaOn8zRcnA659aAOruY1kikHcp2+lFNdgpTJ4I6ZooAfeKDuJzkHOTXM+IlWZSqqTgfIR1NdRI2WYHgZwSaijt1Du7AHuo64oA53RNIaGFWmyik5IHXNdFbw28HEUYRTzwOtQzl1cYxn3NM3lDk9O1AF0siA7fz9qheTOFkAHJwR2qIOcgLj5vT+VKFyuc5PoaACJvLc7gfm/Kp43y25cYqGI5TDZK9cEd/WpCApGwZz/Ce1AFqOTAwMHjGakEu7aFqvEN27kjI7iplXZjJGMcUASKgx2OcU/wAzacZ49PSq/mZBOPzqNpxngbs4PI6UAXA58wj0p+7kY5qlEf3nJ69atqwxk9TQA/dRu5xg0gwGJzz9abncSQfbI9KAHhs00Ek5yfao2wg2/p2o6Ln0oAlJGOT1FNJ+UDGKTnvzjmkOSB1x15oAeTwcfnRjjj1pmePXvTWJHOefSgB5GRn07ikYBmAPHpTEceny4xTwRn27UAIMjdk9RxUVzyuD0I6VNlmUnINQ3ZIicdscGgDldQOLoZxgnP4URXw8lkcDqQD6j8aqa27qu8bTtfk/WsWTUZIpwscJc+hHb3oA2vNMWzAO12Kr3GaUyL5rwucFvukngH/GsfX9WsrPTrQzy/uid2F5YY+lUJr6SBnuUkVkcBkH8Sj1IoA3Jr+S3lVWYMu0kK3cd6mg1GK7QCFgrkZK54P41yPiS/aayhEMiGVMue2PSsnw3rwkKW1wHV+mSvzK3r70AehvcPFCwcdD2brTr2/U2jSxBXL/ADBB39fwrkWl1SK4aAxPcwSHCkdfqDVhdL8U3LZsNLl8sghRMyoF/E0Ac54gY2LXVz9pVbSdNzoW5Vh/KvlfxTetqGrzzOcRhjtI7mvrbXvhH4s17Sbm3fUtPsTKANoDScZ5J4FZGnfstaatoI9U1u4nnB+9GoQY+hzQB8radKjnyJmOfvBs96sX0581ImAIHIAHX8a+ubT9nXwxZKfMtmnYMNrSSMeOPSusg+EnhWJVA0a0Y9mKZ46YOaAPijSTC8rQg8uMlyOmO9a1xOXmiCMQIkxuB+9jvX2NJ8LfC8gVBotmob7xWMA/TNc54h+BPha/jJsbeWwkB+9DKf5HIoA+evDmoeRei4hxtyDJxx9cV6n4V183N+7rNhQnAHQD1qhrPwU1PS7SaPSr8Th+XWVdpbHTBFcXo8OpaHrsdtrEU9qUOS23gr3yRQB9O6PIssChwfMbnjv0rXjh2Sqwxz3rlvC2oxX0CujoXB2kA5wfrXcxxqLYM3LEZAPY0AWnC4RvQY+tFRvwqYHAHrRQBOAWfPIHU06QkDA6elSOQFJxwfWq7SDO0d6AGMuVA7gcE1TIDKd2cZxVmYluR29Dmq4BZS2QSBQA/cVHyHGetOVw2WHUjpUBJ2gHHvQWJOQR1+6KALcbKBwMnHOTUiruOCcfQ9apxZIyc7vT1q1k5OTj60AWIjtxhsCnAjIyMioo269xim7juwOlADnbqcAfqaapGec4x0IpGHXPQUjnAycUASRuqyAjOevPerTPvzwQMcGqceOCcBvenB2bPTOaALW8ck9u3vT8jbwc/Wqe4ZyCD3H1p+85wD9cUAT87h1PGKXIPUnvz0qIsRnHOe9N3Fuhyc/jQBY3jGVOe3pUbHC/KenXNKSdwGBgds0zDNnkDHT6UAO35PIz6gd6k3L2HPvTdnA+T369ajcHaD0HtQA4tzhfypQ53fMDzTV2kDJ9s+lPGCwB9OeKAFY9s81FKSyMBkDFPbaQCSPbApWX5Wbn3z3oA47UreSWSZYweT19K5SW0vFa4knUneQinHOP8969Gmi/fgrgZ4NUb20Xziu3IPSgDzaLQru5gS3unD4yyMRkjrx9fetW08OviIF3SILtYP1ziuvt7PbIx24GMVehtCz9wMdaAOJi8NRNPxF5kq8BmHOK6C18HWkksc86qj8HAHJrpoIo4XztBY9SabNMQ3+FACW8FrZ/6uNN/qcE/wD1qllvpAcoOPzqhK6tg59yMUHDqNpAXPQ0AXJL13iZVYBwMjFV0mdjgE88VWwyYKk9MH2qe3cEAHgnqT3oAso7YIZjkVHI8iOCGO360Ssv3s7SPfrSs+U4wT2z3oARZmyNwyD3FTecrjAIDZrOm+UjbgZ60mcAED8aAL0qh0YEDn2rOudGsrgP59vG+9dpDDIP1qzFOTlHA/GpWIyvPB6UAczYeELWwvfOscQR5yYkHyn8O1dJbwSEKJVIC/qKnOFALfjUltOJVYDtxQBXuMI23cAAMH1orA+IviG38M6WbiY/v5RtijB5Y/570UAdWGZkZQcfWqNwxXAB5NFFAERw6BjwT1NR7wCewIxRRQA2TIUndwaVcHn9fQ0UUACj5hkjI5+lTswAA529eaKKAHRyZA2jKjipFPcdAetFFACxlQ2AMY6ccUpBBwAOTzRRQBIq449qQRjc2enTiiigBHBB+vFMLBSMMcjqMUUUASIzA4OTS7yG4zx3oooAUSEt6YHapAQSSDgk4+lFFADlZlBJOBjHSkkJLEDjiiigBitgcrkU8v8AOeOlFFADS/JI49qc8h27ecEUUUAVTljgjjpUMp3MAMBhwPaiigBkURMhYscA8+9XMgLxwvtRRQBG0gDck9OKgmJznjHU0UUAVSysxHp17U1jg8EjHNFFAB5pXOTmpBJ0wooooAXzgqnPGemB3oeYtw36UUUARLJggckmkd9nQ8e/aiigADBiWGefWrVvMCec5FFFADbmZQOCTk8+1R2V8kE205Z3yAO2aKKAPIPjnOZm067uHb5VmTj2GRRRRQB//9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A chest radiograph shows a slightly smaller right lung, an aberrant right basilar pulmonary vein, and dilated central pulmonary arteries due to left-to-right shunting.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_25_27026=[""].join("\n");
var outline_f26_25_27026=null;
var title_f26_25_27027="Acetohydroxamic acid: Drug information";
var content_f26_25_27027=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Acetohydroxamic acid: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?24/45/25300?source=see_link\">",
"    see \"Acetohydroxamic acid: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F129938\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Lithostat&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F129939\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Lithostat&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F129950\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Urinary Tract Product",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F129940\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Susceptible infections:",
"     </b>",
"     Oral: 250 mg 3-4 times daily for a total daily dose of 10-15 mg/kg/day; maximum dose: 1500 mg daily",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F129947\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Susceptible infections: Oral: Initial: 10 mg/kg/day in 2 or 3 divided doses",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F129941\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F2613486\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Serum creatinine &gt;1.8 mg/dL: 10-15 mg/kg/day every 12 hours; maximum dose: 1000 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Serum creatinine &gt;2.5 mg/dL (or Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;20 mL/minute): Use contraindicated",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15161639\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F129930\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lithostat&reg;: 250 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F129922\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F2613487\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should be administered on an empty stomach, 1 hour before or 2 hours after meals. Administer 1 hour before or 2 hours after taking iron or any product that contains iron.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F129931\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjunctive therapy in chronic urea-splitting urinary infection",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F129952\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Lithostat&reg; may be confused with Lithobid&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F2613479\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Headache (30%), malaise (20% to 25%), anxiety (20%), depression (20%), nervousness (20%), tremulousness (20%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Anorexia (20 to 25%), nausea (20% to 25%), vomiting (20% to 25%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Hemolytic anemia (3% to 15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &le;1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Deep vein thrombosis (rare), flushing, palpitation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Alopecia, macular skin rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Reticulocytosis (5% to 6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Local: Phlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Embolism",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F2523572\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     In patients with disease who can otherwise be treated with surgical or antimicrobial therapy; urinary infection that can be controlled by culture-specific antimicrobial agents or is caused by a non-urease-producing organism; in patients with serum creatinine &gt;2.5 mg/dL or creatinine clearance &lt;20 mL/minute; women of childbearing potential who are not using a reliable form of contraception; pregnancy",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F2613475\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone marrow suppression: May suppress bone marrow function; use with caution in patients with prior bone marrow depression. Close monitoring of hematologic function is recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hemolytic anemia: Has been associated with hemolytic anemia (Coombs' negative), which may be associated with gastrointestinal distress and systemic symptoms; use with caution in patients with anemia. Monitor hematologic parameters during extended therapy. Anemia is usually reversible after treatment is discontinued.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatotoxicity: May cause hepatic injury; close monitoring of hepatic function is recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution; close monitoring of renal function is recommended. Dosage adjustments recommended.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298675\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F2613482\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F129937\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ethanol: Avoid ethanol (may increase incidence of rash and/or flushing).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Food: May decrease absorption of acetohydroxamic acid.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F129927\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13332940\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were observed in animal reproduction studies. Use is contraindicated in pregnant women.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F129942\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F129934\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should be taken on an empty stomach, 1 hour before or 2 hours after meals.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F129933\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Lithostat Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg (100): $172.50",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F2613489\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     In patients receiving therapy &gt;2 weeks, monitor CBC with reticulocytes at 3-month intervals during the duration of treatment; renal function, liver function",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F129935\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Uronefrex (BE, ES, FR, LU)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F2613484\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Acetohydroxamic acid inhibits bacterial urease enzymes, decreasing the formation of ammonia in the urine by urea-splitting organisms. A reduction in urinary ammonia and decreased pH may increase the activity of some antimicrobial agents.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F15160704\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Oral: Well absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: 5-10 hours (increased in patients with reduced renal function)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak: 0.25-1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Urine (36% to 65% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9210 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-115.25.216.6-7AD06D259D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_25_27027=[""].join("\n");
var outline_f26_25_27027=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129938\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129939\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129950\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129940\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129947\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129941\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2613486\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15161639\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129930\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129922\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2613487\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129931\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129952\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2613479\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2523572\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2613475\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298675\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2613482\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129937\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129927\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13332940\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129942\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129934\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129933\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2613489\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129935\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2613484\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15160704\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9210\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9210|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?24/45/25300?source=related_link\">",
"      Acetohydroxamic acid: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_25_27028="Tumor bleeding 15a";
var content_f26_25_27028=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F59211&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F59211&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 545px\">",
"   <div class=\"ttl\">",
"    Pelvic angiogram",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 525px; height: 520px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pelvic angiogram on a 71-year-old woman with chronic vaginal bleeding and anemia secondary to metastatic renal cell carcinoma. Hypervascular neovascularity and tumor staining (arrow) in the vagina can be seen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_25_27028=[""].join("\n");
var outline_f26_25_27028=null;
var title_f26_25_27029="Histiocytosis X High power";
var content_f26_25_27029=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F55413&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F55413&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pulmonary Langerhans cell histiocytosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 386px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The cellular infiltrate of pulmonary Langerhans cell histiocytosis is characterized by Langerhans cells, eosinophils, lymphocytes, neutrophils, and alveolar macrophages.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From Colby, TV, Koss, MN, Travis, WD. Tumors of the Lower Respiratory Tract. Armed Forces Institute of Pathology, Washington, DC.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_25_27029=[""].join("\n");
var outline_f26_25_27029=null;
var title_f26_25_27030="Cutaneous findings of Stevens Johnson syndrome";
var content_f26_25_27030=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F76141&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F76141&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Cutaneous findings of Stevens Johnson syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 379px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note the vesicles and bulla that are characteristic of the cutaneous findings in Stevens Johnson syndrome.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_25_27030=[""].join("\n");
var outline_f26_25_27030=null;
var title_f26_25_27031="Magnesium sulfate: Drug information";
var content_f26_25_27031=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Magnesium sulfate: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?13/3/13365?source=see_link\">",
"    see \"Magnesium sulfate: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/29/34262?source=see_link\">",
"    see \"Magnesium sulfate: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F191096\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Anticonvulsant, Miscellaneous;",
"     </li>",
"     <li>",
"      Electrolyte Supplement, Parenteral;",
"     </li>",
"     <li>",
"      Magnesium Salt",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F191085\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dose represented as magnesium sulfate unless stated otherwise.",
"     <b>",
"      Note:",
"     </b>",
"     Serum magnesium is poor reflection of repletional status as the majority of magnesium is intracellular; serum concentrations may be transiently normal for a few hours after a dose is given, therefore, aim for consistently high normal serum concentrations in patients with normal renal function for most efficient repletion.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     1 g of magnesium sulfate = 98.6 mg elemental magnesium = 8.12 mEq elemental magnesium",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Hypomagnesemia:",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     Treatment depends on severity and clinical status:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mild deficiency: I.M.: 1 g every 6 hours for 4 doses, or as indicated by serum magnesium concentrations",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Severe deficiency:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.M.: Up to 250 mg/kg within a 4-hour period",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.V.: Severe, non-life-threatening: 1-2 g/hour for 3-6 hours then 0.5-1 g/hour as needed to correct deficiency",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Symptomatic deficiency: I.V.: 1-2 g over 5-60 minutes; maintenance infusion may be required to correct deficiency (0.5-1 g/hour).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      With",
"     </i>",
"     polymorphic VT (including torsade de pointes): I.V. push: 1-2 g (ACLS, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      With",
"     </i>",
"     seizures: I.V.: 2 g over 10 minutes; calcium administration may also be appropriate as many patients are also hypocalcemic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Asthma (life-threatening or severe exacerbation after 1 hour of intensive conventional therapy; unlabeled use):",
"     </b>",
"     I.V.: 2 g",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Eclampsia:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     I.V.: 4-5 g infusion; followed by a 1-2 g/hour continuous infusion; or may follow with I.M. doses of 4-5 g in each buttock every 4 hours.",
"     <b>",
"      Note:",
"     </b>",
"     Initial infusion may be given over 3-4 minutes if eclampsia is severe; maximum: 40 g/24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     ACOG Practice Bulletin 2002: 4-6 g over 15-20 minutes followed by 2 g/hour continuous infusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Pre-eclampsia (severe):",
"     </b>",
"     I.V. 4-5 g infusion; followed by a 1-2 g/hour continuous infusion; or may follow with I.M. doses of 4-5 g in each buttock every 4 hours; maximum: 40 g/24 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Torsade de pointes or VF/pulseless VT associated with torsade de pointes:",
"     </b>",
"     I.V., I.O.: 1-2 g over 15 minutes or faster with cardiac arrest (ACLS, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Parenteral nutrition supplementation:",
"     </b>",
"     I.V.: 8-24 mEq elemental magnesium/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Soaking aid:",
"     </b>",
"     Topical: Dissolve 2 cupfuls of powder per gallon of warm water",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      RDA:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     19-30 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Females: 310 mg elemental magnesium/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Pregnant females: 350 mg elemental magnesium/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Males: 400 mg elemental magnesium/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &ge;31 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Females: 320 mg elemental magnesium/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Pregnant females: 360 mg elemental magnesium/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Males: 420 mg elemental magnesium/day",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F191093\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/29/34262?source=see_link\">",
"      see \"Magnesium sulfate: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dose represented as magnesium sulfate unless stated otherwise.",
"     <b>",
"      Note:",
"     </b>",
"     Serum magnesium is poor reflection of repletional status as the majority of magnesium is intracellular; serum concentrations may be transiently normal for a few hours after a dose is given, therefore, aim for consistently high normal serum concentrations in patients with normal renal function for most efficient repletion.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     1 g of magnesium sulfate = 98.6 mg elemental magnesium = 8.12 mEq elemental magnesium",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Hypomagnesemia:",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     Treatment depends on severity and clinical status: I.V., I.O.: 25-50 mg/kg/dose over 10-20 minutes (over several minutes for  torsade de pointes); maximum single dose: 2000 mg (PALS, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Asthma (life-threatening or severe exacerbation after 1 hour of intensive conventional therapy; unlabeled use):",
"     </b>",
"     I.V.: 25-75 mg/kg (maximum: 2 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Parenteral nutrition supplementation:",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &lt;50 kg: 0.3-0.5 mEq elemental magnesium/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &gt;50 kg: 10-30 mEq elemental magnesium/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      RDA:",
"     </b>",
"     Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-3 years: 80 mg elemental magnesium/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4-8 years: 130 mg elemental magnesium/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     9-13 years: 240 mg elemental magnesium/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     14-18 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Females: 360 mg elemental magnesium/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Pregnant females: 400 mg elemental magnesium/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Males: 410 mg elemental magnesium/day",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F191086\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F191087\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: Use with caution; monitor for hypermagnesemia; do not exceed 20 g/48 hours as per manufacturer. Close monitoring is required.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F16317811\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F191066\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed in D",
"     <sub>",
"      5",
"     </sub>",
"     W: 10 mg/mL (100 mL) [equivalent to elemental magnesium 0.99 mg (0.08 mEq)/mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed in water for injection: 40 mg/mL (50 mL, 100 mL, 500 mL, 1000 mL) [equivalent to elemental magnesium 3.94 mg (0.32 mEq)/mL]; 80 mg/mL (50 mL) [equivalent to elemental magnesium 7.89 mg (0.65 mEq)/mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution: 500 mg/mL (20 mL) [equivalent to elemental magnesium 49.3 mg (4.06 mEq)/mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]: 500 mg/mL (2 mL, 10 mL, 20 mL, 50 mL) [equivalent to elemental magnesium 49.3 mg (4.06 mEq)/mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder, oral/topical: USP: 100% (227 g, 454 g, 1810 g, 2720 g)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F191050\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F191070\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection: May be administered I.M. or I.V.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M.: Must be diluted (Adults: 25% or 50% concentration; Children: &le;20% diluted solution)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: Must be diluted to a &le;20% solution for I.V. infusion and may be administered I.V. push, IVPB, or continuous I.V. infusion. When giving I.V. push, must dilute first and should not be given any faster than 150 mg/minute; may administer over 1-2 minutes in patients with persistent pulseless VT or VF with known hypomagnesemia (Dager, 2006). ACLS guidelines recommend administration over 15 minutes in patients with torsade de pointes (ACLS, 2010). In patients not in cardiac arrest, hypotension and asystole may occur with rapid administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maximal rate of infusion: 2 g/hour to avoid hypotension; doses of 4 g/hour have been given in emergencies (eclampsia, seizures); optimally, should add magnesium to I.V. fluids, but bolus doses are also effective",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Topical: May dissolve powder to prepare a solution for use as a soaking aid or as a compress.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F191102\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, LR, NS, R;",
"     <b>",
"      incompatible",
"     </b>",
"     with fat emulsion 10%.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Acyclovir, aldesleukin, amifostine, amikacin, ampicillin, aztreonam, bivalirudin, caspofungin, cefazolin, cefotaxime, cefoxitin, chloramphenicol, cisatracurium, clindamycin, clonidine, dexmedetomidine, dobutamine, docetaxel, doripenem, doxorubicin liposome, doxycycline, enalaprilat, erythromycin lactobionate, esmolol, etoposide phosphate, famotidine, fenoldopam, fludarabine, furosemide, gallium nitrate, gentamicin, granisetron, heparin, hetastarch in lactate electrolyte injection (Hextend&reg;), hydrocortisone sodium succinate, hydromorphone, idarubicin, insulin (regular), kanamycin, labetalol, levofloxacin, linezolid, meperidine, metronidazole, micafungin, milrinone, minocycline, morphine, nafcillin, nicardipine, nitroprusside, ondansetron, oxacillin, oxaliplatin, paclitaxel, pancuronium, penicillin G potassium, piperacillin, piperacillin/tazobactam, potassium chloride, propofol, remifentanil, sargramostim, telavancin, thiotepa, tobramycin, trimethoprim/sulfamethoxazole, vancomycin, vitamin B complex with C.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Amphotericin B cholesteryl sulfate complex, cefepime, drotrecogin alfa.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Amiodarone, amphotericin B, ciprofloxacin, cyclosporine, pantoprazole.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Dimenhydrinate, metoclopramide.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Calcium chloride, pantoprazole, phytonadione.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Folic acid, hydrocortisone sodium succinate, potassium phosphate.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F191069\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment and prevention of hypomagnesemia; prevention and treatment of seizures in severe pre-eclampsia or eclampsia, pediatric acute nephritis; torsade de pointes; treatment of cardiac arrhythmias (VT/VF) caused by hypomagnesemia; soaking aid",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F5358578\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Asthma exacerbation (life-threatening)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F191104\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Magnesium sulfate may be confused with manganese sulfate, morphine sulfate",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       MgSO",
"       <sub>",
"        4",
"       </sub>",
"       is an error-prone abbreviation (mistaken as morphine sulfate)",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication (I.V. formulation) among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F191094\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse effects on neuromuscular function may occur at lower concentrations in patients with neuromuscular disease (eg, myasthenia gravis).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Frequency not defined:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Flushing (I.V.; dose related), hypotension (I.V.; rate related), vasodilation (I.V.; rate related)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F191073\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to any component of the formulation; heart block; myocardial damage",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F191054\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neuromuscular disease: Use with extreme caution in patients with myasthenia gravis or other neuromuscular disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; accumulation of magnesium may lead to magnesium intoxication.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Obstetrics: Vigilant monitoring and safe administration techniques (ISMP Medication Safety Alert, 2005) recommended to avoid potential for errors resulting in toxicity. Monitor patient and fetal status, and serum magnesium concentrations closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Aluminum: Solutions may contain aluminum; toxic concentrations may occur following prolonged administration in premature neonates or patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Irregular/Polymorphic VT (with normal baseline QT interval): Unlikely to effectively terminate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull;Electrolyte abnormalities:  Concurrent hypokalemia or hypocalcemia can accompany a magnesium deficit. Hypomagnesemia is frequently associated with hypokalemia and requires correction in order to normalize potassium.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Parenteral administration: Monitor serum magnesium concentration, respiratory rate, blood pressure, deep tendon reflex, and renal function when administered parenterally, particularly with repeated dosing; magnesium toxicity can lead to fatal cardiovascular arrest and/or respiratory paralysis.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299640\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F191059\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfacalcidol: May increase the serum concentration of Magnesium Salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Magnesium Salts may decrease the serum concentration of Bisphosphonate Derivatives.  Management: Avoid administration of oral magnesium salts within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Pamidronate; Zoledronic Acid.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcitriol: May increase the serum concentration of Magnesium Salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers: May enhance the adverse/toxic effect of Magnesium Salts. Magnesium Salts may enhance the hypotensive effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Polystyrene Sulfonate: Laxatives may enhance the adverse/toxic effect of Calcium Polystyrene Sulfonate. More specifically, concomitant use of calcium polystyrene sulfonate with magnesium-containing laxatives may result in metabolic alkalosis or with sorbitol may result in intestinal necrosis.  Management: Avoid concomitant use of calcium polystyrene sulfonate (rectal or oral) and magnesium-containing laxatives or sorbitol.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: Magnesium Sulfate may enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferiprone: Magnesium Salts may decrease the serum concentration of Deferiprone.  Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eltrombopag: Magnesium Salts may decrease the serum concentration of Eltrombopag.  Management: Separate administration of eltrombopag and any polyvalent cation (e.g., magnesium-containing products) by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Nasal): May diminish the therapeutic effect of Anticonvulsants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Systemic): May diminish the therapeutic effect of Anticonvulsants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mefloquine: May diminish the therapeutic effect of Anticonvulsants. Mefloquine may decrease the serum concentration of Anticonvulsants. Management: Mefloquine is contraindicated for malaria prophylaxis in persons with a history of convulsions.  Monitor anticonvulsant concentrations and treatment response closely with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: Magnesium Salts may decrease the serum concentration of Mycophenolate.  Management: Separate doses of mycophenolate and oral magnesium salts. Monitor for reduced effects of mycophenolate if taken concomitant with oral magnesium salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents: Magnesium Salts may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphate Supplements: Magnesium Salts may decrease the serum concentration of Phosphate Supplements.  Management: Administer oral phosphate supplements at least 1 hour before, or 2 hours after, oral magnesium salt administration.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Potassium Phosphate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Magnesium Salts may decrease the absorption of Quinolone Antibiotics. Of concern only with oral administration of both agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Polystyrene Sulfonate: Laxatives may enhance the adverse/toxic effect of Sodium Polystyrene Sulfonate. More specifically, concomitant use of sodium polystyrene sulfonate with magnesium-containing laxatives may result in metabolic alkalosis or with sorbitol may result in intestinal necrosis.  Management: Avoid concomitant use of sodium polystyrene sulfonate (rectal or oral) and magnesium-containing laxatives or sorbitol.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: Magnesium Salts may decrease the absorption of Tetracycline Derivatives. Only applicable to oral preparations of each agent.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trientine: Magnesium Salts may decrease the serum concentration of Trientine. Trientine may decrease the serum concentration of Magnesium Salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F4104770\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F191062\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A/C (manufacturer dependent) (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F3013521\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Animal reproduction studies have not been conducted; however, studies in pregnant women have not shown an increased risk of fetal abnormalities. Magnesium crosses the placenta; serum concentrations in the fetus are similar to those in the mother (Idama, 1998; Osada, 2002). Magnesium sulfate is used for the prevention and treatment of seizures in pregnant women with severe pre-eclampsia or eclampsia (ACOG, 2002). Magnesium sulfate may also be used prior to early preterm delivery to reduce the risk of cerebral palsy (ACOG, 2010; Reeves, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F3013523\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Enters breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F3013524\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Magnesium is found in breast milk; concentrations remain constant during the first year of lactation and are not influenced by dietary intake under normal conditions. Magnesium requirements are the same in lactating and nonlactating females (IOM, 1997). When magnesium sulfate is used in the intrapartum management of eclampsia, breast milk concentrations are generally increased for only ~24 hours after the end of treatment (Idama, 1998).",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F191076\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Whole grains, legumes and dark-green leafy vegetables are dietary sources of magnesium.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F191064\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V.: Rapid administration: ECG monitoring, vital signs, deep tendon reflexes; magnesium concentrations if frequent or prolonged dosing required particularly in patients with renal dysfunction, calcium, and potassium concentrations",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Obstetrics: Patient status including vital signs, oxygen saturation, deep tendon reflexes, level of consciousness, fetal heart rate, maternal uterine activity.",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F191067\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum magnesium: 1.5-2.5 mg/dL; slightly different ranges are reported by different laboratories",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4088911\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Cholal modificado (MX);",
"     </li>",
"     <li>",
"      Inj. Magnesii Sulfurici (PL);",
"     </li>",
"     <li>",
"      Kiddi Pharmaton (MX);",
"     </li>",
"     <li>",
"      Magnesii Sulfas (PL);",
"     </li>",
"     <li>",
"      Magnesii Sulfas Siccatus (PL);",
"     </li>",
"     <li>",
"      Magnesium Sulfuricum (PL);",
"     </li>",
"     <li>",
"      Magunesin (KP);",
"     </li>",
"     <li>",
"      Vivioptal Junior (MX)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F191053\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     When taken orally, magnesium promotes bowel evacuation by causing osmotic retention of fluid which distends the colon with increased peristaltic activity; parenterally, magnesium decreases acetylcholine in motor nerve terminals and acts on myocardium by slowing rate of S-A node impulse formation and prolonging conduction time. Magnesium is necessary for the movement of calcium, sodium, and potassium in and out of cells, as well as stabilizing excitable membranes.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Intravenous magnesium may improve pulmonary function in patients with asthma; causes relaxation of bronchial smooth muscle independent of serum magnesium concentration.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F191072\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Anticonvulsant: I.M.: 1 hour; I.V.: Immediate",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration of anticonvulsant activity: I.M.: 3-4 hours; I.V.: 30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Bone (50% to 60%); extracellular fluid (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 30%, to albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (as magnesium)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;ACOG Practice Bulletin. Diagnosis and Management of Preeclampsia and Eclampsia. Number 33, January 2002,&rdquo;",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2002, 99(1):159-67.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American College of Obstetricians and Gynecologists Committee on Obstetric Practice, \"Committee Opinion No. 455: Magnesium Sulfate Before Anticipated Preterm Birth for Neuroprotection,\"",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2010, 115(3):669-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/25/27031/abstract-text/20177305/pubmed\" id=\"20177305\" target=\"_blank\">",
"        20177305",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bashuk RG and Krendel DA, &ldquo;Myasthenia Gravis Presenting as Weakness After Magnesium Administration,&rdquo;",
"      <i>",
"       Muscle Nerve",
"      </i>",
"      , 1990, 13(8):708-12.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bohman VR and Cotton DB, &ldquo;Supralethal Magnesemia With Patient Survival,&rdquo;",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 1990, 76(5 Pt 2):984-6.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Catanzarite VA, McHargue AM, Sandberg EC, et al, &ldquo;Respiratory Arrest During Therapy for Premature Labor in a Patient With Myasthenia Gravis,&rdquo;",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 1984, 64(6):819-22.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chernow B, Smith J, Rainey TG, et al, &ldquo;Hypomagnesemia: Implications for the Critical Care Specialist,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 1982, 10(3):193-6.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cohen BA, London RS, and Goldstein PJ, &ldquo;Myasthenia Gravis and Preeclampsia,&rdquo;",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 1976, 48(1 Suppl):35-7.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dager WE, Sanoski CA, Wiggins BS, et al, &ldquo;Pharmacotherapy Considerations in Advanced Cardiac Life Support,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2006, 26(12):1703-29.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/25/27031/abstract-text/17125434/pubmed\" id=\"17125434\" target=\"_blank\">",
"        17125434",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dube L and Granry JC, &ldquo;The Therapeutic Use Of Magnesium In Anesthesiology, Intensive Care And Emergency Medicine: A Review,&rdquo;",
"      <i>",
"       Can J Anaesth",
"      </i>",
"      , 2003, 50(7):732-46.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Field JM, Hazinski MF, Sayre MR, et al, &ldquo;Part 1: Executive Summary: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 122 (18 Suppl 3):640-56.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/25/27031/abstract-text/20956217/pubmed\" id=\"20956217\" target=\"_blank\">",
"        20956217",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ferroggiaro A, Walther JM, and Cairns CB, &ldquo;High Doses of Magnesium Impair Cardiac Oxidative Metabolism,&rdquo;",
"      <i>",
"       Acad Emerg Med",
"      </i>",
"      , 1995, 2:423-9.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ford DC, Leist ER and Phelps SJ,",
"      <i>",
"       Guidelines for Administration of Intravenous Medications to Pediatric Patients",
"      </i>",
"      , 3rd ed, Bethesda, MD: American Society of Hospital Pharmacists, 1988, 49.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gums JG, &ldquo;Clinical Significance of Magnesium: A Review,&rdquo;",
"      <i>",
"       Drug Intell Clin Pharm",
"      </i>",
"      , 1987, 21(3):240-6.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gums JG, &ldquo;Magnesium in Cardiovascular and Other Disorders,&rdquo;",
"      <i>",
"       Am J Health Sys Pharm",
"      </i>",
"      , 2004, 61(15): 1569-76.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Idama TO and Lindow SW, &ldquo;Magnesium Sulphate: A Review of Clinical Pharmacology Applied to Obstetrics,&rdquo;",
"      <i>",
"       Br J Obstet Gynaecol",
"      </i>",
"      , 1998, 105(3):260-8.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Institute for Safe Medication Practice, &ldquo;Preventing Magnesium Toxicity in Obstetrics,&rdquo;",
"      <i>",
"       ISMP Acute Care Medication Safety Alert",
"      </i>",
"      , October 20, 2005. Available online at file://www.ismp.org/Newsletters/acutecare/articles/20051020.asp.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Institute of Medicine (IOM),",
"      <i>",
"       Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride",
"      </i>",
"      , National Academy of Sciences, Washington, DC, 1997.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kaeser HE, &ldquo;Drug-Induced Myasthenia Gravis,&rdquo;",
"      <i>",
"       Acta Neurol Scand Suppl",
"      </i>",
"      , 1984, 100:39-47.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kleinman ME, Chameides L, Schexnayder SM, et al, &ldquo;Part 14: Pediatric Advanced Life Support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 122(18 Suppl 3):876-908.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/25/27031/abstract-text/20956230/pubmed\" id=\"20956230\" target=\"_blank\">",
"        20956230",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lucas MJ, Leveno KJ, and Cunningham FG, &ldquo;A Comparison of Magnesium Sulfate With Phenytoin for the Prevention of Eclampsia,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1995, 333(4):201-5.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mirtallo J, Canada T, Johnson D, et al, &ldquo;Safe Practices for Parenteral Nutrition,&rdquo;",
"      <i>",
"       JPEN J Parenter Enteral Nutr",
"      </i>",
"      , 2004, 28(6):39-70.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Asthma Education and Prevention Program Coordinating Committee, &ldquo;Expert Panel Report 3 (EPR 3): Guidelines for the Diagnosis and Management of Asthma,&rdquo; 2007.  Available online at",
"      <a href=\"file://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm\" target=\"_blank\">",
"       file://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm",
"      </a>",
"      . Last accessed October 8, 2007.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Neumar RW, Otto CW, Link MS, et al, &ldquo;Part 8: Adult Advanced Cardiovascular Life Support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 122(18 Suppl 3):729-67.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/25/27031/abstract-text/20956224/pubmed\" id=\"20956224\" target=\"_blank\">",
"        20956224",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nichols B, &ldquo;Minerals,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , Norwalk, CT: Appleton &amp; Lange, 1987, 176-7.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Osada H, Watanabe Y, Nishimura Y, et al, \"Profile of Trace Element Concentrations in the Feto-placental Unit in Relation to Fetal Growth,\"",
"      <i>",
"       Acta Obstet Gynecol Scand",
"      </i>",
"      , 2002, 81(10):931-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/25/27031/abstract-text/12366483/pubmed\" id=\"12366483\" target=\"_blank\">",
"        12366483",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Reeves SA, Gibbs RS, and Clark SL, \"Magnesium for Fetal Neuroprotection,\"",
"      <i>",
"       Am J Obstet Gynecol",
"      </i>",
"      , 2011, 204(3):202.1-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/25/27031/abstract-text/21376159/pubmed\" id=\"21376159\" target=\"_blank\">",
"        21376159",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vissers R and Purssell R, &ldquo;Iatrogenic Intravenous Magnesium Overdose Causing Cardiac Arrest,&rdquo;",
"      <i>",
"       J Toxicol Clin Toxicol",
"      </i>",
"      , 1995, 33(5):489.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Worthley LT, &ldquo;Lithium Toxicity and Refractory Cardiac Arrhythmia Treated With Intravenous Magnesium,&rdquo;",
"      <i>",
"       Anaesth Intensive Care",
"      </i>",
"      , 1974, 4:357-60.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9585 Version 43.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-118.195.65.247-FCC50AAECF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_25_27031=[""].join("\n");
var outline_f26_25_27031=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191096\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191085\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191093\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191086\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191087\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16317811\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191066\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191050\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191070\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191102\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191069\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5358578\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191104\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191094\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191073\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191054\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299640\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191059\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4104770\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191062\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3013521\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3013523\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3013524\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191076\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191064\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191067\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4088911\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191053\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191072\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9585\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9585|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?13/3/13365?source=related_link\">",
"      Magnesium sulfate: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/29/34262?source=related_link\">",
"      Magnesium sulfate: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_25_27032="Pregnancy in women with a bicuspid aortic valve";
var content_f26_25_27032=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pregnancy in women with a bicuspid aortic valve",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/25/27032/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/25/27032/contributors\">",
"     Joseph K Perloff, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/25/27032/contributors\">",
"     Carol A Waksmonski, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/25/27032/contributors\">",
"     Michael R Foley, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/25/27032/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/25/27032/contributors\">",
"     Heidi M Connolly, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/25/27032/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/25/27032/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/25/27032/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/25/27032/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;It has been estimated that a bicuspid aortic valve is present in approximately 2 percent of the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?26/25/27032/abstract/1,2\">",
"     1,2",
"    </a>",
"    ] with a 4:1 male predominance [",
"    <a class=\"abstract\" href=\"UTD.htm?26/25/27032/abstract/2\">",
"     2",
"    </a>",
"    ]. A bicuspid aortic valve may be functionally normal or it may be stenotic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    regurgitant. Bicuspid aortic valve is the most common cause of isolated valvular aortic stenosis (AS) in adults and the most common cause of isolated aortic regurgitation (AR). In addition, dilation of the ascending aorta is likely to be present independent of valvular dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?26/25/27032/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/1/6169?source=see_link\">",
"     \"Clinical manifestations and diagnosis of bicuspid aortic valve\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/9/38039?source=see_link\">",
"     \"Pathophysiology, clinical features, and evaluation of chronic aortic regurgitation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Issues related to pregnancy in women with a bicuspid aortic valve, according to the function of the valve and the size of the aorta, will be reviewed here. Other issues related to the management of bicuspid AS and AR and general principles of congenital heart disease in pregnancy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/58/7078?source=see_link\">",
"     \"Treatment of bicuspid aortic valve stenosis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/29/25050?source=see_link\">",
"     \"Course and management of chronic aortic regurgitation in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/7/29818?source=see_link\">",
"     \"Pregnancy in women with congenital heart disease: General principles\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DETECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A bicuspid aortic valve is generally detected by echocardiography performed to evaluate a murmur (of AS",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    AR), an ejection click, or for other indications. However, an isolated, functionally normal bicuspid aortic valve is likely to go unrecognized in women of child-bearing age since auscultatory signs are often inconspicuous or unrecognized [",
"    <a class=\"abstract\" href=\"UTD.htm?26/25/27032/abstract/4\">",
"     4",
"    </a>",
"    ]. Rarely, a bicuspid aortic valve is first identified during pregnancy because of dissection of the ascending aorta [",
"    <a class=\"abstract\" href=\"UTD.htm?26/25/27032/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/1/6169?source=see_link\">",
"     \"Clinical manifestations and diagnosis of bicuspid aortic valve\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H5\">",
"     'Aortic aneurysm and dissection'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     COUNSELING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with a bicuspid aortic valve should receive counseling regarding potential risks and treatments prior to and during pregnancy. Potential risks that should be discussed include heritable congenital heart disease, aortic enlargement or dissection, and complications of AS",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    AR.",
"   </p>",
"   <p>",
"    The specific role of counseling in women with aortic dilation is discussed below (see",
"    <a class=\"local\" href=\"#H7\">",
"     'Counseling on aortic dilatation'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     HERITABILITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bicuspid aortic valve is heritable in some families [",
"    <a class=\"abstract\" href=\"UTD.htm?26/25/27032/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. The frequency of bicuspid aortic valve in first-degree relatives was assessed in a study of 30 consecutive patients with bicuspid aortic valve and 190 (91 percent) of 210 first-degree relatives who underwent echocardiography [",
"    <a class=\"abstract\" href=\"UTD.htm?26/25/27032/abstract/6\">",
"     6",
"    </a>",
"    ]. Bicuspid aortic valve was found in 9 percent of first-degree relatives, and 11 of the 30 families had at least one additional member with this lesion.",
"   </p>",
"   <p>",
"    On the basis of such findings, the 2008",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    adult congenital heart disease guidelines recommend echocardiographic screening for bicuspid aortic valve in first-degree relatives [",
"    <a class=\"abstract\" href=\"UTD.htm?26/25/27032/abstract/8\">",
"     8",
"    </a>",
"    ]. We agree with this recommendation.",
"   </p>",
"   <p>",
"    Bicuspid aortic valve is highly associated with congenital abnormalities of the aorta (coarctation of the aorta and patent ductus arteriosus) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/25/27032/abstract/2\">",
"     2",
"    </a>",
"    ]. In a literature review, fetal congenital heart disease occurred in 5 of 121 pregnancies (4.1 percent) in women with congenital AS [",
"    <a class=\"abstract\" href=\"UTD.htm?26/25/27032/abstract/9\">",
"     9",
"    </a>",
"    ]. We suggest fetal ultrasound when the mother has bicuspid aortic valve. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Clinical significance'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/54/4968?source=see_link\">",
"     \"Prenatal sonographic diagnosis of fetal cardiac anomalies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     AORTIC ANEURYSM AND DISSECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnant women with bicuspid aortic valve associated with aortic dilatation are at risk for spontaneous aortic dissection, usually in the third trimester [",
"    <a class=\"abstract\" href=\"UTD.htm?26/25/27032/abstract/10\">",
"     10",
"    </a>",
"    ], especially if there is an associated aortic coarctation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/25/27032/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A literature review of 61 women with pre- or post-partum aortic dissection (including four with bicuspid aortic valve and prepartum type A [ascending] aortic dissection) reported that aortic root enlargement &gt;40 mm",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    an increase in aortic root size during pregnancy were risk factors for type A dissection [",
"    <a class=\"abstract\" href=\"UTD.htm?26/25/27032/abstract/11\">",
"     11",
"    </a>",
"    ]. Maternal and fetal mortality rates associated with type A dissection declined between 1983 and 2002. Maternal mortality rates ranged from 25 to 30 percent from 1983 to 1994 and then declined to 0 percent from 1995 to 2002. Fetal mortality rates ranged from 38 to 50 percent from 1983 to 1994 and declined to 10 percent from 2000 to 2002. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/19/25914?source=see_link\">",
"     \"Clinical manifestations and diagnosis of aortic dissection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/54/25449?source=see_link\">",
"     \"Management of aortic dissection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The predisposition to ascending aortic dissection among patients with a bicuspid aortic valve reflects an inherent abnormality of the ascending aortic media [",
"    <a class=\"abstract\" href=\"UTD.htm?26/25/27032/abstract/5,12\">",
"     5,12",
"    </a>",
"    ]. The development of aortic root",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ascending aorta enlargement is independent of whether the bicuspid aortic valve is functionally normal, stenotic, or regurgitant. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/1/6169?source=see_link\">",
"     \"Clinical manifestations and diagnosis of bicuspid aortic valve\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pregnancy-associated increases in heart rate, blood pressure, and stroke volume result in increased aortic stress, which may promote aortic dilation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    dissection. It has not been established whether pregnancy also exacerbates intrinsic aortic structural changes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20105?source=see_link\">",
"     \"Maternal cardiovascular and hemodynamic adaptations to pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with bicuspid aortic valve should undergo transthoracic echocardiography to assess aortic root and ascending aorta size as well as the aortic valve [",
"    <a class=\"abstract\" href=\"UTD.htm?26/25/27032/abstract/10,13\">",
"     10,13",
"    </a>",
"    ]. In addition, we agree with the recommendation in the 2010",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    thoracic aortic disease guidelines that all pregnant women with thoracic aortic dilatation should undergo monthly or bimonthly echocardiographic measurement of the ascending aortic dimensions until delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?26/25/27032/abstract/13\">",
"     13",
"    </a>",
"    ]. Magnetic resonance imaging, rather than computed tomography, is recommended for imaging of the aortic arch, descending, and abdominal aortic dilatation to avoid maternal and fetal radiation exposure. Transesophageal echocardiography is another option for thoracic aortic imaging. Measurements of aortic size will vary depending on the technique used and some recommend correction for age and body surface area.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Counseling on aortic dilatation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2008",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    adult congenital heart disease guidelines recommend that women with bicuspid aortic valve and ascending aortic diameter greater than 45 mm should be counseled about the high risks of pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/25/27032/abstract/8\">",
"     8",
"    </a>",
"    ]. There are no definite recommendations for a threshold aortic size beyond which women with bicuspid aortic valves should be counseled against pregnancy.",
"   </p>",
"   <p>",
"    This is in contrast to the presence of specific",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    and ESC recommendations for pregnancy in women with Marfan syndrome, another disorder associated with aortic dilation and dissection. Enlargement of the aortic root to greater than 40 mm identifies a particularly high-risk group among Marfan syndrome patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/50/20262?source=see_link\">",
"     \"Pregnancy and Marfan syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;A threshold for prophylactic preconception aortic root or ascending aorta surgery has not been established for women with bicuspid aortic valve. In the general population, repair of the aortic root or replacement of the ascending aorta is indicated if the aortic root and ascending aorta diameter is greater than 50 mm or the rate of increase is &ge;5 mm per year. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/58/7078?source=see_link&amp;anchor=H10#H10\">",
"     \"Treatment of bicuspid aortic valve stenosis in adults\", section on 'Valve and aortic root replacement'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Given the risk of aortic dissection in patients with aortic dilatation and bicuspid aortic valve, some have advocated a lower threshold of 40 mm for prophylactic repair prior to pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/25/27032/abstract/11\">",
"     11",
"    </a>",
"    ]. The 2010",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    thoracic aortic guidelines note that prophylactic aortic root or ascending aorta surgery may be considered if aortic dilatation is progressive",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    there is worsening aortic regurgitation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/25/27032/abstract/13\">",
"     13",
"    </a>",
"    ]. For women planning pregnancy prophylactic aortic root or ascending aorta surgery should be considered if the aortic diameter is &gt;45mm, the rate of increase in diameter is &ge;5",
"    <span class=\"nowrap\">",
"     mm/year",
"    </span>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    there is worsening aortic regurgitation (AR).",
"   </p>",
"   <p>",
"    As recommended in the 2010",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    thoracic aortic guidelines, all pregnant women with thoracic aortic dilatation should maintain strict blood pressure control to prevent stage 2 hypertension (&ge;160 mmHg systolic or &ge;100 mmHg diastolic) (",
"    <a class=\"graphic graphic_table graphicRef72683 \" href=\"UTD.htm?34/41/35484\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?26/25/27032/abstract/13\">",
"     13",
"    </a>",
"    ]. Angiotensin converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) are",
"    <strong>",
"     contraindicated",
"    </strong>",
"    during pregnancy (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13434?source=see_link\">",
"     \"Management of hypertension in pregnant and postpartum women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1543?source=see_link\">",
"     \"Angiotensin converting enzyme inhibitors and receptor blockers in pregnancy\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    For patients with bicuspid aortic valves, the 2008 focused update of the 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    valve disease guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?26/25/27032/abstract/10\">",
"     10",
"    </a>",
"    ] and the 2008",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    adult congenital heart disease guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?26/25/27032/abstract/8\">",
"     8",
"    </a>",
"    ] concluded that is it reasonable to administer beta blockers in patients with a bicuspid aortic valve and aortic dilatation, which was defined as greater than 40 mm in patients with less than moderate aortic regurgitation.",
"   </p>",
"   <p>",
"    The guidelines did not address the issue of beta blockers in pregnancy in patients with a bicuspid aortic valve [",
"    <a class=\"abstract\" href=\"UTD.htm?26/25/27032/abstract/8\">",
"     8",
"    </a>",
"    ]. However, they did conclude that beta blockers should be given to all pregnant patients with Marfan syndrome. In the absence of specific data, we suggest beta blocker use in pregnant women with bicuspid aortic valve and a dilated aorta. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/50/20262?source=see_link\">",
"     \"Pregnancy and Marfan syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Recommendations for fetal delivery are discussed below (see",
"    <a class=\"local\" href=\"#H21\">",
"     'Delivery'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     BICUSPID AORTIC STENOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Clinical significance",
"    </span>",
"    &nbsp;&mdash;&nbsp;In developed countries, aortic stenosis (AS) in women of child-bearing age is primarily due to a congenital bicuspid aortic valve. A unicuspid valve is much less common and is likely to be stenotic in early life. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/1/6169?source=see_link\">",
"     \"Clinical manifestations and diagnosis of bicuspid aortic valve\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The increased cardiac output of pregnancy in a woman with congenital bicuspid AS adds volume overload to an already pressure-loaded left ventricle [",
"    <a class=\"abstract\" href=\"UTD.htm?26/25/27032/abstract/14\">",
"     14",
"    </a>",
"    ]. Mild to moderate bicuspid AS (",
"    <a class=\"graphic graphic_table graphicRef65280 \" href=\"UTD.htm?17/33/17948\">",
"     table 2",
"    </a>",
"    ) is well tolerated during pregnancy because left ventricular systolic function is generally preserved and the left ventricular ejection fraction (LVEF) is usually above normal [",
"    <a class=\"abstract\" href=\"UTD.htm?26/25/27032/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20105?source=see_link\">",
"     \"Maternal cardiovascular and hemodynamic adaptations to pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A literature review of studies published between 1985 and 2007 reported rates of complications during completed (&gt;20 weeks gestation) pregnancies among women with congenital AS (combined repaired and unrepaired) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/25/27032/abstract/9\">",
"     9",
"    </a>",
"    ]. A major limitation of the following data is that outcomes were not stratified according to the severity of AS:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      With respect to the mother, arrhythmias occurred in 4 of 168 pregnancies (2.4 percent), heart failure in 14 of 200 pregnancies (7 percent), and cardiovascular events (myocardial infarction, stroke, cardiovascular mortality) in 5 of 200 pregnancies (2.5 percent).",
"     </li>",
"     <li>",
"      With respect to the fetus",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Premature delivery occurred in 12 of 145 pregnancies (8.3 percent), fetal mortality in none of 158 pregnancies, and perinatal mortality in 1 of 158 pregnancies (0.6 percent). These numbers were not significantly different from expected rates in the general obstetrical population.",
"     </li>",
"     <li>",
"      The prevalence of fetal congenital heart disease was increased, occurring in 5 of 121 pregnancies (4.1 percent). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/7/29818?source=see_link&amp;anchor=H31#H31\">",
"       \"Pregnancy in women with congenital heart disease: General principles\", section on 'Inheritance'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2008 focused update of the 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines identified two risk factors for high maternal",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fetal risk in pregnant women with AS [",
"    <a class=\"abstract\" href=\"UTD.htm?26/25/27032/abstract/10\">",
"     10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Severe AS (",
"      <a class=\"graphic graphic_table graphicRef65280 \" href=\"UTD.htm?17/33/17948\">",
"       table 2",
"      </a>",
"      ), with or without symptoms such as dyspnea, syncope, or angina",
"     </li>",
"     <li>",
"      Left ventricular ejection fraction less than 40 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The importance of aortic abnormalities is discussed above. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Aortic aneurysm and dissection'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Data quantifying maternal and fetal risk of pregnancy in women with these high-risk features are limited. Heart failure during pregnancy with severe AS was reported in three of three patients in one series [",
"    <a class=\"abstract\" href=\"UTD.htm?26/25/27032/abstract/16\">",
"     16",
"    </a>",
"    ] and in two of twelve patients in another, with one requiring aortic valve replacement at the end of the first trimester [",
"    <a class=\"abstract\" href=\"UTD.htm?26/25/27032/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     AS treatment prior to pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2008",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    adult congenital heart disease guidelines recommend prepregnancy counseling for women with AS who are contemplating pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/25/27032/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We recommend that patients with bicuspid AS with symptoms",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    risk factors (severe AS",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    left ventricular ejection fraction less than 40 percent) be advised to delay conception until the AS has been addressed. This recommendation is consistent with the 2008 focused update of the 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    valve disease guidelines recommendation to advise delaying conception for AS patients with moderate to severe obstruction or symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?26/25/27032/abstract/10\">",
"     10",
"    </a>",
"    ]. In comparison, the 2009 Canadian Cardiovascular Society consensus conference recommended delayed conception only for women with symptomatic AS [",
"    <a class=\"abstract\" href=\"UTD.htm?26/25/27032/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some young women with congenital AS can be treated with percutaneous aortic balloon valvotomy (PABV), which reduces the transvalvular gradient but does not affect the risk of ascending aorta complications. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/58/7078?source=see_link&amp;anchor=H9#H9\">",
"     \"Treatment of bicuspid aortic valve stenosis in adults\", section on 'Balloon valvotomy in young adults'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    valve disease guidelines included recommendations for the use of PABV for AS in adolescents and young adults in a variety of settings (",
"    <a class=\"graphic graphic_table graphicRef51270 \" href=\"UTD.htm?6/35/6716\">",
"     table 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?26/25/27032/abstract/10\">",
"     10",
"    </a>",
"    ]. For asymptomatic women who want to become pregnant, PABV was considered reasonable if they have minimally calcified valves and are less than 30 years of age. Selected patients over 30 years of age who have minimally calcified valves may also benefit from PABV. This is a potentially important issue in women planning pregnancy, since PABV has limited efficacy and an appreciable complication rate in older adults. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/8/31881?source=see_link\">",
"     \"Indications for valve replacement in aortic stenosis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among patients with a repaired bicuspid aortic valve, the risk of pregnancy is lowest when the mean valve gradient is &le;25 mmHg and left ventricular function is normal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     AS treatment during pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a woman with bicuspid AS presents early in pregnancy with severe AS",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a left ventricular ejection fraction below 40 percent, some experts suggest termination of pregnancy followed by reparative surgery before another attempt at pregnancy. The magnitude of risk should be explained to the patient, although data are limited. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Risk factors'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Alternatively, pregnant women with severe AS who have no or only mild symptoms can often be managed conservatively with bed rest, beta blockers, and oxygen, if needed [",
"    <a class=\"abstract\" href=\"UTD.htm?26/25/27032/abstract/10\">",
"     10",
"    </a>",
"    ]. Intervention during pregnancy is recommended only for refractory NYHA class III or IV symptoms (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    When women with severe AS develop major symptoms during pregnancy, case reports suggest that balloon valvotomy can reduce the risks of gestation, labor, and delivery and avoid the risks of valve replacement [",
"    <a class=\"abstract\" href=\"UTD.htm?26/25/27032/abstract/19-22\">",
"     19-22",
"    </a>",
"    ]. However, even in experienced hands, balloon valvotomy can induce aortic regurgitation, recurrent stenosis is common within 6 to 12 months and the ascending aorta still harbors an abnormal media. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/31/39411?source=see_link\">",
"     \"Percutaneous aortic valvotomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     BICUSPID AORTIC REGURGITATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although data are scant, moderate or severe chronic bicuspid aortic regurgitation (AR) is generally well tolerated during pregnancy if left ventricular function and functional reserve are preserved [",
"    <a class=\"abstract\" href=\"UTD.htm?26/25/27032/abstract/23\">",
"     23",
"    </a>",
"    ]. The more rapid heart rate of pregnancy shortens diastole; this change coupled with the gestational fall in systemic vascular resistance reduces regurgitant flow.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     AR treatment prior to pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Asymptomatic women with moderate or severe AR with normal left ventricular function without established indications for valve replacement should",
"    <strong>",
"     not",
"    </strong>",
"    have prophylactic valve surgery before pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/25/27032/abstract/10,24\">",
"     10,24",
"    </a>",
"    ]. Data are limited but clinical observations and hemodynamic considerations suggest that such patients do well during pregnancy so the risk associated with prophylactic valve replacement is not warranted. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/29/25050?source=see_link\">",
"     \"Course and management of chronic aortic regurgitation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     AR treatment during pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    valve disease guidelines note that isolated AR can usually be managed medically during pregnancy with diuretics and, if necessary, vasodilators [",
"    <a class=\"abstract\" href=\"UTD.htm?26/25/27032/abstract/10\">",
"     10",
"    </a>",
"    ]. Angiotensin converting enzyme inhibitors and angiotensin II receptor blockers are contraindicated because of their adverse effects on fetal development. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1543?source=see_link\">",
"     \"Angiotensin converting enzyme inhibitors and receptor blockers in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Aortic valve replacement for AR should be considered only for control of refractory NYHA functional class III or IV symptoms (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"     table 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?26/25/27032/abstract/10\">",
"     10",
"    </a>",
"    ]. General recommendations for aortic valve replacement based on LV cavity size do not apply to pregnant patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/7/29818?source=see_link&amp;anchor=H13#H13\">",
"     \"Pregnancy in women with congenital heart disease: General principles\", section on 'Cardiac surgery during pregnancy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SURGERY PRIOR TO OR DURING PREGNANCY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Risks",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac surgery should be",
"    <strong>",
"     avoided",
"    </strong>",
"    during pregnancy whenever possible. The maternal risks are similar to those in nonpregnant women, but cardiopulmonary bypass during pregnancy incurs risks for the fetus. These issues are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/7/29818?source=see_link&amp;anchor=H13#H13\">",
"     \"Pregnancy in women with congenital heart disease: General principles\", section on 'Cardiac surgery during pregnancy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, preconception aortic valve replacement is recommended for symptomatic or high-risk patients with bicuspid aortic stenosis (AS) who are not candidates for percutaneous aortic valvotomy. Prophylactic aortic root or ascending aorta surgery should be considered if aortic dilatation is progressive (&ge;5",
"    <span class=\"nowrap\">",
"     mm/y),",
"    </span>",
"    if aortic diameter is &gt;45mm",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    there is worsening aortic regurgitation (AR). (See",
"    <a class=\"local\" href=\"#H12\">",
"     'AS treatment prior to pregnancy'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H8\">",
"     'Management'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    During pregnancy, aortic valve replacement is indicated in patients with NYHA class III or IV HF with bicuspid AS (if valvotomy is not an option) or refractory NYHA class III or IV HF (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"     table 4",
"    </a>",
"    ) and bicuspid AR. Type A aortic dissection is an indication for immediate aortic root or ascending aorta surgery and fetal and maternal risks are significant. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'AS treatment during pregnancy'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H16\">",
"     'AR treatment during pregnancy'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/54/25449?source=see_link\">",
"     \"Management of aortic dissection\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H5\">",
"     'Aortic aneurysm and dissection'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Timing and choice of valve",
"    </span>",
"    &nbsp;&mdash;&nbsp;If indications for aortic valve surgery are present, preconception (or postpartum) surgery is preferred to surgery during pregnancy given the fetal risks of surgery.",
"   </p>",
"   <p>",
"    If surgery must be performed during pregnancy, most perinatal and neonatal experts recommend surgical intervention during the second trimester to avoid the teratogenic risks of the first trimester and the third trimester risk of iatrogenic premature delivery. In certain situations it may be preferable to delay surgery until the fetus is viable.",
"   </p>",
"   <p>",
"    Aortic valve replacement is often required in symptomatic women with valve calcification or unfavorable anatomy. The choices are a bioprosthetic valve, a homograft valve, a pulmonary autograft (Ross procedure), and a mechanical valve [",
"    <a class=\"abstract\" href=\"UTD.htm?26/25/27032/abstract/10,25\">",
"     10,25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/37/11865?source=see_link&amp;anchor=H2#H2\">",
"     \"Surgical valve replacement in aortic stenosis in adults\", section on 'Choice of valve'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/53/1882?source=see_link\">",
"     \"Management of pregnant women with prosthetic heart valves\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    valve disease guidelines concluded that the usefulness of implantation of a bioprosthetic aortic valve in women of child-bearing age is not well established (",
"    <a class=\"graphic graphic_table graphicRef63902 \" href=\"UTD.htm?9/61/10204\">",
"     table 5",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?26/25/27032/abstract/10\">",
"     10",
"    </a>",
"    ]. Although anticoagulation is not required for bioprosthetic valves in the absence of accompanying risk factors, there is a high rate of structural failure, which may exceed 60 percent at 15 years in younger patients. The failure rate may not be as high for newer generation bioprosthetic valves. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/57/25497?source=see_link&amp;anchor=H5#H5\">",
"     \"Complications of prosthetic heart valves\", section on 'Structural failure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another surgical option is the Ross procedure that replaces the aortic valve with the patient's own pulmonary valve, and replaces the pulmonary valve with a homograft. The advantage of this procedure is that anticoagulation, with its attendant fetal risks, is not required. However, cardiovascular complications are common after the Ross procedure, and reoperation is often required involving one or both valves. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/37/11865?source=see_link&amp;anchor=H13#H13\">",
"     \"Surgical valve replacement in aortic stenosis in adults\", section on 'Pulmonary autograft (Ross procedure)'",
"    </a>",
"    .) and (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/46/18153?source=see_link\">",
"     \"Anticoagulation during pregnancy\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The efficacy of the Ross procedure was evaluated in eight non-anticoagulated women who had 14 pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?26/25/27032/abstract/25\">",
"     25",
"    </a>",
"    ]. There were no maternal deaths, no thromboembolic or hemorrhagic events, and no evidence of deterioration of valve function.",
"   </p>",
"   <p>",
"    The least satisfactory option in anticipation of pregnancy is valve replacement with a mechanical prosthesis because of the need for anticoagulation.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     Warfarin",
"    </a>",
"    crosses the placenta; therapy between 6 and 12 weeks of gestation is associated with a risk of embryopathy and later in gestation may increase the risk of fetal bleeding and fetal loss.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     Heparin",
"    </a>",
"    does not cross the placenta but therapeutic levels are difficult to maintain with subcutaneous dosing, leading to an increased rate of valve thrombosis. Low-molecular weight heparin with regular monitoring of antifactor Xa levels may provide the best protection against valve thrombosis. However the efficacy of low molecular weight heparin in patients with mechanical valve prostheses has not been established. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/53/1882?source=see_link&amp;anchor=H10#H10\">",
"     \"Management of pregnant women with prosthetic heart valves\", section on 'Anticoagulation during pregnancy for women with mechanical heart valves'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/46/18153?source=see_link\">",
"     \"Anticoagulation during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     DELIVERY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Mode of delivery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Controlled vaginal delivery is preferable in the majority of patients. As indicated in the 2008",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    adult congenital heart disease guidelines, cesarean delivery is recommended only for obstetric indications or in the presence of severe cardiovascular disease such as aortic aneurysm, dissection or critical AS (because intrapartum increases in cardiac output related to contractions may significantly increase the risk of a cardiac event) or in the setting of ongoing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    anticoagulation (to reduce the risk of delivery-related intracranial bleeding in the newborn) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/25/27032/abstract/8\">",
"     8",
"    </a>",
"    ]. The 2010",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    thoracic aortic disease guidelines suggest that cesarean delivery is reasonable for patients with significant aortic enlargement, dissection, or severe aortic valve regurgitation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/25/27032/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Delivery at a center experienced with high-risk heart disease is recommended for patients with greater than mild AS [",
"    <a class=\"abstract\" href=\"UTD.htm?26/25/27032/abstract/8\">",
"     8",
"    </a>",
"    ] or dilated aortic diameter (&gt;40mm). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/36/3657?source=see_link\">",
"     \"Obstetric anesthetic management of women with acquired or congenital heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Endocarditis prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;According to the 2007 American Heart Association guidelines on prevention on infective endocarditis, a bicuspid aortic valve is not considered a lesion requiring endocarditis prophylaxis unless it has been treated with valve replacement [",
"    <a class=\"abstract\" href=\"UTD.htm?26/25/27032/abstract/26\">",
"     26",
"    </a>",
"    ]. This recommendation has been questioned by some. In addition, uncomplicated vaginal or cesarean delivery is not considered an indication for antibiotic prophylaxis. Nevertheless, endocarditis prophylaxis may be considered in women with the highest risk cardiac substrates, such as those with a prosthetic aortic valve [",
"    <a class=\"abstract\" href=\"UTD.htm?26/25/27032/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/36/585?source=see_link\">",
"     \"Antimicrobial prophylaxis for bacterial endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Women with a bicuspid aortic valve should receive counseling prior to and during pregnancy. Potential risks should be discussed including heritable congenital heart disease, aortic dissection (particularly if the ascending aortic diameter is &gt;45 mm), and complications of aortic stenosis (AS)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      aortic regurgitation (AR). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Counseling'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All patients with bicuspid aortic valve should undergo preconception transthoracic echocardiography to assess ascending aorta size. In addition, we recommend that patients with bicuspid aortic valve undergo echocardiographic aortic imaging during pregnancy. If the aorta is dilated, we recommend monthly or bimonthly serial echocardiographic imaging during pregnancy. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Imaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with bicuspid aortic valve who are planning pregnancy, we suggest pre-conception aortic root or ascending aorta surgery if the aortic diameter is &gt;45 mm, the rate of increase is &ge;5 mm per year, or there is worsening aortic regurgitation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All pregnant women with bicuspid aortic valve and thoracic aortic dilatation should maintain strict blood pressure control to prevent Stage II hypertension. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For pregnant women with a bicuspid aortic valve and aortic root diameter &gt;40 mm who do not have moderate or severe AR, we suggest beta blocker therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Women with symptomatic bicuspid AS",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      high-risk features (severe AS or LVEF less than 40 percent) should be counseled to delay of conception until the AS has been addressed. Potential options include percutaneous aortic valvotomy (if the valve is suitable) or aortic valve replacement. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'AS treatment prior to pregnancy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Moderate or severe chronic bicuspid AR with preserved left ventricular function is generally well tolerated during pregnancy.",
"     </li>",
"     <li>",
"      Surgery during pregnancy should generally be avoided due to significant fetal risks although it is indicated if there is severely symptomatic aortic valve disease and if valvotomy is not an option to treat AS (see",
"      <a class=\"local\" href=\"#H17\">",
"       'Surgery prior to or during pregnancy'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Controlled vaginal delivery is preferable in the majority of patients. Cesarean delivery is recommended only for obstetric indications or in the presence of severe cardiovascular disease such as aortic dissection, severe AR or critical AS or in the setting of ongoing anticoagulation (to reduce the risk of delivery-related intracranial bleeding in the newborn).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27032/abstract/1\">",
"      Roberts WC. The congenitally bicuspid aortic valve. A study of 85 autopsy cases. Am J Cardiol 1970; 26:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27032/abstract/2\">",
"      Fedak PW, Verma S, David TE, et al. Clinical and pathophysiological implications of a bicuspid aortic valve. Circulation 2002; 106:900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27032/abstract/3\">",
"      Keane MG, Wiegers SE, Plappert T, et al. Bicuspid aortic valves are associated with aortic dilatation out of proportion to coexistent valvular lesions. Circulation 2000; 102:III35.",
"     </a>",
"    </li>",
"    <li>",
"     Perloff, JK. The Clinical Recognition of Congenital Heart Disease, 6th ed, Elsevier/Saunders, Philadelphia 2012.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27032/abstract/5\">",
"      Anderson RA, Fineron PW. Aortic dissection in pregnancy: importance of pregnancy-induced changes in the vessel wall and bicuspid aortic valve in pathogenesis. Br J Obstet Gynaecol 1994; 101:1085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27032/abstract/6\">",
"      Huntington K, Hunter AG, Chan KL. A prospective study to assess the frequency of familial clustering of congenital bicuspid aortic valve. J Am Coll Cardiol 1997; 30:1809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27032/abstract/7\">",
"      Cripe L, Andelfinger G, Martin LJ, et al. Bicuspid aortic valve is heritable. J Am Coll Cardiol 2004; 44:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27032/abstract/8\">",
"      Warnes CA, Williams RG, Bashore TM, et al. ACC/AHA 2008 Guidelines for the Management of Adults with Congenital Heart Disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to develop guidelines on the management of adults with congenital heart disease). Circulation 2008; 118:e714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27032/abstract/9\">",
"      Drenthen W, Pieper PG, Roos-Hesselink JW, et al. Outcome of pregnancy in women with congenital heart disease: a literature review. J Am Coll Cardiol 2007; 49:2303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27032/abstract/10\">",
"      Bonow RO, Carabello BA, Chatterjee K, et al. 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2008; 118:e523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27032/abstract/11\">",
"      Immer FF, Bansi AG, Immer-Bansi AS, et al. Aortic dissection in pregnancy: analysis of risk factors and outcome. Ann Thorac Surg 2003; 76:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27032/abstract/12\">",
"      Tadros TM, Klein MD, Shapira OM. Ascending aortic dilatation associated with bicuspid aortic valve: pathophysiology, molecular biology, and clinical implications. Circulation 2009; 119:880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27032/abstract/13\">",
"      Hiratzka LF, Bakris GL, Beckman JA, et al. 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with Thoracic Aortic Disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine. Circulation 2010; 121:e266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27032/abstract/14\">",
"      Easterling TR, Chadwick HS, Otto CM, Benedetti TJ. Aortic stenosis in pregnancy. Obstet Gynecol 1988; 72:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27032/abstract/15\">",
"      Lao TT, Sermer M, MaGee L, et al. Congenital aortic stenosis and pregnancy--a reappraisal. Am J Obstet Gynecol 1993; 169:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27032/abstract/16\">",
"      Hameed A, Karaalp IS, Tummala PP, et al. The effect of valvular heart disease on maternal and fetal outcome of pregnancy. J Am Coll Cardiol 2001; 37:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27032/abstract/17\">",
"      Yap SC, Drenthen W, Pieper PG, et al. Risk of complications during pregnancy in women with congenital aortic stenosis. Int J Cardiol 2008; 126:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27032/abstract/18\">",
"      Silversides CK, Kiess M, Beauchesne L, et al. Canadian Cardiovascular Society 2009 Consensus Conference on the management of adults with congenital heart disease: outflow tract obstruction, coarctation of the aorta, tetralogy of Fallot, Ebstein anomaly and Marfan's syndrome. Can J Cardiol 2010; 26:e80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27032/abstract/19\">",
"      Task Force on the Management of Cardiovascular Diseases During Pregnancy of the European Society of Cardiology. Expert consensus document on management of cardiovascular diseases during pregnancy. Eur Heart J 2003; 24:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27032/abstract/20\">",
"      Banning AP, Pearson JF, Hall RJ. Role of balloon dilatation of the aortic valve in pregnant patients with severe aortic stenosis. Br Heart J 1993; 70:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27032/abstract/21\">",
"      McIvor RA. Percutaneous balloon aortic valvuloplasty during pregnancy. Int J Cardiol 1991; 32:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27032/abstract/22\">",
"      Lao TT, Adelman AG, Sermer M, Colman JM. Balloon valvuloplasty for congenital aortic stenosis in pregnancy. Br J Obstet Gynaecol 1993; 100:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27032/abstract/23\">",
"      Sheikh F, Rangwala S, DeSimone C, et al. Management of the parturient with severe aortic incompetence. J Cardiothorac Vasc Anesth 1995; 9:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27032/abstract/24\">",
"      Elkayam U, Bitar F. Valvular heart disease and pregnancy part I: native valves. J Am Coll Cardiol 2005; 46:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27032/abstract/25\">",
"      Dore A, Somerville J. Pregnancy in patients with pulmonary autograft valve replacement. Eur Heart J 1997; 18:1659.",
"     </a>",
"    </li>",
"    <li>",
"     Wilson W, Taubert KA, Gewitz M, et al. Prevention of Infective Endocarditis. Guidelines From the American Heart Association. A Guideline From the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation 2007; 115 published online April 19, 2007. www.circ.ahajournals.org/cgi/reprint/CIRCULATIONAHA.106.183095v1 (Accessed on May 04, 2007).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1425 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-47BF19C4B0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_25_27032=[""].join("\n");
var outline_f26_25_27032=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DETECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      COUNSELING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      HERITABILITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      AORTIC ANEURYSM AND DISSECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Counseling on aortic dilatation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      BICUSPID AORTIC STENOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Clinical significance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      AS treatment prior to pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      AS treatment during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      BICUSPID AORTIC REGURGITATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      AR treatment prior to pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      AR treatment during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SURGERY PRIOR TO OR DURING PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Risks",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Timing and choice of valve",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      DELIVERY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Mode of delivery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Endocarditis prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1425\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1425|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/41/35484\" title=\"table 1\">",
"      Classification and management of blood pressure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/33/17948\" title=\"table 2\">",
"      Severity of AS in adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/35/6716\" title=\"table 3\">",
"      BAV AS adolescents young adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/2/3117\" title=\"table 4\">",
"      Methods to assess cardiovascular disability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/61/10204\" title=\"table 5\">",
"      ACC AHA selection aortic valve",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1543?source=related_link\">",
"      Angiotensin converting enzyme inhibitors and receptor blockers in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/46/18153?source=related_link\">",
"      Anticoagulation during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/36/585?source=related_link\">",
"      Antimicrobial prophylaxis for bacterial endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/19/25914?source=related_link\">",
"      Clinical manifestations and diagnosis of aortic dissection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/1/6169?source=related_link\">",
"      Clinical manifestations and diagnosis of bicuspid aortic valve",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/57/25497?source=related_link\">",
"      Complications of prosthetic heart valves",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/29/25050?source=related_link\">",
"      Course and management of chronic aortic regurgitation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/8/31881?source=related_link\">",
"      Indications for valve replacement in aortic stenosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/54/25449?source=related_link\">",
"      Management of aortic dissection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13434?source=related_link\">",
"      Management of hypertension in pregnant and postpartum women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/53/1882?source=related_link\">",
"      Management of pregnant women with prosthetic heart valves",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20105?source=related_link\">",
"      Maternal cardiovascular and hemodynamic adaptations to pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/36/3657?source=related_link\">",
"      Obstetric anesthetic management of women with acquired or congenital heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/9/38039?source=related_link\">",
"      Pathophysiology, clinical features, and evaluation of chronic aortic regurgitation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/31/39411?source=related_link\">",
"      Percutaneous aortic valvotomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/50/20262?source=related_link\">",
"      Pregnancy and Marfan syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/7/29818?source=related_link\">",
"      Pregnancy in women with congenital heart disease: General principles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/54/4968?source=related_link\">",
"      Prenatal sonographic diagnosis of fetal cardiac anomalies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/37/11865?source=related_link\">",
"      Surgical valve replacement in aortic stenosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/58/7078?source=related_link\">",
"      Treatment of bicuspid aortic valve stenosis in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_25_27033="Ribavirin: Drug information";
var content_f26_25_27033=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ribavirin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?36/17/37142?source=see_link\">",
"    see \"Ribavirin: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/59/12216?source=see_link\">",
"    see \"Ribavirin: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709400\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F217944\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Copegus&reg;;",
"     </li>",
"     <li>",
"      Rebetol&reg;;",
"     </li>",
"     <li>",
"      Ribasphere&reg;;",
"     </li>",
"     <li>",
"      Ribasphere&reg; RibaPak&reg;;",
"     </li>",
"     <li>",
"      Virazole&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F217945\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Virazole&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F217983\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antiviral Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F217949\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Oral solution may be used those unable to swallow capsules.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chronic hepatitis C monoinfection (in combination with peginterferon alfa-2b):",
"     </b>",
"     <i>",
"      Oral capsule, oral solution (Rebetol&reg;, Ribasphere&reg;):",
"     </i>",
"     <b>",
"      Note:",
"     </b>",
"     Recommended therapy duration [manufacturer labeling]: Genotype 1: 48 weeks; genotypes 2,3: 24 weeks); recommended therapy duration for patients who previously failed therapy: 48 weeks [regardless of genotype])",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &le;65 kg: 800 mg daily (400 mg in the morning and evening)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     66-80 kg: 1000 mg daily (400 mg in the morning, 600 mg in the evening)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     81-105 kg: 1200 mg daily (600 mg in the morning, 600 mg in the evening)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &gt;105 kg: 1400 mg daily (600 mg in the morning, 800 mg in the evening)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Chronic hepatitis C monoinfection (in combination with interferon alfa-2b):",
"     </b>",
"     <i>",
"      Oral capsule (Rebetol&reg;, Ribasphere&reg;):",
"     </i>",
"     <b>",
"      Note:",
"     </b>",
"     Individualized therapy duration [manufacturer labeling] 24-48 weeks):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &le;75 kg: 1000 mg daily (400 mg in the morning, 600 mg in the evening)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &gt;75 kg: 1200 mg daily (600 mg in the morning, 600 mg in the evening)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Chronic hepatitis C monoinfection (in combination with peginterferon alfa-2a):",
"     </b>",
"     <i>",
"      Oral tablet (Copegus&reg;, Ribasphere&reg;):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genotype 1,4:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &lt;75 kg: 1000 mg daily in 2 divided doses for 48 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &ge;75 kg: 1200 mg daily in 2 divided doses for 48 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genotype 2,3: 800 mg daily in 2 divided doses for 24 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chronic hepatitis C coinfection with HIV (in combination with peginterferon alfa-2a):",
"     </b>",
"     <i>",
"      Oral tablet (Copegus&reg;, Ribasphere&reg;):",
"     </i>",
"     800 mg daily in 2 divided doses for 48 weeks (regardless of genotype)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Alternative recommendation:",
"      </i>",
"     </b>",
"     <i>",
"      American Association for the Study of Liver Diseases (AASLD) guidelines:",
"     </i>",
"     Adults with chronic hepatitis C infection (Ghany, 2009): Treatment of choice: Ribavirin plus peginterferon; clinical condition and ability of patient to tolerate therapy should be evaluated to determine length and/or likely benefit of therapy. Recommended treatment duration (AASLD guidelines): Genotypes 1,4: 48 weeks; Genotypes 2,3: 24 weeks; Coinfection with HIV: 48 weeks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      RSV infection in hematopoietic cell or heart/lung transplant recipients (unlabeled use):",
"     </b>",
"     <i>",
"      Aerosol inhalation:",
"     </i>",
"     2000 mg (over 2 hours) every 8 hours (Boeckh, 2007; Liu, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Heart/lung transplant recipients also received IVIG, methylprednisolone and palivizumab. Dosage and protocol may be institution specific. (Boeckh, 2007; Chemaly, 2006; Liu, 2010).",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F217968\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/59/12216?source=see_link\">",
"      see \"Ribavirin: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chronic hepatitis C monoinfection (in combination with pegylated or nonpegylated interferon alfa-2b):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &ge;3 years:",
"     <i>",
"      Oral capsule or solution (Rebetol&reg;, Ribasphere&reg;):",
"     </i>",
"     <b>",
"      Note:",
"     </b>",
"     Oral solution should be used in children &lt;47 kg, or those unable to swallow capsules. Children who start treatment prior to age 18 years  should continue on pediatric dosing regimen through therapy completion. Recommended therapy duration (manufacturer labeling): Genotypes 2,3: 24 weeks; all other genotypes: 48 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oral capsule, oral solution dosing recommendations:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &lt;47 kg: 15 mg/kg/day in 2 divided doses (morning and evening) as oral solution",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     47-59 kg: 800 mg daily (400 mg in morning and evening)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     60-73 kg: 1000 mg daily (400 mg in morning and 600 mg in the evening)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &gt;73 kg: 1200 mg daily (600 mg in morning and evening)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Alternative recommendations:",
"      </i>",
"     </b>",
"     <i>",
"      American Association for the Study of Liver Diseases (AASLD) guidelines:",
"     </i>",
"     Children 2-17 years  with chronic hepatitis C infection (Ghany, 2009): Treatment of choice: Ribavirin 15 mg/kg daily (in combination with SubQ peginterferon alfa-2b) once weekly for 48 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chronic hepatitis C monoinfection (in combination with peginterferon alfa-2a):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &ge;5 years:",
"     <i>",
"      Oral tablet (Copegus&reg;):",
"     </i>",
"     <b>",
"      Note:",
"     </b>",
"     Assess child&rsquo;s ability to swallow tablet; children who start treatment prior to age 18 years should continue on pediatric dosing regimen through therapy completion. Recommended therapy duration (manufacturer labeling): Genotypes 2,3: 24 weeks; all other genotypes: 48 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     23-33 kg: 400 mg daily (200 mg in the morning and evening)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     34-46 kg: 600 mg daily (200 mg in the morning and 400 mg in the evening)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     47-59 kg: 800 mg daily (400 mg in the morning and evening)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     60-74 kg: 1000 mg daily (400 mg in the morning and 600 mg in the evening)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &ge;75 kg: 1200 mg daily (600 mg in the morning and evening)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      RSV infection:",
"     </b>",
"     Infants and Children:",
"     <i>",
"      Aerosol inhalation:",
"     </i>",
"     Use with Viratek&reg; small particle aerosol generator (SPAG-2): A concentration of 20 mg/mL (6",
"     <b>",
"      g",
"     </b>",
"     reconstituted with 300 mL of sterile water without preservatives) administered for 12-18 hours/day for 3 days, up to 7 days in length.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F217950\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F217951\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      CHC infection:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Rebetol&reg; capsules/solution, Ribasphere&reg; capsules: Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;50 mL/minute: No dosage adjustments are recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/minute: Use is contraindicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Ribasphere&reg; tablets: Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;50 mL/minute: No dosage adjustments are recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/minute: Use is not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Copegus&reg; tablets: Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;50 mL/minute: No dosage adjustments are recommended.",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:6em;margin-right:2em;margin-top:0em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-50 mL/minute: Alternate 200 mg and 400 mg every other day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: 200 mg once daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     ESRD requiring hemodialysis: 200 mg once daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     The dose of Copegus&reg; should not be further modified in patients with renal impairment. If severe adverse reactions or laboratory abnormalities develop it should be discontinued, if appropriate, until the adverse reactions resolve or decrease in severity. If abnormalitis persist after restarting, therapy should be discontinued.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F5184988\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     CHC infection: Hepatic decompensation (Child-Pugh class B and C): Manufacturer&rsquo;s labeling: Oral tablets: Use contraindicated.",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F217984\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Patient",
"     <b>",
"      without",
"     </b>",
"     cardiac history:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hemoglobin &lt;10 g/dL:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &ge;3 years: Oral capsules, oral solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     First reduction: Decrease to 12 mg/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Second reduction: Decrease to 8 mg/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &ge;5 years: Oral tablets (Copegus&reg;):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     23-33 kg: Decrease dose to 200 mg daily (in the morning)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     34-59 kg: Decrease dose to 400 mg daily (200 mg in the morning and evening)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &ge;60 kg: Decrease dose to 600 mg daily (200 mg in the morning and 400 mg in the evening)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Oral capsules, oral solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     First reduction:  &le;105 kg: Decrease by 200 mg daily; &gt;105 kg: Decrease by 400 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Second reduction: Decrease by an additional 200 mg daily (not weight-based)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Oral tablets: Decrease dose to 600 mg daily (200 mg in the morning, 400 mg in the evening)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hemoglobin &lt;8.5 g/dL: Children and Adults: Oral capsules, solution, tablets: Permanently discontinue treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     WBC &lt;1000 mm",
"     <sup>",
"      3",
"     </sup>",
"     , neutrophils &lt;500 mm",
"     <sup>",
"      3",
"     </sup>",
"     : Children and Adults: Oral capsules, solution: Permanently discontinue treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Platelets &lt;50 x 10",
"     <sup>",
"      9",
"     </sup>",
"     /L: Children: Oral capsules, solution: Permanently discontinue treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Platelets &lt;25 x 10",
"     <sup>",
"      9",
"     </sup>",
"     /L: Adults: Oral capsules, solution: Permanently discontinue treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Creatinine (serum) &gt;2 mg/dL: Children: Oral capsules, solution: Permanently discontinue treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Patient",
"     <b>",
"      with",
"     </b>",
"     cardiac history:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hemoglobin has decreased &ge;2 g/dL during any 4-week period of treatment:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children: Oral capsules, solution: Weekly evaluation and hematologic testing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &ge;5 years: Oral tablets (Copegus&reg;):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     23-33 kg: Decrease dose to 200 mg daily (in the morning)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     34-59 kg: Decrease dose to 400 mg daily (200 mg in the morning and evening)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &ge;60 kg: 600 mg daily (200 mg in the morning, 400 mg in the evening)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hemoglobin has decreased &gt;2 g/dL during any 4-week period of treatment: Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oral capsules, solution: Decrease dose by 200 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oral tablets: 600 mg (200 mg in the morning, 400 mg in the evening)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hemoglobin &lt;12 g/dL after 4 weeks of reduced dose: Children and Adults: Oral capsules, solution, tablets: Permanently discontinue treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hemoglobin &lt;8.5 g/dL: Children and Adults: Oral capsules, solution, tablets: Permanently discontinue treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     WBC &lt;1000 mm",
"     <sup>",
"      3",
"     </sup>",
"     , neutrophils &lt;500 mm",
"     <sup>",
"      3",
"     </sup>",
"     : Children and Adults: Oral capsules, solution: Permanently discontinue treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Platelets &lt;50 x 10",
"     <sup>",
"      9",
"     </sup>",
"     /L: Children: Oral capsules, solution: Permanently discontinue treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Platelets &lt;25 x 10",
"     <sup>",
"      9",
"     </sup>",
"     /L: Adults: Oral capsules, solution: Permanently discontinue treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Creatinine (serum) &gt;2 mg/dL at any time during therapy: Children: Oral capsules, solution: Permanently discontinue treatment.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F217918\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral: 200 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rebetol&reg;: 200 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ribasphere&reg;: 200 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder for solution, for nebulization:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Virazole&reg;: 6 g [reconstituted product contains ribavirin 20 mg/mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rebetol&reg;: 40 mg/mL (100 mL) [contains propylene glycol, sodium benzoate; bubblegum flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 200 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Copegus&reg;: 200 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ribasphere&reg;: 200 mg, 400 mg, 600 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral [dose-pack]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ribasphere&reg; RibaPak&reg; 600: 200 mg AM dose, 400 mg PM dose (14s, 56s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ribasphere&reg; RibaPak&reg; 800: 400 mg AM dose, 400 mg PM dose (14s, 56s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ribasphere&reg; RibaPak&reg; 1000: 600 mg AM dose, 400 mg PM dose (14s, 56s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ribasphere&reg; RibaPak&reg; 1200: 600 mg AM dose, 600 mg PM dose (14s, 56s)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F217902\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Capsule, tablet",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874826\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Copegus&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088576.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088576.pdf",
"     </a>",
"     ,",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Rebetol&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089017.pdf%20\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089017.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ribasphere&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm111342.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm111342.pdf",
"     </a>",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F217920\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Inhalation: Ribavirin should be administered in well-ventilated rooms (at least 6 air changes/hour). In mechanically-ventilated patients, ribavirin can potentially be deposited in the ventilator delivery system depending on temperature, humidity, and electrostatic forces; this deposition can lead to malfunction or obstruction of the expiratory valve, resulting in inadvertently high positive end-expiratory pressures. The use of one-way valves in the inspiratory lines, a breathing circuit filter in the expiratory line, and frequent monitoring and filter replacement have been effective in preventing these problems. Solutions in SPAG-2 unit should be discarded at least every 24 hours and when the liquid level is low before adding newly reconstituted solution. Should not be mixed with other aerosolized medication.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Administer concurrently with interferon alfa injection. Capsule should not be opened, crushed, chewed, or broken. Use oral solution for children &lt;47 kg, or those who cannot swallow capsules.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Capsule, solution, tablet: Administer with food.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F217990\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhalation: Should not be mixed with other aerosolized medication.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F217919\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Inhalation: Treatment of hospitalized infants and young children  with respiratory syncytial virus (RSV) infections; specially indicated for treatment of severe lower respiratory tract RSV infections in patients with an underlying compromising condition (prematurity, cardiopulmonary disease, or immunosuppression)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral capsule: In combination with interferon alfa 2b (pegylated or nonpegylated) injection for the treatment of chronic hepatitis C in interferon alfa-naive  or experienced-patients with compensated liver disease. Patients likely to fail retreatment after a prior failed course include previous nonresponders, those who received previous pegylated interferon treatment, patients who have significant bridging fibrosis or cirrhosis, or those with genotype 1 infection.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral solution: In combination with interferon alfa-2b (pegylated or nonpegylated) injection for the treatment of chronic hepatitis C in interferon alfa-naive or experienced patients &ge;3 years of age with compensated liver disease. Patients likely to fail retreatment after a prior failed course include previous nonresponders, those who received previous pegylated interferon treatment, patients who have significant bridging fibrosis or cirrhosis, or those with genotype 1 infection.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral tablet: In combination with peginterferon alfa-2a (Pegasys&reg;) injection for the treatment of chronic hepatitis C in patients with compensated liver disease who were previously untreated with alpha interferons, and in adult chronic hepatitis C patients coinfected with HIV.",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F217979\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Inhalation: Treatment for RSV in adult hematopoietic stem cell or heart/lung  transplant recipients",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Used in other viral infections including influenza A and B and adenovirus",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F217991\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Ribavirin may be confused with riboflavin, rifampin, Robaxin&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F217981\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Inhalation:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fatigue, headache, insomnia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea, anorexia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Anemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Hypotension, cardiac arrest, digitalis toxicity, conjunctivitis, mild bronchospasm, worsening of respiratory function, apnea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Incidence of adverse effects (approximate) in healthcare workers: Headache (51%); conjunctivitis (32%); rhinitis, nausea, rash, dizziness, pharyngitis, and lacrimation (10% to 20%); bronchospasm and/or chest pain (case reports in individuals with underlying airway disease)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Oral",
"     </b>",
"     (all adverse reactions are documented while receiving combination therapy with alfa interferons; percentages as reported in adults unless noted, most common pediatric adverse reactions were similar to adults); asterisked (*) percentages are those similar to interferon therapy alone:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fatigue (60% to 70% [30% in pediatric patients])*, headache (43% to 66%)*, fever (32% to 55%)*, insomnia (26% to 41% [9% in pediatric patients]), depression (20% to 36%)*, irritability (23% to 33%), dizziness (14% to 26%), impaired concentration (10% to 21%)*, emotional lability (7% to 12%)*",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Alopecia (27% to 36% [17% in pediatric patients]), pruritus (13% to 29% [11% in pediatric patients]), rash (5% to 28%), dry skin (10% to 24%), dermatitis (&le;16%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine and metabolic: Growth suppression (pediatric) percentile decrease (&ge;15 percentiles: weight 43%; height 25%), hyperuricemia (33% to 38%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (25% to 47% [18% in pediatric patients]), anorexia (21% to 32%), weight decrease (10% to 29%), vomiting (9% to 25%)*, diarrhea (10% to 22%), dyspepsia (6% to 16%), abdominal pain (8% to 13%), xerostomia (&le;12%), RUQ pain (&le;12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Leukopenia (6% to 45%), neutropenia (8% to 42%; grade 4: 2% to 11%; 40% with HIV coinfection), hemoglobin decreased (11% to 35%), anemia (11% to 17%), thrombocytopenia (&lt;1% to 15%),  lymphopenia (12% to 14%), hemolytic anemia (10% to 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Bilirubin increase (10% to 32%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Myalgia (40% to 64% [17% in pediatric patients])*, rigors (25% to 48%), arthralgia (22% to 34%)*, musculoskeletal pain (19% to 28% [35% in pediatric patients])",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Upper respiratory tract infection (60% in pediatric patients), dyspnea  (13% to 26%), cough (7% to 23%), pharyngitis (&le;13%), sinusitis (&le;12%)*",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Flu-like syndrome (13% to 18% [up to 91% in pediatric patients])*, viral infection (&le;12%), diaphoresis (&le;11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Chest pain (5% to 9%)*, flushing (&le;4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Pain (&le;10%), mood alteration (&le;6%; 9% with HIV coinfection), agitation (5% to 8%), nervousness (6%)*, memory impairment (&le;6%), malaise (&le;6%), suicidal ideation (adolescents: 2%; adults: 1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Eczema (4% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Menstrual disorder (&le;7%), hypothyroidism (&le;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Taste perversion (4% to 9%), constipation (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Hepatomegaly (4%), transaminases increased (1% to 3%), hepatic decompensation (2% with HIV coinfection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (9% to 10%), back pain (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Blurred vision (&le;6%), conjunctivitis (&le;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Rhinitis (&le;8%), exertional dyspnea (&le;7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Fungal infection (&le;6%), bacterial infection (3% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Aggression, angina, anxiety, aplastic anemia, arrhythmia; autoimmune disorders (systemic lupus erythematosus, rheumatoid arthritis, sarcoidosis); bone marrow suppression, cerebral hemorrhage, cholangitis, colitis, coma, corneal ulcer, dehydration, diabetes mellitus, drug abuse relapse/overdose, exfoliative dermatitis, fatty liver, hearing impairment/loss, gastrointestinal bleeding, gout, hallucination, hepatic dysfunction, hyper-/hypothyroidism, hypersensitivity (including anaphylaxis, angioedema, bronchoconstriction, and urticaria), macular edema, myositis, optic neuritis, papilledema, pancreatitis, peptic ulcer, peripheral neuropathy, pneumonitis, psychosis, psychotic disorder, pulmonary dysfunction, pulmonary embolism, pulmonary infiltrates, pure red cell aplasia, retinal artery/vein thrombosis, retinal detachment, retinal hemorrhage, retinopathy, sarcoidosis exacerbation; skin reactions (erythema multiforme, exfoliative dermatitis, urticaria, vesiculobullous eruptions); Stevens-Johnson syndrome, suicide, thrombotic thrombocytopenic purpura, thyroid function test abnormalities; transplant rejection (kidney, liver); vision loss",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Incidence of headache, fever, suicidal ideation, and vomiting are higher in children.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F217923\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;margin-top:0em;text-align:justify;\">",
"     Inhalation: Hypersensitivity to ribavirin or any component of the formulation; women who are pregnant or may become pregnant",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Oral formulations: Hypersensitivity to ribavirin or any component of the formulation; women who are pregnant or may become pregnant; males whose female partners are pregnant; patients with hemoglobinopathies (eg, thalassemia major, sickle cell anemia); patients with autoimmune hepatitis; concomitant use with didanosine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Ribasphere&reg; capsules and Rebetol&reg; capsules/solution: Additional contraindications: Patients with a Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/minute",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Oral combination therapy: Refer to individual monographs for Interferon Alfa-2b (Intron&reg; A), Peginterferon Alfa-2b, and Peginterferon Alfa-2a (Pegasys&reg;) for additional contraindication information.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F217906\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hemolytic anemia:",
"     <b>",
"      [U.S. Boxed Warning]: Hemolytic anemia is the primary clinical toxicity of oral therapy; anemia associated with ribavirin may worsen underlying cardiac disease and lead to fatal and nonfatal myocardial infarctions. Avoid use in patients with significant/unstable cardiac disease.",
"     </b>",
"     Anemia usually occurs within 1-2 weeks of therapy initiation; observed in ~10% to 13% of patients when alfa interferons were combined with ribavirin. Assess cardiac function before initiation of therapy. If patient has underlying cardiac disease, assess electrocardiogram prior to and periodically during treatment. If any deterioration in cardiovascular status occurs, discontinue therapy. Use caution in patients with baseline risk of severe anemia. Assess hemoglobin and hematocrit at baseline and, at minimum, weeks 2 and 4 of therapy since initial drop may be significant. Patients with renal dysfunction and/or those &gt;50 years of age should be carefully assessed for development of anemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Risk of hepatic decompensation in chronic hepatitis C patients treated with combination therapy; monitor hepatic function closely and discontinue therapy immediately if evidence of hepatic decompensation is observed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatitis C: Appropriate use:",
"     <b>",
"      [U.S. Boxed Warning]: Ribavirin monotherapy is  not effective for chronic hepatitis C infection and should not be used alone for hepatitis C.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; dosage adjustment or discontinuation may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Combination therapy with alfa interferons:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Autoimmune/infectious disorders: Have occurred with combination therapy; use with caution in patients with autoimmune disease or severe infection.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone marrow suppression: Pancytopenia has occurred with combination therapy and concomitant use of azathioprine; onset occurs within 3-7 weeks; discontinue combination therapy and azathioprine if occurs; may be reversible (usually within 4-6 weeks).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dental and periodontal disorders: Have been reported with combination therapy; patients should be instructed to brush teeth twice daily and have regular dental exams. Xerostomia may contribute to and/or exacerbate dental disorders.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dermatologic reactions: Severe cutaneous reactions, including Stevens-Johnson syndrome and exfoliative dermatitis have been reported (rarely) with combination therapy; discontinue immediately with signs or symptoms of severe skin reactions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Has occurred with combination therapy; monitor blood sugars closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Acute hypersensitivity reactions (eg, anaphylaxis, angioedema, bronchoconstriction, and urticaria) have been observed (rarely) with combination therapy; discontinue immediately with signs or symptoms of severe hypersensitivity reactions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ophthalmologic disorders: Serious disorders (eg, retinopathy, macular edema, retinal artery/vein thrombosis, optic neuritis, retinal detachment) have occurred with combination therapy. All patients require an eye exam at baseline; those with pre-existing ophthalmologic disorders (eg, diabetic or hypertensive retinopathy) require periodic follow up. Discontinue therapy in patients with new or worsening ophthalmologic disorders.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pancreatitis: Has occurred with combination therapy;  interrupt therapy if pancreatitis is suspected and discontinue if confirmed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Psychiatric disorders: Severe psychiatric events have occurred including depression and suicidal behavior during combination therapy. Suicidal ideation or attempts occurred more often in pediatric patients versus reports in adults during treatment and off-therapy follow- up (2.4% vs 1%). Avoid use in patients with a psychiatric history; discontinue if severe psychiatric symptoms occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pulmonary events: Pulmonary symptoms (eg, dyspnea, pulmonary infiltrates, pneumonitis, pneumonia [rarely fatal]) have been associated with combination therapy; use with caution in patients with pulmonary disease, including sarcoidosis (exacerbation reported).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly; may be more susceptible to adverse effects such as anemia. Monitor renal function closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatric: In combination therapy with alfa interferons, ribavirin may cause a reduction in growth velocity in pediatric patients for the length of treatment. Delay in weight and height increases have been noted in children treated with combination therapy. In clinical studies, decreases were noted in weight and height for age z-scores and normative growth curve percentiles.  At two-year follow up after treatment, most children had returned to their baseline normative growth curve percentiles; however, a small percentage did not. Growth should be closely monitored in pediatric patients during therapy and post-treatment until growth catch up has occurred.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pregnancy:",
"     <b>",
"      [U.S. Boxed Warning]: Significant teratogenic effects have been observed in all animal studies.",
"     </b>",
"     A negative pregnancy test is required before initiation and monthly thereafter. Avoid pregnancy in female patients and female partners of male patients, during therapy, and for at least 6 months after treatment; two forms of contraception should be used.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Inhalation:",
"     <b>",
"      [U.S. Boxed Warning]: Use with caution in patients requiring assisted ventilation because precipitation of the drug in the respiratory equipment may interfere with safe and effective patient ventilation; sudden deterioration of respiratory function has been observed;",
"     </b>",
"     monitor carefully in patients with COPD and asthma for deterioration of respiratory function. Ribavirin is potentially mutagenic, tumor-promoting, and gonadotoxic. Although anemia has not been reported with inhalation therapy, consider monitoring for anemia 1-2 weeks post-treatment. Pregnant healthcare workers may consider unnecessary occupational exposure; ribavirin has been detected in healthcare workers' urine. Healthcare professionals or family members who are pregnant (or may become pregnant) should be counseled about potential risks of exposure and counseled about risk reduction strategies.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Safety and efficacy have not been established in patients who have failed other alfa interferon therapy, received organ transplants, or been coinfected with hepatitis B or HIV (ribavirin tablets [Copegus&reg;, Ribasphere&reg;] may be used in HIV coinfected patients unless CD4+ cell count is &lt;100 cells/microliter and HIV-1 RNA &lt;5000 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     ). Hemoglobin at initiation must be &ge;12 g/dL (women) or &ge;13 g/dL (men) in CHC monoinfected patients and &ge;11 g/dL (women) or &ge;12 g/dL (men) in CHC and HIV coinfected patients. Oral ribavirin should not be used for adenovirus, RSV, influenza or parainfluenza infections; ribavirin inhalation is approved for severe RSV infection in children.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299997\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F217911\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AzaTHIOprine: Ribavirin may increase serum concentrations of the active metabolite(s) of AzaTHIOprine. Specifically, concentrations of potentially myelotoxic methylated metabolites may be increased, while concentrations of active 6-thioguanine nucleotides may be decreased.  Management: Consider using alternative agent(s) when possible.  When these drugs are used in combination, monitor patients extra closely for signs/symptoms of myelosuppression.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Didanosine: Ribavirin may enhance the adverse/toxic effect of Didanosine. Ribavirin may increase serum concentrations of the active metabolite(s) of Didanosine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Influenza Virus Vaccine (Live/Attenuated): Antiviral Agents (Influenza A and B) may diminish the therapeutic effect of Influenza Virus Vaccine (Live/Attenuated).  Management: Avoid anti-influenza antivirals during the period beginning 48 hours prior to and ending 2 weeks after vaccine administration.  Persons receiving these agents within 2 weeks of the live intranasal spray vaccine should receive a repeat vaccine dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Interferons (Alfa): May enhance the adverse/toxic effect of Ribavirin. Hemolytic anemia has been observed.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Reverse Transcriptase Inhibitors (Nucleoside): Ribavirin may enhance the hepatotoxic effect of Reverse Transcriptase Inhibitors (Nucleoside). Lactic acidosis may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zidovudine: May enhance the adverse/toxic effect of Ribavirin. Specifically, the risk/severity of anemia may be increased. Management: Due to significantly increased risk of anemia, consider even closer monitoring for anemia than routinely recommended for ribavirin.  Alternative therapies should be considered when clinically possible, particularly for patients with other risk factors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F217940\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food: Oral: High-fat meal increases the AUC and C",
"     <sub>",
"      max",
"     </sub>",
"     . Management: Capsule (in combination with peginterferon alfa-2b) and tablet should be administered with food. Other dosage forms and combinations should be taken consistently in regards to food.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F217913\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F217926\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      [U.S. Boxed Warning]: Significant teratogenic effects have been observed in all animal studies",
"     </b>",
"     at ~0.01 times the maximum recommended daily human dose. Use is contraindicated in pregnancy. Negative pregnancy test is required before initiation and monthly thereafter. Avoid pregnancy in female patients and female partners of male patients during therapy by using two effective forms of contraception; continue contraceptive measures for at least 6 months after completion of therapy. If patient or female partner becomes pregnant during treatment, she should be counseled about potential risks of exposure. If pregnancy occurs during use or within 6 months after treatment, report to the ribavirin pregnancy registry (800-593-2214).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F217955\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F217927\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Capsules, solution, and tablets should be taken with food.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F217925\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Rebetol Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (70): $741.74",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Ribasphere Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (70): $328.44",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Ribavirin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (56): $556.29",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Misc",
"     </b>",
"     (RibaPak Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 &amp; 400 mg (14): $219.14",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Rebetol Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg/mL (100 mL): $232.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Virazole Inhalation)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6 g (1): $6212.37",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Copegus Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (168): $3305.38",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (RibaPak Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400 mg (14): $230.67",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400 &amp; 600 mg (14): $288.34",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     600 mg (14): $346.01",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Ribasphere Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (168): $474.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400 mg (56): $922.68",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     600 mg (56): $1384.02",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Ribavirin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (168): $1390.00",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F217915\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Inhalation:",
"     </b>",
"     Respiratory function, hemoglobin, reticulocyte count, CBC with differential, I &amp; O",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Oral:",
"     </b>",
"     For combination treatment: pretreatment hematological and biochemical tests are recommended for all patients; pregnancy screening (if woman of childbearing age) and ECG (if preexisting cardiac abnormalities) are also recommended.  In adults, hematologic tests should be at treatment weeks 2 and 4, biochemical tests at week 4, TSH at week 12, and pregnancy tests monthly during and for 6 months after treatment discontinuation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     In pediatric clinical studies, hematologic and biochemical assessments were made at weeks 1, 3, 5 and 8, then every 4 weeks thereafter.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Baseline values used in adult clinical trials:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Platelet count &ge;90,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     (75,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     for cirrhosis or 70,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     for coinfection with HIV)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ANC &ge;1500/mm",
"     <sup>",
"      3",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hemoglobin &ge;12 g/dL for women and &ge;13 g/dL for men (11 g/dL for HIV coinfected women and 12 g/dL for HIV coinfected men)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     TSH and T",
"     <sub>",
"      4",
"     </sub>",
"     within normal limits or adequately controlled",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     CD4",
"     <sup>",
"      +",
"     </sup>",
"     cell count &ge;200 cells/microL or CD4",
"     <sup>",
"      +",
"     </sup>",
"     cell count 100-200 cells/microL and HIV-1 RNA &lt;5000 copies/mL for coinfection with HIV",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Serum HCV RNA (pretreatment, week 12 and week 24, and 24 weeks after completion of therapy).",
"     <b>",
"      Note:",
"     </b>",
"     Discontinuation of therapy may be considered after 12 weeks in patients with HCV (genotypes 1,4) who fail to achieve an early virologic response (EVR) (defined as &ge;2-log decrease in HCV RNA compared to pretreatment) or after 24 weeks with detectable HCV RNA. Treat patients with HCV (genotypes 2,3) for 24 weeks (if tolerated) and then evaluate HCV RNA levels (Ghany, 2009).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Pretreatment and monthly pregnancy test up to 6 months following discontinuation of therapy for women of childbearing age; pretreatment ECG in patients with pre-existing cardiac disease; dental exams; ophthalmic exam pretreatment (all patients) and periodically for those with pre-existing ophthalmologic disorders. In pediatric patients, monitor growth closely during and after treatment.",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F4799962\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rapid virological response (RVR): Absence of detectable HCV RNA after 4 weeks of treatment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Early viral response (EVR): &ge;2-log decrease in HCV RNA after 12 weeks of treatment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     End of treatment response (ETR): Absence of detectable HCV RNA at end of the recommended treatment period",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sustained treatment response (STR) or sustained virologic response (SVR): Absence of HCV RNA in the serum 6 months following completion of full treatment course",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F2869403\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Copegus (AR, AT, BE, BG, CH, CO, CZ, DE, DK, EC, EE, FI, FR, GB, GR, HK, IE, IL, IT, MX, NL, NO, NZ, PL, PT, SE, TH, UY);",
"     </li>",
"     <li>",
"      Desiken (MX);",
"     </li>",
"     <li>",
"      Hepaviral (ID);",
"     </li>",
"     <li>",
"      Probirina (MX);",
"     </li>",
"     <li>",
"      Rebetol (AT, AU, BE, BG, CH, CN, CZ, DE, DK, DO, EE, ES, FI, FR, GB, GR, ID, IE, IL, IT, MT, MY, NL, NO, NZ, PA, PH, PL, PT, RU, SE, SG, SK, TH, TR, VE);",
"     </li>",
"     <li>",
"      Ribavin (IN);",
"     </li>",
"     <li>",
"      Robatrol (TW);",
"     </li>",
"     <li>",
"      Robavin (KP);",
"     </li>",
"     <li>",
"      Rui Di (CL);",
"     </li>",
"     <li>",
"      Trivorin (MX);",
"     </li>",
"     <li>",
"      Vibuzol (AR);",
"     </li>",
"     <li>",
"      Vilona (MX);",
"     </li>",
"     <li>",
"      Viramid (IT, KP);",
"     </li>",
"     <li>",
"      Virazide (AU, MX, PK);",
"     </li>",
"     <li>",
"      Virazin (KP);",
"     </li>",
"     <li>",
"      Virazole (AE, BE, BH, BR, CR, CY, EG, GB, GT, HN, IQ, IR, JO, KW, LB, LY, NI, OM, QA, SA, SE, SV, SY, YE);",
"     </li>",
"     <li>",
"      Zyverin (TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F217905\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits replication of RNA and DNA viruses; inhibits influenza virus RNA polymerase activity and inhibits the initiation and elongation of RNA fragments resulting in inhibition of viral protein synthesis",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F217922\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Inhalation: Systemic; dependent upon respiratory factors and method of drug delivery; maximal absorption occurs with the use of aerosol generator via endotracheal tube; highest concentrations in respiratory tract and erythrocytes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Oral capsule: Single dose: V",
"     <sub>",
"      d",
"     </sub>",
"     : 2825 L; distribution significantly prolonged in the erythrocyte (16-40 days), which can be used as a marker for intracellular metabolism",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: Oral: None",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatically and intracellularly (forms active metabolites); may be necessary for drug action",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Oral: 64%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination, plasma:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: Inhalation: 6.5-11 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Capsule, single dose (Rebetol&reg;, Ribasphere&reg;): 24 hours in healthy adults, 44 hours with chronic hepatitis C infection (increases to ~298 hours at steady state)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Tablet, single dose (Copegus&reg;): ~120-170 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: Inhalation: At end of inhalation period; Oral capsule: Multiple doses: 3 hours; Tablet: 2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Inhalation: Urine (40% as unchanged drug and metabolites); Oral capsule: Urine (61%), feces (12%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Infectious Diseases, &ldquo;Reassessment of the Indications for Ribavirin Therapy in Respiratory Syncytial Virus Infections,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1996, 97(1):137-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/25/27033/abstract-text/8545210/pubmed\" id=\"8545210\" target=\"_blank\">",
"        8545210",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Infectious Diseases, &ldquo;Use of Ribavirin in the Treatment of Respiratory Syncytial Virus Infection,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1993, 92(3):501-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/25/27033/abstract-text/8361820/pubmed\" id=\"8361820\" target=\"_blank\">",
"        8361820",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Barry M, Russi M, Armstrong L, et al, &ldquo;Brief Report: Treatment of a Laboratory-Acquired Saria Virus Infection,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1995, 333(5):294-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/25/27033/abstract-text/7596373/pubmed\" id=\"7596373\" target=\"_blank\">",
"        7596373",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Boeckh M, Englund J, Li Y, et al, &ldquo;Randomized Controlled Multicenter Trial of Aerosolized Ribavirin For Respiratory Syncytial Virus Upper Respiratory Tract Infection in Hematopoietic Cell Transplant Recipients,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2007, 44(2):245-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/25/27033/abstract-text/17173225/pubmed\" id=\"17173225\" target=\"_blank\">",
"        17173225",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chemaly RF, Ghosh S, Bodey GP, et al, &ldquo;Respiratory Viral Infections in Adults With Hematologic Malignancies and Human Stem Cell Transplant Recipients: A Retrospective Study at a Major Cancer Center,&rdquo;",
"      <i>",
"       Medicine (Baltimore)",
"      </i>",
"      , 2006, 85(5):278-87.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/25/27033/abstract-text/16974212/pubmed\" id=\"16974212\" target=\"_blank\">",
"        16974212",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Davis GL, Esteban-Mur R, Rustgi V, et al, &ldquo;Interferon Alfa-2b Alone or in Combination With Ribavirin for the Treatment of Relapse of Chronic Hepatitis C. International Hepatitis Interventional Therapy Group,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1998, 339(21):1493-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/25/27033/abstract-text/9819447/pubmed\" id=\"9819447\" target=\"_blank\">",
"        9819447",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dienstag JL and McHutchinson JG, &ldquo;American Gastroenterological Association Medical Position Statement on the Management of Hepatitis C,&rdquo;",
"      <i>",
"       Gastroenterology",
"      </i>",
"      , 2006, 130(1):225-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/25/27033/abstract-text/16401485/pubmed\" id=\"16401485\" target=\"_blank\">",
"        16401485",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Englund JA, Piedra PA, Ahn YM, et al, &ldquo;High-Dose, Short-Duration Ribavirin Aerosol Therapy Compared With Standard Ribavirin Therapy in Children With Suspected Respiratory Syncytial Virus Infection,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1994, 125:635-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/25/27033/abstract-text/7931890/pubmed\" id=\"7931890\" target=\"_blank\">",
"        7931890",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ghany MG, Nelson DR, Strader DB, et al, &ldquo;An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection:  2011 Practice Guideline by the American Association for the Study of Liver Diseases,&rdquo;",
"      <i>",
"       Hepatology",
"      </i>",
"      , 2011, 54(4):1433-44.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/25/27033/abstract-text/21898493/pubmed\" id=\"21898493\" target=\"_blank\">",
"        21898493",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ghany MG, Strader DB, Thomas DL, et al, &ldquo;Diagnosis, Management And Treatment Of Hepatitis C: An Update,&rdquo;",
"      <i>",
"       Hepatology",
"      </i>",
"      , 2009, 49(4):1335-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/25/27033/abstract-text/19330875/pubmed\" id=\"19330875\" target=\"_blank\">",
"        19330875",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hoofnagle JH and Seeff LB,&rdquo;Peginterferon and Ribavirin for Chronic Hepatitis C,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2006, 355(23):2444-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/25/27033/abstract-text/17151366/pubmed\" id=\"17151366\" target=\"_blank\">",
"        17151366",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lauer GM and Walker BD, &ldquo;Hepatitis C Virus Infection,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2001, 345(1):41-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/25/27033/abstract-text/11439948/pubmed\" id=\"11439948\" target=\"_blank\">",
"        11439948",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Liu V, Dhillon GS, and Weill D, &ldquo;A Multi-Drug Regimen for Respiratory Syncytial Virus and Parainfluenza Virus Infections in Adult Lung and Heart-Lung Transplant Recipients,&rdquo;",
"      <i>",
"       Transp Infect Dis",
"      </i>",
"      , 2010, 12(1):38-44.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/25/27033/abstract-text/19761558/pubmed\" id=\"19761558\" target=\"_blank\">",
"        19761558",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McHutchison JG, Gordon SC, Schiff ER, et al, &ldquo;Interferon Alfa-2b Alone or in Combination With Ribavirin as Initial Treatment for Chronic Hepatitis C. Hepatitis Interventional Therapy Group,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1998, 339(21):1485-92.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/25/27033/abstract-text/9819446/pubmed\" id=\"9819446\" target=\"_blank\">",
"        9819446",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Meert KL, Sarnaik AP, Gelmini MJ, et al, &ldquo;Aerosolized Ribavirin in Mechanically Ventilated Children With Respiratory Syncytial Virus Lower Respiratory Tract Disease: A Prospective, Double-Blind, Randomized Trial,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 1994, 22(4):566-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/25/27033/abstract-text/8143465/pubmed\" id=\"8143465\" target=\"_blank\">",
"        8143465",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nicholson KG, &ldquo;Properties of Antiviral Agents,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1984, 2(8401):503-6 and 2(8402):562-4.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ottolini MG and Hemming VG, &ldquo;Prevention and Treatment Recommendations for Respiratory Syncytial Virus Infection. Background and Clinical Experience 40 Years After Discovery,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1997, 54(6):867-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/25/27033/abstract-text/9421694/pubmed\" id=\"9421694\" target=\"_blank\">",
"        9421694",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      \"PEDS-C: Pegylated Interferon +/- Ribavirin for Children With Hepatitis C,\"  NCT0010065, updated November 2012. Available at",
"      <a href=\"file://clinicaltrials.gov/ct2/show/NCT00100659\" target=\"_blank\">",
"       file://clinicaltrials.gov/ct2/show/NCT00100659",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schwarz KB, Gonzalez-Peralta RP, Murray KF, et al, &ldquo;The Combination of Ribavirin and Peginterferon is Superior to Peginterferon and Placebo for Children and Adolescents With Chronic Hepatitis C,&rdquo;",
"      <i>",
"       Gastroenterology",
"      </i>",
"      , 2011, 140(2):450-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/25/27033/abstract-text/21036173/pubmed\" id=\"21036173\" target=\"_blank\">",
"        21036173",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smith DW, Frankel LR, Mathers LH, et al, &ldquo;A Controlled Trial of Aerosolized Ribavirin in Infants Receiving Mechanical Ventilation for Severe Respiratory Syncytial Virus Infection,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1991, 325(1):24-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/25/27033/abstract-text/1904551/pubmed\" id=\"1904551\" target=\"_blank\">",
"        1904551",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sokal E, Bourgois A, Stephenne X, et al, &ldquo;Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C Virus Infection in Children and Adolescents,&rdquo;",
"      <i>",
"       J Hepatol",
"      </i>",
"      , 2010, 52(6):827-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/25/27033/abstract-text/20400194/pubmed\" id=\"20400194\" target=\"_blank\">",
"        20400194",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Van Bever HP, Desager KS, Van Hoeck K, et al, &ldquo;Water Intoxication After Nebulised Tribavirin,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1995, 345(8947):451.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9860 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.131.240.2-31C67D9254-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_25_27033=[""].join("\n");
var outline_f26_25_27033=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709400\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217944\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217945\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217983\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217949\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217968\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217950\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217951\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5184988\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217984\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217918\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217902\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874826\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217920\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217990\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217919\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217979\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217991\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217981\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217923\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217906\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299997\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217911\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217940\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217913\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217926\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217955\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217927\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217925\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217915\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4799962\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2869403\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217905\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217922\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9860\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9860|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?36/17/37142?source=related_link\">",
"      Ribavirin: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/59/12216?source=related_link\">",
"      Ribavirin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_25_27034="Clinical features and diagnosis of inflammatory bowel disease in children and adolescents";
var content_f26_25_27034=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical features and diagnosis of inflammatory bowel disease in children and adolescents",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/25/27034/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/25/27034/contributors\">",
"     Leslie M Higuchi, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/25/27034/contributors\">",
"     Athos Bousvaros, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/25/27034/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/25/27034/contributors\">",
"     George D Ferry, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/25/27034/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/25/27034/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/25/27034/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 1, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inflammatory bowel disease (IBD) is comprised of two major disorders: ulcerative colitis (UC) and Crohn's disease (CD). UC affects the colon and is characterized by inflammation of the mucosal layer. CD can involve any component of the gastrointestinal tract from the oral cavity to the anus and is characterized by transmural inflammation. These disorders have distinct pathologic and clinical characteristics, but their pathogenesis remains poorly understood. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/17/7450?source=see_link\">",
"     \"Definition, epidemiology, and risk factors in inflammatory bowel disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/48/27401?source=see_link\">",
"     \"Immune and microbial mechanisms in the pathogenesis of inflammatory bowel disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The peak incidence of IBD occurs in patients between the ages of 15 and 25 years. Approximately 25 to 30 percent of patients with CD and 20 percent of patients with UC present before the age of 20 years [",
"    <a class=\"abstract\" href=\"UTD.htm?26/25/27034/abstract/1\">",
"     1",
"    </a>",
"    ]. Adults and children with IBD may present with similar clinical features; however, children can develop unique complications, including growth failure and delayed puberty. Thus, clinicians caring for children and adolescents with one of these disorders must treat the underlying disease and its complications and also must carefully monitor linear growth, skeletal development, and puberty. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/13/3288?source=see_link\">",
"     \"Epidemiology and environmental factors in inflammatory bowel disease in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/46/2794?source=see_link\">",
"     \"Growth failure and poor weight gain in children with inflammatory bowel disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The suspicion of IBD typically arises from a combination of symptoms and screening laboratory data. The diagnosis is established by radiographic studies and endoscopy. These studies also help to localize the disease and to differentiate between UC and CD. The diagnosis of IBD in children is reviewed here. The clinical manifestations of CD, and the treatment of CD and UC are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/7/24693?source=see_link\">",
"     \"Clinical manifestations of Crohn's disease in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/47/41722?source=see_link\">",
"     \"Overview of the management of Crohn's disease in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/34/4650?source=see_link\">",
"     \"Treatment of ulcerative colitis in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H184210419\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inflammatory bowel disease (IBD) should be suspected based upon suggestive features in the history and clinical presentation (",
"    <a class=\"graphic graphic_table graphicRef77827 \" href=\"UTD.htm?11/2/11309\">",
"     table 1",
"    </a>",
"    ). Patients typically present in late childhood or adolescence with one or several of the following features:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gastrointestinal symptoms &ndash; Loose stools or bloody diarrhea, abdominal pain, or tenesmus",
"     </li>",
"     <li>",
"      Growth &ndash; Growth failure (subnormal gains in height or weight, or weight loss),",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      delayed puberty. Although growth failure is a common feature, a substantial number of children are overweight when they present with IBD (particularly those with UC) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/25/27034/abstract/2\">",
"       2",
"      </a>",
"      ]. Thus, obesity or lack of growth failure should not preclude a diagnosis of IBD. &nbsp;",
"     </li>",
"     <li>",
"      Physical findings &ndash; Abdominal tenderness (especially in the right lower quadrant), perianal disease (fistulae, anal skin tags, or fissures), or occult blood in stool",
"     </li>",
"     <li>",
"      Extraintestinal manifestations &ndash; Oral ulcerations (aphthous stomatitis), clubbing, rash (erythema nodosum or pyoderma gangenosum), eye inflammation (uveitis), or arthritis (See",
"      <a class=\"local\" href=\"#H1351752\">",
"       'Extraintestinal manifestations'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Symptoms suggesting colitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Colitis usually presents as a subacute illness characterized by diarrhea that almost always contains blood, fatigue, anemia, and sometimes weight loss. The onset of symptoms may be insidious, with diarrhea that is initially non-bloody, and sometimes poor weight gain. Some children have a more fulminant presentation, with severe abdominal pain, frankly bloody diarrhea, tenesmus, fever, leukocytosis, and hypoalbuminemia.",
"   </p>",
"   <p>",
"    Colitis can occur in patients with either UC or CD. By definition, patients with UC have colitis that affects the rectum and extends proximally to a variable degree. CD also may involve the colon, either exclusively (Crohn&rsquo;s colitis), or in combination with small intestinal involvement (Crohn&rsquo;s ileocolitis). Patients with either CD or UC may also exhibit gastritis or duodenitis at the time of diagnosis. Individuals with IBD presenting at a young age are particularly likely to present with symptoms of colitis: approximately 15 percent of children and adolescents with IBD present prior to six years of age, and the majority of these children have isolated colonic disease (either UC or Crohn&rsquo;s colitis) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/25/27034/abstract/3\">",
"     3",
"    </a>",
"    ]. CD tends to present in late childhood or adolescence, and is the predominant form of IBD after eight years of age (",
"    <a class=\"graphic graphic_figure graphicRef88089 \" href=\"UTD.htm?11/14/11502\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/25/27034/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Other gastrointestinal symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients, particularly those with CD, present with nonspecific gastrointestinal symptoms that may be difficult to distinguish from more common conditions such as functional abdominal pain. The most useful indicators of possible IBD in a child with abdominal pain are: diarrhea, growth failure, pubertal delay, weight loss, rectal bleeding,",
"    <span class=\"nowrap\">",
"     pallor/fatigue,",
"    </span>",
"    perianal skin tags (which may be misdiagnosed as hemorrhoids), perianal fistulae or abscesses, a palpable abdominal mass, and a family history of inflammatory bowel disease. The abdominal pain associated with CD is often focal and located in the right lower quadrant. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/7/24693?source=see_link\">",
"     \"Clinical manifestations of Crohn's disease in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11172431\">",
"    <span class=\"h2\">",
"     Growth failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Growth failure is common at presentation, particularly in children with CD. The earliest and most subtle form of growth failure is a decrease in height velocity; this may progress to short stature for age, delayed bone age,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pubertal delay. Up to 50 percent of patients with CD have a decrease in height velocity before the onset of any other intestinal symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?26/25/27034/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/46/2794?source=see_link\">",
"     \"Growth failure and poor weight gain in children with inflammatory bowel disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1351752\">",
"    <span class=\"h2\">",
"     Extraintestinal manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extraintestinal conditions associated with IBD (including nonspecific symptoms such as arthralgias) are identified in about 10 percent of patients at presentation, and up to 30 percent of patients within the first few years after the IBD is diagnosed [",
"    <a class=\"abstract\" href=\"UTD.htm?26/25/27034/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. These may involve the mouth, skin, joints, liver, eye, and (rarely) other organs (",
"    <a class=\"graphic graphic_table graphicRef81867 \" href=\"UTD.htm?27/32/28173\">",
"     table 2",
"    </a>",
"    ). These disorders appear idiosyncratically in some patients and not others, but are more often associated with colonic disease (ie, Crohn&rsquo;s colitis or UC). Certain extraintestinal manifestations are more common in CD as compared with UC, including oral ulcers (aphthous stomatitis), erythema nodosum, digital clubbing, and arthritis. They do not consistently correlate with the degree of intestinal inflammation. Occasionally, patients present with extraintestinal symptoms (such as aphthous stomatitis or arthritis) before any obvious gastrointestinal symptoms develop [",
"    <a class=\"abstract\" href=\"UTD.htm?26/25/27034/abstract/6,8\">",
"     6,8",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Oral cavity",
"      </strong>",
"      &ndash; Aphthous stomatitis of the mouth occurs in about 10 percent of children with IBD [",
"      <a class=\"abstract\" href=\"UTD.htm?26/25/27034/abstract/6,7\">",
"       6,7",
"      </a>",
"      ], and is about three times more common among those with CD as compared with UC [",
"      <a class=\"abstract\" href=\"UTD.htm?26/25/27034/abstract/7\">",
"       7",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"     <li>",
"      <strong>",
"       Skin",
"      </strong>",
"      &ndash; Erythema nodosum is characterized by painful raised red lesions 1 to 3 cm in diameter, and seen most commonly on the shins (",
"      <a class=\"graphic graphic_picture graphicRef80056 \" href=\"UTD.htm?8/46/8943\">",
"       picture 1",
"      </a>",
"      ). It is a presenting feature in about 5 percent of children with IBD and typically resolves rapidly when therapy of the IBD is instituted; it is seen more often in patients with CD than UC [",
"      <a class=\"abstract\" href=\"UTD.htm?26/25/27034/abstract/6,7,9\">",
"       6,7,9",
"      </a>",
"      ]. Erythema nodosum also may be caused by disorders other than IBD, including infections (eg, Group A Streptococcus, tuberculosis), medications (eg, penicillin,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/19/33082?source=see_link\">",
"       phenytoin",
"      </a>",
"      ), autoimmune disease (eg, rheumatoid arthritis, lupus), and malignancy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41350?source=see_link&amp;anchor=H4#H4\">",
"       \"Skin and eye manifestations of inflammatory bowel disease\", section on 'Erythema nodosum'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Pyoderma gangrenosum, a severe ulcerating rash that responds to immunosuppression, is rare in children and is seen more often in patients with long-standing UC than in patients with CD. However, it has been described in an infant with CD [",
"      <a class=\"abstract\" href=\"UTD.htm?26/25/27034/abstract/10\">",
"       10",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41350?source=see_link&amp;anchor=H5#H5\">",
"       \"Skin and eye manifestations of inflammatory bowel disease\", section on 'Pyoderma gangrenosum'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Eye",
"      </strong>",
"      &ndash;",
"      <span class=\"nowrap\">",
"       Episcleritis/scleritis",
"      </span>",
"      occurs in 2 to 5 percent of patients with IBD [",
"      <a class=\"abstract\" href=\"UTD.htm?26/25/27034/abstract/6,11\">",
"       6,11",
"      </a>",
"      ]. Affected patients may be asymptomatic or complain of burning and itching. Injection of the ciliary vessels and inflammation of the episcleral tissues are the prominent features on physical examination (",
"      <a class=\"graphic graphic_picture graphicRef67740 \" href=\"UTD.htm?25/48/26383\">",
"       picture 2",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      Uveitis is less common than episcleritis, occurring in 0.5 to 3 percent of patients with IBD. However, its consequences often are more severe. The uveitis is frequently bilateral, posterior to the lens, insidious in onset, chronic in duration, and is more common in females than males [",
"      <a class=\"abstract\" href=\"UTD.htm?26/25/27034/abstract/12\">",
"       12",
"      </a>",
"      ]. &ldquo;Iritis&rdquo; is an alternate term for anterior uveitis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41350?source=see_link\">",
"       \"Skin and eye manifestations of inflammatory bowel disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Joints",
"      </strong>",
"      &ndash; About 4 percent of patients with IBD have arthritis within the first few years after diagnosis, and up to 17 percent have arthralgias [",
"      <a class=\"abstract\" href=\"UTD.htm?26/25/27034/abstract/6,7\">",
"       6,7",
"      </a>",
"      ]. Arthritis is about twice as common in CD as compared to UC, but is more common in patients with Crohn&rsquo;s colitis as compared to those with gastroduodenal CD [",
"      <a class=\"abstract\" href=\"UTD.htm?26/25/27034/abstract/7,13,14\">",
"       7,13,14",
"      </a>",
"      ]. The arthritis typically is nonerosive and asymmetric, affects large joints, including the hips, knees, and wrists, and parallels the activity of the intestinal involvement [",
"      <a class=\"abstract\" href=\"UTD.htm?26/25/27034/abstract/13,15\">",
"       13,15",
"      </a>",
"      ]. In contrast, axial skeletal involvement, in the form of ankylosing spondylitis and sacroiliac joint arthritis, may follow an independent course [",
"      <a class=\"abstract\" href=\"UTD.htm?26/25/27034/abstract/16\">",
"       16",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/44/25289?source=see_link\">",
"       \"Arthritis associated with gastrointestinal disease\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Chronic recurrent multifocal osteomyelitis is a rare complication of both CD and UC [",
"      <a class=\"abstract\" href=\"UTD.htm?26/25/27034/abstract/17\">",
"       17",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/32/33289?source=see_link&amp;anchor=H31#H31\">",
"       \"Evaluation and diagnosis of hematogenous osteomyelitis in children\", section on 'Chronic nonbacterial osteomyelitis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Liver",
"      </strong>",
"      &ndash; Nonspecific mild elevations of serum aminotransferases (AST, ALT) are common and often are caused by medications or hepatic steatosis [",
"      <a class=\"abstract\" href=\"UTD.htm?26/25/27034/abstract/18\">",
"       18",
"      </a>",
"      ]. Individuals with CD have an increased risk for cholelithiasis, but this is uncommon in UC [",
"      <a class=\"abstract\" href=\"UTD.htm?26/25/27034/abstract/19,20\">",
"       19,20",
"      </a>",
"      ]. Patients with UC also have an increased risk for autoimmune hepatitis [",
"      <a class=\"abstract\" href=\"UTD.htm?26/25/27034/abstract/21\">",
"       21",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/31/22006?source=see_link\">",
"       \"Hepatobiliary manifestations of inflammatory bowel disease\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The most serious liver disease associated with IBD is primary sclerosing cholangitis (PSC), a condition causing inflammation and scarring of the bile ducts, which may lead to hepatic cirrhosis. PSC occurs in 2 to 5 percent of patients with UC, and a slightly smaller proportion of patients with Crohn colitis [",
"      <a class=\"abstract\" href=\"UTD.htm?26/25/27034/abstract/7,22\">",
"       7,22",
"      </a>",
"      ]. Patients with PSC may present with fatigue, pruritus, and intermittent jaundice; the severity of the PSC is not correlated with the colitis disease activity. Biochemical tests demonstrate an elevation of gamma-glutamyl transpeptidase (GGTP), alkaline phosphatase, and a less pronounced elevation of aminotransferases. Diagnosis is made by a combination of radiographic imaging (ultrasound, magnetic resonance cholangiopancreatography [MRCP]), endoscopic retrograde cholangiopancreatography (ERCP), and liver biopsy. Treatment with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/19/13621?source=see_link\">",
"       ursodeoxycholic acid",
"      </a>",
"      results in improvement of laboratory markers of hepatic inflammation and cholestasis [",
"      <a class=\"abstract\" href=\"UTD.htm?26/25/27034/abstract/23\">",
"       23",
"      </a>",
"      ]. However, no therapy has been shown to alter the natural history of the disease, and there is some evidence that high-dose treatment may be detrimental [",
"      <a class=\"abstract\" href=\"UTD.htm?26/25/27034/abstract/24\">",
"       24",
"      </a>",
"      ]. Individuals with UC and PSC appear to be at higher risk for developing colorectal cancer as compared with patients with UC alone, so early and frequent surveillance colonoscopy is recommended for this group. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/63/22521?source=see_link\">",
"       \"Clinical manifestations and diagnosis of primary sclerosing cholangitis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/8/41097?source=see_link\">",
"       \"Treatment of primary sclerosing cholangitis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/25/40342?source=see_link\">",
"       \"Colorectal cancer and primary sclerosing cholangitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Other",
"      </strong>",
"      &ndash; Other complications of inflammatory bowel disease include kidney stones (due to malabsorption of calcium and increased absorption of oxalate), gallstones (due to bile acid malabsorption) and osteopenia (which may be caused by vitamin D deficiency or by treatment with glucocorticoids). Granulomatous inflammation of other areas, including the lymph nodes, genitalia, and lungs also may be seen in individuals with CD [",
"      <a class=\"abstract\" href=\"UTD.htm?26/25/27034/abstract/25\">",
"       25",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/0/20490?source=see_link&amp;anchor=H12689078#H12689078\">",
"       \"Clinical manifestations, diagnosis and prognosis of Crohn's disease in adults\", section on 'Malabsorption'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/54/30569?source=see_link\">",
"       \"Metabolic bone disease in inflammatory bowel disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/22/29034?source=see_link\">",
"       \"Pulmonary complications of inflammatory bowel disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H184210643\">",
"    <span class=\"h2\">",
"     Laboratory features",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following laboratory features are suggestive of IBD: &nbsp;",
"   </p>",
"   <p>",
"    <strong>",
"     Blood tests",
"    </strong>",
"    :",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anemia, increased white blood cell and platelet count &ndash; Approximately 70 percent of patients have anemia at diagnosis of IBD (eg, hemoglobin level &lt;11",
"      <span class=\"nowrap\">",
"       g/L)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?26/25/27034/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Elevated erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) &ndash; Approximately 65 to 75 percent of patients have an elevated ESR at diagnosis of IBD, and about 85 percent have elevated CRP [",
"      <a class=\"abstract\" href=\"UTD.htm?26/25/27034/abstract/26,27\">",
"       26,27",
"      </a>",
"      ]. However, estimates vary depending on disease type (CD versus UC), disease severity, and on the cutoff value used to define abnormal ESR or CRP. There are no widely accepted cutoff values for ESR and CRP for identifying patients at risk for IBD, and the normal range for CRP varies among laboratories. In studies evaluating the predictive value of these inflammatory markers, an ESR &gt;20 or &gt;25",
"      <span class=\"nowrap\">",
"       mm/hr,",
"      </span>",
"      and CRP &gt;5 or &gt;10",
"      <span class=\"nowrap\">",
"       mg/L",
"      </span>",
"      have been used [",
"      <a class=\"abstract\" href=\"UTD.htm?26/25/27034/abstract/27-29\">",
"       27-29",
"      </a>",
"      ]. These markers are somewhat more sensitive for detecting CD than UC, and CRP is more sensitive than ESR. As an example, among children evaluated at a referral center for IBD, CRP was elevated in 100 percent of those with CD and 60 percent of those with UC [",
"      <a class=\"abstract\" href=\"UTD.htm?26/25/27034/abstract/27\">",
"       27",
"      </a>",
"      ]. In the same study, ESR was elevated in 85 percent of patients with CD and 23 percent of those with UC. &nbsp; &nbsp;",
"     </li>",
"     <li>",
"      Depressed albumin level &ndash; Approximately 40 percent of patients with IBD have depressed albumin levels at diagnosis (eg, &lt;3.4",
"      <span class=\"nowrap\">",
"       g/L)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?26/25/27034/abstract/26\">",
"       26",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Normal laboratory tests do not exclude the diagnosis of IBD. In a study of more than 500 children who ultimately were diagnosed with IBD, the ESR, hemoglobin, platelet count, and albumin level were all normal in 19 percent of children with UC and 9 percent of children with CD [",
"    <a class=\"abstract\" href=\"UTD.htm?26/25/27034/abstract/26\">",
"     26",
"    </a>",
"    ]. Patients with more severe disease were more likely to have abnormal values on these laboratory tests, particularly the ESR. Thus, endoscopic and radiographic evaluation is sometimes appropriate in some patients in whom there is a strong clinical suspicion of IBD, even if initial blood tests are normal. (See",
"    <a class=\"local\" href=\"#H13111353\">",
"     'Endoscopy'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H13111361\">",
"     'Imaging'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <strong>",
"     Stool tests:",
"    </strong>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gross or occult blood &ndash; Rectal bleeding is a presenting feature in at least 80 percent of patients with UC, and 40 percent of those with CD [",
"      <a class=\"abstract\" href=\"UTD.htm?26/25/27034/abstract/30,31\">",
"       30,31",
"      </a>",
"      ]. If IBD is suspected, but there is no history of gross rectal bleeding, a stool guaiac test may be useful. &nbsp;",
"     </li>",
"     <li>",
"      Elevated fecal calprotectin or leukocytes &ndash; Fecal calprotectin levels are elevated in inflammatory intestinal diseases, and may be useful for distinguishing inflammatory gastrointestinal disease including IBD from noninflammatory causes of chronic diarrhea (such as functional abdominal pain) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/25/27034/abstract/32\">",
"       32",
"      </a>",
"      ]. However, the test characteristics vary depending on the prevalence of IBD in the study population. In settings with a high prevalence of IBD, such as a gastroenterology clinic, elevated fecal calprotectin (eg, &gt;200",
"      <span class=\"nowrap\">",
"       mcg/g)",
"      </span>",
"      is useful for identifying patients with a high likelihood of having IBD. One study from a referral center for pediatric gastroenterology found that fecal calprotectin had better performance characteristics for this purpose than ESR, CRP, or hypoalbuminemia [",
"      <a class=\"abstract\" href=\"UTD.htm?26/25/27034/abstract/28\">",
"       28",
"      </a>",
"      ]. By contrast, in settings with a low prevalence of IBD, such as a primary care setting, fecal calprotectin is more useful to rule out IBD (ie, if fecal calprotectin is normal [eg, &lt;50",
"      <span class=\"nowrap\">",
"       mcg/g],",
"      </span>",
"      then IBD is unlikely) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/25/27034/abstract/33\">",
"       33",
"      </a>",
"      ]. As compared with fecal calprotectin, fecal leukocytes have considerably lower specificity and sensitivity for detecting inflammatory diarrhea. Elevated levels of fecal calprotectin are also found in other causes of inflammatory diarrhea including bacterial and viral enteritis, intestinal lymphoma, celiac disease, food allergy, and immunodeficiency [",
"      <a class=\"abstract\" href=\"UTD.htm?26/25/27034/abstract/32\">",
"       32",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/55/43897?source=see_link&amp;anchor=H22#H22\">",
"       \"Approach to the adult with chronic diarrhea in developed countries\", section on 'Fecal calprotectin'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Fecal calprotectin levels are correlated with disease activity in both CD and UC [",
"      <a class=\"abstract\" href=\"UTD.htm?26/25/27034/abstract/34-37\">",
"       34-37",
"      </a>",
"      ]. Therefore, this test can be useful in monitoring response to treatment, but because of limited sensitivity and specificity it should be used in conjunction with other laboratory tests and symptoms to arrive at clinical decisions. The potential benefits of this test also must be weighed against the cost, and against the fact that it will not provide a definitive IBD diagnosis. &nbsp; &nbsp; &nbsp; &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20369433\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no specific diagnostic criteria for IBD. The diagnosis of IBD is usually established by the combination of clinical features, with or without laboratory abnormalities, coupled with characteristic findings on imaging and endoscopy, including histopathologic analysis. Endoscopy and imaging also help to exclude some other causes of the symptoms, and usually can distinguish between UC and CD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11172589\">",
"    <span class=\"h2\">",
"     Diagnostic approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;IBD should be suspected in a child presenting with one or more of the following clinical features:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bloody diarrhea",
"     </li>",
"     <li>",
"      Growth failure (subnormal gains in height or weight, or weight loss) or pubertal delay",
"     </li>",
"     <li>",
"      Chronic watery diarrhea",
"     </li>",
"     <li>",
"      Chronic abdominal pain, especially in the right lower quadrant",
"     </li>",
"     <li>",
"      Perianal abscesses, fistulae, and fissures, oral ulcers, or arthritis &nbsp;",
"     </li>",
"     <li>",
"      Laboratory abnormalities including anemia, elevated white blood cell and platelet count, elevated erythrocyte sedimentation rate (ESR), elevated C-reactive protein (CRP), depressed albumin level, occult blood in the stool, elevated fecal calprotectin or leukocytes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most patients with suspected IBD should be evaluated with each of the following steps. A definitive diagnosis and classification cannot be made without imaging and endoscopic evaluation. The order of evaluation depends on the type and severity of presenting features. Patients with isolated mild symptoms may not require completion of each of these steps, but should be monitored.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Testing of the stool for enteric pathogens, including C. difficile",
"     </li>",
"     <li>",
"      Endoscopy &ndash; Usually both colonoscopy and upper endoscopy",
"     </li>",
"     <li>",
"      Small bowel imaging (eg, abdominal MR enterography, upper gastrointestinal series with small bowel follow-through)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Depending on the dominant clinical symptoms, testing to exclude other conditions also may be required. (See",
"    <a class=\"local\" href=\"#H9479602\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8243939\">",
"    <span class=\"h2\">",
"     Stool testing for enteric pathogens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients presenting with diarrhea (especially bloody diarrhea) should be evaluated with a stool culture, and tests for C. difficile toxin [",
"    <a class=\"abstract\" href=\"UTD.htm?26/25/27034/abstract/38\">",
"     38",
"    </a>",
"    ]. Infection with an enteric pathogen can mimic IBD. However, they can also trigger IBD, so the presence of an enteric pathogen does not exclude the possibility of IBD. Therefore, if enteric pathogens are identified, they should be treated. However, patients that fail to respond to treatment, or those with symptoms of IBD other than bloody diarrhea, including growth failure, should also be fully evaluated with endoscopy and imaging. If colonoscopy is performed, histopathologic features that suggest chronicity support the diagnosis of IBD rather than an infectious colitis. (See",
"    <a class=\"local\" href=\"#H9479602\">",
"     'Differential diagnosis'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H9480161\">",
"     'Features of UC'",
"    </a>",
"    below.) &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13111353\">",
"    <span class=\"h2\">",
"     Endoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Colonoscopy should be performed in patients with suspected IBD, even in the absence of clear lower gastrointestinal symptoms such as bloody diarrhea. During colonoscopy, the terminal ileum should be examined if possible, and random biopsies should be taken from the terminal ileum and from each segment of the colon. The specimens should be labeled separately for histopathologic examination to document the location of microscopic abnormalities. Many centers routinely perform upper endoscopy at the time of colonoscopy even in the absence of upper gastrointestinal symptoms, in an effort to help differentiate between UC and CD [",
"    <a class=\"abstract\" href=\"UTD.htm?26/25/27034/abstract/1,30,38-40\">",
"     1,30,38-40",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H9481834\">",
"     'Differentiation between Crohn's disease and ulcerative colitis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    We and many other endoscopists prefer to perform colonoscopy in children under general anesthesia. This approach improves patient comfort and increases the likelihood of a complete endoscopic examination. In a registry of children undergoing colonoscopy for a variety of indications, the short-term complication rate of the procedure was approximately 1 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/25/27034/abstract/41\">",
"     41",
"    </a>",
"    ]. Cardiopulmonary compromise associated with sedation and bleeding from polypectomy accounted for many of the complications in this series. The rate of complications is considerably lower when general anesthesia is used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13111361\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to endoscopy, imaging of the upper gastrointestinal tract (esophagus, stomach, duodenum, and the small intestine) is recommended, primarily to distinguish between UC and CD. This is because parts of the upper gastrointestinal tract are not accessible to the endoscope, and because certain features of CD, such as stricturing and transmural inflammation, are better assessed by imaging techniques.",
"   </p>",
"   <p>",
"    At this time, the test of choice for radiographic imaging of the small bowel is changing. Traditionally, upper GI series with small bowel follow-through",
"    <span class=\"nowrap\">",
"     (UGI/SBFT)",
"    </span>",
"    has been utilized. However, magnetic resonance (MR) enterography is increasingly being utilized at many centers, primarily because it avoids radiation exposure. The relative advantages and disadvantages of each modality are outlined below [",
"    <a class=\"abstract\" href=\"UTD.htm?26/25/27034/abstract/42\">",
"     42",
"    </a>",
"    ]. Additional information on imaging safety is available at",
"    <a class=\"external\" href=\"file://www.imagegently.com/\">",
"     www.imagegently.com",
"    </a>",
"    , and in a separate topic. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/17/21785?source=see_link\">",
"     \"Radiation-related risks of imaging studies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       UGI/SBFT",
"      </span>",
"      &ndash;",
"      <span class=\"nowrap\">",
"       UGI/SBFT",
"      </span>",
"      is the best established imaging technique to evaluate the small bowel for suspected CD [",
"      <a class=\"abstract\" href=\"UTD.htm?26/25/27034/abstract/30\">",
"       30",
"      </a>",
"      ]. This modality provides good visualization of the small bowel lumen, revealing strictures and fistulas, but does not generally detect ulcers or erosions. It exposes the patient to a moderate amount of radiation, but less radiation than a CT scan, particularly if pediatric dose-minimizing protocols are used [",
"      <a class=\"abstract\" href=\"UTD.htm?26/25/27034/abstract/43,44\">",
"       43,44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Computed tomography (CT) &ndash; CT with oral contrast also provides good visualization of the bowel lumen and bowel wall, with the additional advantage of imaging extraintestinal complications such as abscess. Thus, this modality is often preferred over",
"      <span class=\"nowrap\">",
"       UGI/SBFT",
"      </span>",
"      for patients with a clinical suspicion of abscess. The radiation dose of CT is generally higher than for",
"      <span class=\"nowrap\">",
"       UGI/SBFT,",
"      </span>",
"      although this varies with the fluoroscopy time and CT technique used [",
"      <a class=\"abstract\" href=\"UTD.htm?26/25/27034/abstract/43,44\">",
"       43,44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Magnetic resonance imaging (MRI) &ndash; MRI is increasingly being used for imaging of the small bowel and extraintestinal findings (eg, perianal fistula) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/25/27034/abstract/45,46\">",
"       45,46",
"      </a>",
"      ]. The main advantage of MRI is avoidance of radiation exposure [",
"      <a class=\"abstract\" href=\"UTD.htm?26/25/27034/abstract/47\">",
"       47",
"      </a>",
"      ]. However, the technique is less well established than",
"      <span class=\"nowrap\">",
"       UGI/SBFT",
"      </span>",
"      and is more costly. MR enterography combines large volume oral contrast distension of the bowel with intravenous administration of a gadolinium-based contrast material to increase the detection of bowel wall lesions and inflammatory activity [",
"      <a class=\"abstract\" href=\"UTD.htm?26/25/27034/abstract/48\">",
"       48",
"      </a>",
"      ]. The patient is prepared with the oral administration of an osmotic agent, such as",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/38/25189?source=see_link\">",
"       polyethylene glycol-electrolyte solution",
"      </a>",
"      (PEG) or mixture of dilute",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"       barium",
"      </a>",
"      and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/33/32275?source=see_link\">",
"       sorbitol",
"      </a>",
"      (VoLumen, E-Z-EM) to distend the bowel. The quality of the study is affected by the patient&rsquo;s ability to drink adequate amounts of contrast and cooperate with breath holding sequences. Preliminary studies suggest that MR enterography has moderately good sensitivity for detecting abnormalities of the terminal ileum in children (80 to 87 percent sensitivity) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/25/27034/abstract/48-52\">",
"       48-52",
"      </a>",
"      ]. &nbsp; &nbsp; &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The relative merits of fistulography, CT, MRI, and ultrasonography in evaluating anal fistulas are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/25/39319?source=see_link\">",
"     \"The role of imaging tests in the evaluation of anal abscesses and fistulas\"",
"    </a>",
"    .) &nbsp; &nbsp; &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23926440\">",
"    <span class=\"h2\">",
"     Other modalities",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Video capsule endoscopy &ndash; Video capsule endoscopy (VCE) is increasingly used in adults for diagnosis and assessment of severity of CD [",
"      <a class=\"abstract\" href=\"UTD.htm?26/25/27034/abstract/53\">",
"       53",
"      </a>",
"      ]. The role of this procedure in children with suspected IBD is evolving; it is approved by the United States Food and Drug Administration for children older than 10 years. The technique has been effective in identifying small bowel involvement in IBD, which may be important for treatment decisions [",
"      <a class=\"abstract\" href=\"UTD.htm?26/25/27034/abstract/54-60\">",
"       54-60",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14089?source=see_link\">",
"       \"Endoscopic diagnosis of inflammatory bowel disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17178?source=see_link\">",
"       \"Wireless video capsule endoscopy\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      It is unclear if the complication rate is higher in pediatric patients undergoing VCE as compared with adults. In a series of 207 capsule endoscopies performed on pediatric patients (age range 8 to 21 years), the risk of symptomatic capsule retention was 5 percent among patients with known IBD (3 of 58 patients) and 38 percent among those with CD and known small bowel abnormalities (3 of 8 patients) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/25/27034/abstract/58\">",
"       58",
"      </a>",
"      ]. A meta-analysis that included the above study and 14 others reported capsule retention rates of 2.5 percent among patients with CD",
"      <span class=\"nowrap\">",
"       (9/359",
"      </span>",
"      procedures), which is similar to retention rates in adults with CD, but somewhat higher than for children undergoing VCE for other indications [",
"      <a class=\"abstract\" href=\"UTD.htm?26/25/27034/abstract/61\">",
"       61",
"      </a>",
"      ]. VCE detected a greater extent of CD as compared to",
"      <span class=\"nowrap\">",
"       UGI/SBFT,",
"      </span>",
"      and refined medical management for about half of the patients with known CD [",
"      <a class=\"abstract\" href=\"UTD.htm?26/25/27034/abstract/62\">",
"       62",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Ultrasonography &ndash; Ultrasonography is utilized for small bowel imaging of IBD at some centers. The sensitivity and specificity are highly dependent on the experience of the operator, but are reported to be between 76 and 92 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?26/25/27034/abstract/42,63\">",
"       42,63",
"      </a>",
"      ]. Sonographic features suggesting small bowel involvement include bowel wall thickening and stiffness, and changes in the bowel wall stratification. Superficial mucosal abnormalities are not detectable by ultrasound [",
"      <a class=\"abstract\" href=\"UTD.htm?26/25/27034/abstract/64-67\">",
"       64-67",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9479602\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Considerations in the differential diagnosis depend on dominant clinical features of an individual patient:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11173222\">",
"    <span class=\"h2\">",
"     Rectal bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infectious causes of intestinal inflammation that can mimic UC or CD include Salmonella, Shigella, Yersinia, Campylobacter, Aeromonas, enterohemorrhagic E. coli, amoeba, and C. difficile. In some cases, inflammatory bowel disease (IBD) can be triggered by an enteric infection, particularly C. difficile [",
"    <a class=\"abstract\" href=\"UTD.htm?26/25/27034/abstract/68\">",
"     68",
"    </a>",
"    ]. Therefore, the presence of one of these pathogens does not exclude IBD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/5/14426?source=see_link\">",
"     \"Clostridium difficile infection in children: Treatment and prevention\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H8243939\">",
"     'Stool testing for enteric pathogens'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Henoch-Sch&ouml;nlein purpura (HSP) also can cause rectal bleeding and abdominal pain, but almost all patients with HSP also have characteristic purpuric skin lesions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/49/40729?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Henoch-Sch&ouml;nlein purpura (IgA vasculitis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are case reports of apparent UC presenting in infants with genetic mutations of familial Mediterranean fever [",
"    <a class=\"abstract\" href=\"UTD.htm?26/25/27034/abstract/69\">",
"     69",
"    </a>",
"    ]. These reports and epidemiologic studies in populations of adults suggest that the genes responsible for familial Mediterranean fever may have a disease-modifying effect on inflammatory bowel disease [",
"    <a class=\"abstract\" href=\"UTD.htm?26/25/27034/abstract/70\">",
"     70",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/31/25078?source=see_link\">",
"     \"Clinical manifestations and diagnosis of familial Mediterranean fever\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In children with rectal bleeding but few other symptoms suggestive of IBD, other causes of rectal bleeding should be ruled out, including anal fissures or hemorrhoids, polyps, intussusception, and Meckel's diverticulum. These children also may have UC limited to the rectum (ulcerative proctitis). In infants and very young children (eg, younger than two years), intolerance to milk or other dietary protein is a common cause of colitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/52/29513?source=see_link\">",
"     \"Diagnostic approach to lower gastrointestinal bleeding in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11173229\">",
"    <span class=\"h2\">",
"     Growth failure and diarrhea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children presenting with growth failure",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    non-bloody diarrhea should be evaluated for celiac disease. This can be done by serologic testing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/3/37946?source=see_link\">",
"     \"Clinical manifestations and diagnosis of celiac disease in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11173236\">",
"    <span class=\"h2\">",
"     Abdominal pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with diffuse or poorly localized abdominal pain, the differential diagnosis includes functional gastrointestinal disease (including constipation and irritable bowel syndrome), which is very common. IBD is generally distinguished from functional abdominal pain by the presence of additional symptoms (including diarrhea, rectal bleeding",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    growth failure) and laboratory abnormalities. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/17/1306?source=see_link&amp;anchor=H12#H12\">",
"     \"Evaluation of the child and adolescent with chronic abdominal pain\", section on 'Functional disorders'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Focal abdominal pain, particularly in the right lower quadrant, is more suspicious for IBD (particularly CD). For patients presenting with right lower quadrant pain, the differential diagnosis includes appendicitis and (very rarely) tuberculosis or lymphoma. In adolescent girls, gynecologic disease must be considered. In patients with an abdominal abscess, the differential diagnosis includes a perforated appendix, vasculitic perforation, or trauma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/20/11593?source=see_link\">",
"     \"Causes of acute abdominal pain in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11173243\">",
"    <span class=\"h2\">",
"     Extraintestinal symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extraintestinal symptoms associated with IBD include arthritis, oral ulcers (aphthous stomatitis), skin disease (erythema nodosum and pyoderma gangrenosum) and",
"    <span class=\"nowrap\">",
"     episcleritis/iritis.",
"    </span>",
"    These manifestations rarely occur in the absence of gastrointestinal symptoms. The differential diagnosis of each is discussed above. (See",
"    <a class=\"local\" href=\"#H1351752\">",
"     'Extraintestinal manifestations'",
"    </a>",
"    above.) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9481834\">",
"    <span class=\"h1\">",
"     DIFFERENTIATION BETWEEN CROHN'S DISEASE AND ULCERATIVE COLITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Classification of the inflammatory bowel disease (IBD) facilitates clinical decisions, discussions with the family, eligibility for clinical trials, and epidemiologic research. If possible, the disease should be classified as either Crohn's disease (CD) or ulcerative colitis (UC) (",
"    <a class=\"graphic graphic_table graphicRef74564 \" href=\"UTD.htm?40/50/41772\">",
"     table 3",
"    </a>",
"    ). This classification usually is accomplished with the combination of endoscopy and imaging of the upper gastrointestinal tract. The provider should make every effort to classify the disease using standardized criteria. If the disease type remains uncertain after complete evaluation, the term \"indeterminate\" colitis is used. Some newer classifications schemes suggest using the term \"colonic IBD, type unclassified\", reserving \"indeterminate colitis\" for patients in whom the type of IBD remains uncertain after colectomy and pathological evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/25/27034/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Guidelines for the classification of IBD in children were developed by a committee of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/25/27034/abstract/30\">",
"     30",
"    </a>",
"    ], and are summarized in the algorithm (",
"    <a class=\"graphic graphic_algorithm graphicRef81966 \" href=\"UTD.htm?24/33/25107\">",
"     algorithm 1",
"    </a>",
"    ). &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9480154\">",
"    <span class=\"h2\">",
"     Features of CD",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a patient with IBD involving the colon, UC is distinguished from CD by a process of elimination. Any of the following features are diagnostic of CD in a patient with IBD [",
"    <a class=\"abstract\" href=\"UTD.htm?26/25/27034/abstract/30\">",
"     30",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Physical examination &ndash; Perianal fistulae, abscess, or large (&gt;5mm) skin tags.",
"     </li>",
"     <li>",
"      Imaging",
"      <span class=\"nowrap\">",
"       (UGI/SBFT,",
"      </span>",
"      MRI, CT) &ndash; Definitive small bowel involvement, with mucosal ulceration, cobblestoning, narrowing or obstruction, or enteric fistulae. Note that some MRI or CT findings (eg &ldquo;small bowel enhancement\", or wall thickening) may be nonspecific &ldquo;false positives&rdquo;.",
"     </li>",
"     <li>",
"      Gross features at colonoscopy &ndash; Colonoscopic findings diagnostic of CD include ulceration and stenosis of the ileocecal valve, cobblestoning or linear ulcerations in the ileum, and stricture and fistula formation. &nbsp;",
"     </li>",
"     <li>",
"      Histopathologic features &ndash; Noncaseating granulomas (",
"      <a class=\"graphic graphic_picture graphicRef60769 \" href=\"UTD.htm?8/26/8615\">",
"       picture 3",
"      </a>",
"      ) in a patient with IBD are diagnostic of CD, unless they are adjacent to ruptured crypts. However, mucosal biopsies reveal these lesions in only 25 to 50 percent of patients with CD [",
"      <a class=\"abstract\" href=\"UTD.htm?26/25/27034/abstract/30,72,73\">",
"       30,72,73",
"      </a>",
"      ]. Transmural lymphoid aggregates are also diagnostic, but these can only be identified at colectomy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In patients lacking the above diagnostic findings, CD should still be suspected if any of the following suggestive features are present: growth failure or right lower quadrant mass, imaging studies showing cecal narrowing, bowel rigidity, and bowel wall edema manifested by separation of bowel loops (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef71543 \" href=\"UTD.htm?20/18/20768\">",
"     image 1",
"    </a>",
"    ), or colonoscopic findings of small ulcers (aphthous lesions) in the colon, or discontinuous colitis with intervening areas of normal mucosa (\"skip areas\") (",
"    <a class=\"graphic graphic_picture graphicRef78561 graphicRef68093 graphicRef71769 \" href=\"UTD.htm?12/31/12791\">",
"     picture 4A-C",
"    </a>",
"    ). Patients with these suggestive features but no diagnostic findings of CD should be provisionally classified as indeterminate colitis (or provisionally classified as CD), and the suspicious features should be followed closely over time in an effort to establish a definitive diagnosis of CD or UC.",
"   </p>",
"   <p>",
"    Although upper gastrointestinal tract involvement is a feature of CD but not UC, the finding of a nonspecific gastritis on upper endoscopy does not help to distinguish the two disorders. This was shown in a prospective study in a cohort of patients with CD or UC who underwent upper endoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/25/27034/abstract/16\">",
"     16",
"    </a>",
"    ]. Both groups had endoscopic and histologic features of gastritis (92 versus 69 percent in CD versus UC, respectively) and duodenitis (33 versus 23 percent in CD versus UC, respectively).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9480161\">",
"    <span class=\"h2\">",
"     Features of UC",
"    </span>",
"    &nbsp;&mdash;&nbsp;In UC, typical findings on colonoscopy include a diffuse, continuous process starting at the rectum and extending more proximally into the colon (",
"    <a class=\"graphic graphic_picture graphicRef76332 \" href=\"UTD.htm?43/47/44786\">",
"     picture 5",
"    </a>",
"    ). Active disease is characterized by diffuse and continuous edema, erythema, induced and spontaneous friability, and ulceration. The distal colon is usually more severely involved than more proximal aspects of the colon. In severe, relatively acute disease, extensive erosions and ulcerations may be present. Patients with longer-standing disease may have \"pseudopolyps,\" which are islands of regenerating mucosa that appear polypoid, surrounded by relatively atrophic tissue.",
"   </p>",
"   <p>",
"    The histological features of UC include mucosal and submucosal inflammation, cryptitis, and crypt abscess formation; distortion of the architecture; basal lymphoid aggregates; and the presence of Paneth cells in the left colon. The last three features listed suggest chronicity, which if present helps to distinguish the disease from an infectious colitis, which tends to be acute. The inflammation is typically diffuse, as compared with the patchy patterns often observed in patients with CD. However, early in the course of pediatric ulcerative colitis, atypical histologic features may be seen, including patchy disease and relative rectal sparing [",
"    <a class=\"abstract\" href=\"UTD.htm?26/25/27034/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following clinical features are not typical of UC, so they are sometimes called &ldquo;nonclassic&rdquo; features. They are found with sufficient frequency in patients with UC that they do not necessarily exclude that diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/25/27034/abstract/30\">",
"     30",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Small anal fissures and skin tags; oral ulcers",
"     </li>",
"     <li>",
"      Gross or histologic evidence of gastritis (without aphthae)",
"     </li>",
"     <li>",
"      \"Backwash\" ileitis, defined as ileal erythema or histologic inflammation (but no linear ulceration or granuloma)",
"     </li>",
"     <li>",
"      Periappendiceal inflammation, even in a patient without pancolitis (\"cecal patch\") (",
"      <a class=\"graphic graphic_picture graphicRef53637 \" href=\"UTD.htm?41/40/42627\">",
"       picture 6",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Rectal inflammation that is less severe than in the more proximal colon (relative rectal sparing)",
"     </li>",
"     <li>",
"      Patchy distribution of colitis (histopathologically normal colonic mucosa between two areas of colonic inflammation)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9480168\">",
"    <span class=\"h2\">",
"     Antibody testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;It has been proposed that certain serum antibodies, specifically perinuclear antineutrophil cytoplasmic antibodies (P-ANCA) and anti-saccharomyces cerevisiae antibodies (ASCA), may be helpful for screening for IBD and discriminating UC from CD [",
"    <a class=\"abstract\" href=\"UTD.htm?26/25/27034/abstract/74-76\">",
"     74-76",
"    </a>",
"    ]. When combined into panels, the antibody tests have reasonably high sensitivities for detecting IBD (&gt;90 percent in populations with symptoms), but their ability to distinguish between UC and CD is not well validated [",
"    <a class=\"abstract\" href=\"UTD.htm?26/25/27034/abstract/77-79\">",
"     77-79",
"    </a>",
"    ]. Practice guidelines for children and adults are equivocal as to whether antibody testing may contribute useful information to the evaluation of a patient with indeterminate colitis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/25/27034/abstract/30,80\">",
"     30,80",
"    </a>",
"    ]. The sensitivity and specificity of P-ANCA and ASCA tests are similar in adults and children with IBD [",
"    <a class=\"abstract\" href=\"UTD.htm?26/25/27034/abstract/74-76,81\">",
"     74-76,81",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/0/20490?source=see_link&amp;anchor=H12689197#H12689197\">",
"     \"Clinical manifestations, diagnosis and prognosis of Crohn's disease in adults\", section on 'Antibody tests'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    The positive predictive value (PPV) of these tests depends on the prior likelihood of disease. Patients with low levels of symptoms, or patients from populations with a low incidence of IBD, are more likely to have false-positive results [",
"    <a class=\"abstract\" href=\"UTD.htm?26/25/27034/abstract/78\">",
"     78",
"    </a>",
"    ]. The tests have greater PPV for patients with higher levels of symptoms, but in most cases these symptoms would be sufficient indication for proceeding with an endoscopic evaluation. Thus, antibody testing for IBD does not generally contribute useful information to management decisions.",
"   </p>",
"   <p>",
"    Positive ASCA tests are weakly associated with CD, and positive P-ANCA is weakly associated with UC:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      ASCA antibodies are found in 40 to 80 percent of individuals with CD, tend to identify patients with disease of the terminal ileum and cecum, and are unusual in patients with UC.",
"     </li>",
"     <li>",
"      P-ANCA can be detected in 60 to 80 percent of children and adults with ulcerative colitis compared to 10 to 27 percent of adults with CD (in whom only low titers may be present) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/25/27034/abstract/74,82,83\">",
"       74,82,83",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with CD who have P-ANCA antibodies often exhibit UC-like features, with disease limited to the colon. Thus, the serotype may be more closely associated with colonic disease location than with disease type [",
"      <a class=\"abstract\" href=\"UTD.htm?26/25/27034/abstract/30,84,85\">",
"       30,84,85",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The anti-OmpC antibody has been identified as a potential serologic marker of IBD [",
"    <a class=\"abstract\" href=\"UTD.htm?26/25/27034/abstract/86\">",
"     86",
"    </a>",
"    ]. The OmpC is an outer membrane porin, E. coli protein that is immunoreactive to P-ANCA monoclonal antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?26/25/27034/abstract/87\">",
"     87",
"    </a>",
"    ]. In a study of 198 children, anti-OmpC was detected in 25 percent of patients with CD (n = 81), 11 percent of patients with UC (n = 54), and 5 percent of controls (n = 63) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/25/27034/abstract/76\">",
"     76",
"    </a>",
"    ]. Because anti-OmpC was positive in nine children with IBD who were not detected by ASCA (IgA and IgG) or P-ANCA, the addition of anti-OmpC to these antibody assays increased the sensitivity from 63 to 70 percent, but decreased the specificity from 97 to 94 percent.",
"   </p>",
"   <p>",
"    Antibodies to the bacterial flagellin CBir1 are found in approximately 50 percent of individuals with CD, and have been associated with small bowel, internal-penetrating and fibrostenosing patterns [",
"    <a class=\"abstract\" href=\"UTD.htm?26/25/27034/abstract/78,88\">",
"     78,88",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     LOCALIZATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The location of the disease should be determined as accurately as possible, based on a combination of imaging, endoscopic and histopathologic results. For ulcerative colitis (UC), the disease involvement should be categorized as proctitis (rectal involvement limited to 15 cm or less), left-sided colitis, or pancolitis (extending past the splenic flexure). For Crohn's disease (CD), localizing disease means identifying whether the mouth, esophagus, stomach, small bowel, colon, or anus are involved. By defining the affected areas of the gastrointestinal tract, the clinician will be able to better target medical management appropriately.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?28/55/29554?source=see_link\">",
"       \"Patient information: Crohn&rsquo;s disease in children (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?37/33/38418?source=see_link\">",
"       \"Patient information: Ulcerative colitis in children (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with suspected inflammatory bowel disease (IBD), a series of steps are taken to establish whether IBD is present, whether the disease is of the Crohn versus ulcerative colitis (UC) subtype, and to identify the extent of involvement in the bowel and other organs.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      IBD should be considered in a child or adolescent presenting with loose stools or bloody diarrhea, abdominal pain, weight loss or growth failure, perianal disease, anemia, arthritis, or delayed onset of puberty (",
"      <a class=\"graphic graphic_table graphicRef77827 \" href=\"UTD.htm?11/2/11309\">",
"       table 1",
"      </a>",
"      ). Clinical features supportive of the diagnosis include abdominal tenderness, oral ulcers, or perianal disease. Laboratory testing often reveals anemia, hypoalbuminemia,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      an elevated erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP); however, laboratory studies are normal in a significant number of children with IBD. (See",
"      <a class=\"local\" href=\"#H184210419\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Extraintestinal manifestations of IBD may involve the skin, joints, liver, eye, bones, and (rarely) other organs (",
"      <a class=\"graphic graphic_table graphicRef81867 \" href=\"UTD.htm?27/32/28173\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1351752\">",
"       'Extraintestinal manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients presenting with rectal bleeding, laboratory testing should be performed to exclude other illnesses. If diarrhea or loose stools are present, stool cultures should be performed to identify enteric pathogens. A vasculitic rash or arthralgia suggests the possibility of Henoch-Sch&ouml;nlein purpura. If stools are formed (ie, not diarrhea), other causes of rectal bleeding should be explored, including Meckel's diverticulum and anal fissures. (See",
"      <a class=\"local\" href=\"#H9479602\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If the clinical presentation",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      initial laboratory testing support the diagnosis of IBD, further evaluation should include both small bowel imaging and colonoscopy, (with biopsies taken from the terminal ileum, if possible). Biopsies from the terminal ileum and each segment of the colon should be sent for histopathologic examination. Upper endoscopy is also routinely performed at the time of the initial colonoscopy in many centers, and provides further information as to disease type and extent (",
"      <a class=\"graphic graphic_table graphicRef77827 \" href=\"UTD.htm?11/2/11309\">",
"       table 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/25/27034/abstract/40\">",
"       40",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H13111353\">",
"       'Endoscopy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13111361\">",
"       'Imaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with colitis, these tests also are used to differentiate between UC and Crohn's disease (CD) (",
"      <a class=\"graphic graphic_algorithm graphicRef81966 \" href=\"UTD.htm?24/33/25107\">",
"       algorithm 1",
"      </a>",
"      ). Features diagnostic of CD include evidence of small bowel involvement on upper GI series with small bowel follow-through",
"      <span class=\"nowrap\">",
"       (UGI/SBFT)",
"      </span>",
"      or magnetic resonance (MR) enterography, noncaseating granulomas on histopathologic examination, or marked perianal disease (",
"      <a class=\"graphic graphic_table graphicRef74564 \" href=\"UTD.htm?40/50/41772\">",
"       table 3",
"      </a>",
"      ). Antibody tests for P-ANCA, ASCA, and anti-OmpC are sometimes used to supplement the diagnostic evaluation, but do not reliably differentiate between the disease subtypes. (See",
"      <a class=\"local\" href=\"#H9481834\">",
"       'Differentiation between Crohn's disease and ulcerative colitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The location of the bowel disease is identified with the small bowel imaging, colonoscopy, and at certain centers, upper endoscopy. In addition to helping to classify the IBD into CD or UC subtypes, this information is often important in choosing types of therapy. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Localization'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27034/abstract/1\">",
"      Abdullah BA, Gupta SK, Croffie JM, et al. The role of esophagogastroduodenoscopy in the initial evaluation of childhood inflammatory bowel disease: a 7-year study. J Pediatr Gastroenterol Nutr 2002; 35:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27034/abstract/2\">",
"      Kugathasan S, Nebel J, Skelton JA, et al. Body mass index in children with newly diagnosed inflammatory bowel disease: observations from two multicenter North American inception cohorts. J Pediatr 2007; 151:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27034/abstract/3\">",
"      Heyman MB, Kirschner BS, Gold BD, et al. Children with early-onset inflammatory bowel disease (IBD): analysis of a pediatric IBD consortium registry. J Pediatr 2005; 146:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27034/abstract/4\">",
"      Gryboski JD. Crohn's disease in children 10 years old and younger: comparison with ulcerative colitis. J Pediatr Gastroenterol Nutr 1994; 18:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27034/abstract/5\">",
"      Kanof ME, Lake AM, Bayless TM. Decreased height velocity in children and adolescents before the diagnosis of Crohn's disease. Gastroenterology 1988; 95:1523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27034/abstract/6\">",
"      Jose FA, Garnett EA, Vittinghoff E, et al. Development of extraintestinal manifestations in pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis 2009; 15:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27034/abstract/7\">",
"      Dotson JL, Hyams JS, Markowitz J, et al. Extraintestinal manifestations of pediatric inflammatory bowel disease and their relation to disease type and severity. J Pediatr Gastroenterol Nutr 2010; 51:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27034/abstract/8\">",
"      Galbraith SS, Drolet BA, Kugathasan S, et al. Asymptomatic inflammatory bowel disease presenting with mucocutaneous findings. Pediatrics 2005; 116:e439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27034/abstract/9\">",
"      Farhi D, Cosnes J, Zizi N, et al. Significance of erythema nodosum and pyoderma gangrenosum in inflammatory bowel diseases: a cohort study of 2402 patients. Medicine (Baltimore) 2008; 87:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27034/abstract/10\">",
"      Dinulos JG, Darmstadt GL, Len MK, et al. Infantile Crohn disease presenting with diarrhea and pyoderma gangrenosum. Pediatr Dermatol 2006; 23:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27034/abstract/11\">",
"      Petrelli EA, McKinley M, Troncale FJ. Ocular manifestations of inflammatory bowel disease. Ann Ophthalmol 1982; 14:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27034/abstract/12\">",
"      Lyons JL, Rosenbaum JT. Uveitis associated with inflammatory bowel disease compared with uveitis associated with spondyloarthropathy. Arch Ophthalmol 1997; 115:61.",
"     </a>",
"    </li>",
"    <li>",
"     Levine, J. Arthropathies and ocular complications of inflammatory bowel disease. In: Targan, S, Shanahan, F (Eds). Inflammatory bowel disease: from bench to bedside. Williams and Wilkins, Baltimore 1994. p.450.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27034/abstract/14\">",
"      Passo MH, Fitzgerald JF, Brandt KD. Arthritis associated with inflammatory bowel disease in children. Relationship of joint disease to activity and severity of bowel lesion. Dig Dis Sci 1986; 31:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27034/abstract/15\">",
"      Palm &Oslash;, Moum B, Jahnsen J, Gran JT. The prevalence and incidence of peripheral arthritis in patients with inflammatory bowel disease, a prospective population-based study (the IBSEN study). Rheumatology (Oxford) 2001; 40:1256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27034/abstract/16\">",
"      Tobin JM, Sinha B, Ramani P, et al. Upper gastrointestinal mucosal disease in pediatric Crohn disease and ulcerative colitis: a blinded, controlled study. J Pediatr Gastroenterol Nutr 2001; 32:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27034/abstract/17\">",
"      Bousvaros A, Marcon M, Treem W, et al. Chronic recurrent multifocal osteomyelitis associated with chronic inflammatory bowel disease in children. Dig Dis Sci 1999; 44:2500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27034/abstract/18\">",
"      Mendes FD, Levy C, Enders FB, et al. Abnormal hepatic biochemistries in patients with inflammatory bowel disease. Am J Gastroenterol 2007; 102:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27034/abstract/19\">",
"      Lorusso D, Leo S, Mossa A, et al. Cholelithiasis in inflammatory bowel disease. A case-control study. Dis Colon Rectum 1990; 33:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27034/abstract/20\">",
"      Parente F, Pastore L, Bargiggia S, et al. Incidence and risk factors for gallstones in patients with inflammatory bowel disease: a large case-control study. Hepatology 2007; 45:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27034/abstract/21\">",
"      Perdigoto R, Carpenter HA, Czaja AJ. Frequency and significance of chronic ulcerative colitis in severe corticosteroid-treated autoimmune hepatitis. J Hepatol 1992; 14:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27034/abstract/22\">",
"      Hyams, J, Markowitz, J, Treem, W, et al. Characterization of hepatic abnormalities in children with inflammatory bowel disease. Inflamm Bowel Dis 1995; 1:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27034/abstract/23\">",
"      Gilger MA, Gann ME, Opekun AR, Gleason WA Jr. Efficacy of ursodeoxycholic acid in the treatment of primary sclerosing cholangitis in children. J Pediatr Gastroenterol Nutr 2000; 31:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27034/abstract/24\">",
"      Chapman R, Fevery J, Kalloo A, et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology 2010; 51:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27034/abstract/25\">",
"      Krishnan S, Banquet A, Newman L, et al. Lung lesions in children with Crohn's disease presenting as nonresolving pneumonias and response to infliximab therapy. Pediatrics 2006; 117:1440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27034/abstract/26\">",
"      Mack DR, Langton C, Markowitz J, et al. Laboratory values for children with newly diagnosed inflammatory bowel disease. Pediatrics 2007; 119:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27034/abstract/27\">",
"      Beattie RM, Walker-Smith JA, Murch SH. Indications for investigation of chronic gastrointestinal symptoms. Arch Dis Child 1995; 73:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27034/abstract/28\">",
"      Henderson P, Casey A, Lawrence SJ, et al. The diagnostic accuracy of fecal calprotectin during the investigation of suspected pediatric inflammatory bowel disease. Am J Gastroenterol 2012; 107:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27034/abstract/29\">",
"      Shaoul R, Sladek M, Turner D, et al. Limitations of fecal calprotectin at diagnosis in untreated pediatric Crohn's disease. Inflamm Bowel Dis 2012; 18:1493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27034/abstract/30\">",
"      North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition, Colitis Foundation of America, Bousvaros A, et al. Differentiating ulcerative colitis from Crohn disease in children and young adults: report of a working group of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the Crohn's and Colitis Foundation of America. J Pediatr Gastroenterol Nutr 2007; 44:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27034/abstract/31\">",
"      Kugathasan S, Judd RH, Hoffmann RG, et al. Epidemiologic and clinical characteristics of children with newly diagnosed inflammatory bowel disease in Wisconsin: a statewide population-based study. J Pediatr 2003; 143:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27034/abstract/32\">",
"      van Rheenen PF, Van de Vijver E, Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ 2010; 341:c3369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27034/abstract/33\">",
"      Van de Vijver E, Schreuder AB, Cnossen WR, et al. Safely ruling out inflammatory bowel disease in children and teenagers without referral for endoscopy. Arch Dis Child 2012; 97:1014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27034/abstract/34\">",
"      Sipponen T, Savilahti E, K&auml;rkk&auml;inen P, et al. Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn's disease. Inflamm Bowel Dis 2008; 14:1392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27034/abstract/35\">",
"      Lewis JD. The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. Gastroenterology 2011; 140:1817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27034/abstract/36\">",
"      D'Haens G, Ferrante M, Vermeire S, et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis 2012; 18:2218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27034/abstract/37\">",
"      Aomatsu T, Yoden A, Matsumoto K, et al. Fecal calprotectin is a useful marker for disease activity in pediatric patients with inflammatory bowel disease. Dig Dis Sci 2011; 56:2372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27034/abstract/38\">",
"      Turner D, Levine A, Escher JC, et al. Management of pediatric ulcerative colitis: joint ECCO and ESPGHAN evidence-based consensus guidelines. J Pediatr Gastroenterol Nutr 2012; 55:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27034/abstract/39\">",
"      Lemberg DA, Clarkson CM, Bohane TD, Day AS. Role of esophagogastroduodenoscopy in the initial assessment of children with inflammatory bowel disease. J Gastroenterol Hepatol 2005; 20:1696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27034/abstract/40\">",
"      IBD Working Group of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition. Inflammatory bowel disease in children and adolescents: recommendations for diagnosis--the Porto criteria. J Pediatr Gastroenterol Nutr 2005; 41:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27034/abstract/41\">",
"      Thakkar K, El-Serag HB, Mattek N, Gilger M. Complications of pediatric colonoscopy: a five-year multicenter experience. Clin Gastroenterol Hepatol 2008; 6:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27034/abstract/42\">",
"      Hiorns MP. Imaging of inflammatory bowel disease. How? Pediatr Radiol 2008; 38 Suppl 3:S512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27034/abstract/43\">",
"      Gaca AM, Jaffe TA, Delaney S, et al. Radiation doses from small-bowel follow-through and abdomen/pelvis MDCT in pediatric Crohn disease. Pediatr Radiol 2008; 38:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27034/abstract/44\">",
"      Desmond AN, O'Regan K, Curran C, et al. Crohn's disease: factors associated with exposure to high levels of diagnostic radiation. Gut 2008; 57:1524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27034/abstract/45\">",
"      Giles E, Hanci O, McLean A, et al. Optimal assessment of paediatric IBD with MRI and barium follow-through. J Pediatr Gastroenterol Nutr 2012; 54:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27034/abstract/46\">",
"      de Bie CI, Buderus S, Sandhu BK, et al. Diagnostic workup of paediatric patients with inflammatory bowel disease in Europe: results of a 5-year audit of the EUROKIDS registry. J Pediatr Gastroenterol Nutr 2012; 54:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27034/abstract/47\">",
"      Huang JS, Tobin A, Harvey L, Nelson TR. Diagnostic medical radiation in pediatric patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2011; 53:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27034/abstract/48\">",
"      Gee MS, Nimkin K, Hsu M, et al. Prospective evaluation of MR enterography as the primary imaging modality for pediatric Crohn disease assessment. AJR Am J Roentgenol 2011; 197:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27034/abstract/49\">",
"      Laghi A, Borrelli O, Paolantonio P, et al. Contrast enhanced magnetic resonance imaging of the terminal ileum in children with Crohn's disease. Gut 2003; 52:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27034/abstract/50\">",
"      Borthne AS, Abdelnoor M, Rugtveit J, et al. Bowel magnetic resonance imaging of pediatric patients with oral mannitol MRI compared to endoscopy and intestinal ultrasound. Eur Radiol 2006; 16:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27034/abstract/51\">",
"      Chalian M, Ozturk A, Oliva-Hemker M, et al. MR enterography findings of inflammatory bowel disease in pediatric patients. AJR Am J Roentgenol 2011; 196:W810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27034/abstract/52\">",
"      Absah I, Bruining DH, Matsumoto JM, et al. MR enterography in pediatric inflammatory bowel disease: retrospective assessment of patient tolerance, image quality, and initial performance estimates. AJR Am J Roentgenol 2012; 199:W367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27034/abstract/53\">",
"      Hara AK, Leighton JA, Heigh RI, et al. Crohn disease of the small bowel: preliminary comparison among CT enterography, capsule endoscopy, small-bowel follow-through, and ileoscopy. Radiology 2006; 238:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27034/abstract/54\">",
"      Guilhon de Araujo Sant'Anna AM, Dubois J, Miron MC, Seidman EG. Wireless capsule endoscopy for obscure small-bowel disorders: final results of the first pediatric controlled trial. Clin Gastroenterol Hepatol 2005; 3:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27034/abstract/55\">",
"      Mackalski BA, Bernstein CN. New diagnostic imaging tools for inflammatory bowel disease. Gut 2006; 55:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27034/abstract/56\">",
"      Moy L, Levine J. Wireless capsule endoscopy in the pediatric age group: experience and complications. J Pediatr Gastroenterol Nutr 2007; 44:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27034/abstract/57\">",
"      Moy L, Levine J. Capsule endoscopy in the evaluation of patients with unexplained growth failure. J Pediatr Gastroenterol Nutr 2009; 48:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27034/abstract/58\">",
"      Atay O, Mahajan L, Kay M, et al. Risk of capsule endoscope retention in pediatric patients: a large single-center experience and review of the literature. J Pediatr Gastroenterol Nutr 2009; 49:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27034/abstract/59\">",
"      Jensen MK, Tipnis NA, Bajorunaite R, et al. Capsule endoscopy performed across the pediatric age range: indications, incomplete studies, and utility in management of inflammatory bowel disease. Gastrointest Endosc 2010; 72:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27034/abstract/60\">",
"      Gralnek IM, Cohen SA, Ephrath H, et al. Small bowel capsule endoscopy impacts diagnosis and management of pediatric inflammatory bowel disease: a prospective study. Dig Dis Sci 2012; 57:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27034/abstract/61\">",
"      Cohen SA, Klevens AI. Use of capsule endoscopy in diagnosis and management of pediatric patients, based on meta-analysis. Clin Gastroenterol Hepatol 2011; 9:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27034/abstract/62\">",
"      Thomson M, Fritscher-Ravens A, Mylonaki M, et al. Wireless capsule endoscopy in children: a study to assess diagnostic yield in small bowel disease in paediatric patients. J Pediatr Gastroenterol Nutr 2007; 44:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27034/abstract/63\">",
"      Horsthuis K, Stokkers PC, Stoker J. Detection of inflammatory bowel disease: diagnostic performance of cross-sectional imaging modalities. Abdom Imaging 2008; 33:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27034/abstract/64\">",
"      Charron M, del Rosario FJ, Kocoshis SA. Pediatric inflammatory bowel disease: assessment with scintigraphy with 99mTc white blood cells. Radiology 1999; 212:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27034/abstract/65\">",
"      Alberini JL, Badran A, Freneaux E, et al. Technetium-99m HMPAO-labeled leukocyte imaging compared with endoscopy, ultrasonography, and contrast radiology in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2001; 32:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27034/abstract/66\">",
"      Charron M, Di Lorenzo C, Kocoshis S. Are 99mTc leukocyte scintigraphy and SBFT studies useful in children suspected of having inflammatory bowel disease? Am J Gastroenterol 2000; 95:1208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27034/abstract/67\">",
"      Charron M, del Rosario JF, Kocoshis S. Use of technetium-tagged white blood cells in patients with Crohn's disease and ulcerative colitis: is differential diagnosis possible? Pediatr Radiol 1998; 28:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27034/abstract/68\">",
"      Banaszkiewicz A, Kowalska-Duplaga K, Pytrus T, et al. Clostridium difficile infection in newly diagnosed pediatric patients with inflammatory bowel disease: prevalence and risk factors. Inflamm Bowel Dis 2012; 18:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27034/abstract/69\">",
"      Sari S, Egritas O, Dalgic B. The familial Mediterranean fever (MEFV) gene may be a modifier factor of inflammatory bowel disease in infancy. Eur J Pediatr 2008; 167:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27034/abstract/70\">",
"      Cattan D, Notarnicola C, Molinari N, Touitou I. Inflammatory bowel disease in non-Ashkenazi Jews with familial Mediterranean fever. Lancet 2000; 355:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27034/abstract/71\">",
"      Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005; 19 Suppl A:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27034/abstract/72\">",
"      Ruuska T, Vaajalahti P, Araj&auml;rvi P, M&auml;ki M. Prospective evaluation of upper gastrointestinal mucosal lesions in children with ulcerative colitis and Crohn's disease. J Pediatr Gastroenterol Nutr 1994; 19:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27034/abstract/73\">",
"      De Matos V, Russo PA, Cohen AB, et al. Frequency and clinical correlations of granulomas in children with Crohn disease. J Pediatr Gastroenterol Nutr 2008; 46:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27034/abstract/74\">",
"      Ruemmele FM, Targan SR, Levy G, et al. Diagnostic accuracy of serological assays in pediatric inflammatory bowel disease. Gastroenterology 1998; 115:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27034/abstract/75\">",
"      Dubinsky MC, Ofman JJ, Urman M, et al. Clinical utility of serodiagnostic testing in suspected pediatric inflammatory bowel disease. Am J Gastroenterol 2001; 96:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27034/abstract/76\">",
"      Zholudev A, Zurakowski D, Young W, et al. Serologic testing with ANCA, ASCA, and anti-OmpC in children and young adults with Crohn's disease and ulcerative colitis: diagnostic value and correlation with disease phenotype. Am J Gastroenterol 2004; 99:2235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27034/abstract/77\">",
"      Sabery N, Bass D. Use of serologic markers as a screening tool in inflammatory bowel disease compared with elevated erythrocyte sedimentation rate and anemia. Pediatrics 2007; 119:e193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27034/abstract/78\">",
"      Austin GL, Herfarth HH, Sandler RS. A critical evaluation of serologic markers for inflammatory bowel disease. Clin Gastroenterol Hepatol 2007; 5:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27034/abstract/79\">",
"      Benor S, Russell GH, Silver M, et al. Shortcomings of the inflammatory bowel disease Serology 7 panel. Pediatrics 2010; 125:1230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27034/abstract/80\">",
"      Kornbluth A, Sachar DB, Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2004; 99:1371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27034/abstract/81\">",
"      Quinton JF, Sendid B, Reumaux D, et al. Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut 1998; 42:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27034/abstract/82\">",
"      Winter HS, Landers CJ, Winkelstein A, et al. Anti-neutrophil cytoplasmic antibodies in children with ulcerative colitis. J Pediatr 1994; 125:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27034/abstract/83\">",
"      Terjung B, Spengler U, Sauerbruch T, Worman HJ. \"Atypical p-ANCA\" in IBD and hepatobiliary disorders react with a 50-kilodalton nuclear envelope protein of neutrophils and myeloid cell lines. Gastroenterology 2000; 119:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27034/abstract/84\">",
"      Rutgeerts P, Vermeire S. Serological diagnosis of inflammatory bowel disease. Lancet 2000; 356:2117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27034/abstract/85\">",
"      Joossens S, Reinisch W, Vermeire S, et al. The value of serologic markers in indeterminate colitis: a prospective follow-up study. Gastroenterology 2002; 122:1242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27034/abstract/86\">",
"      Nakamura RM, Barry M. Serologic markers in inflammatory bowel disease (IBD). MLO Med Lab Obs 2001; 33:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27034/abstract/87\">",
"      Cohavy O, Bruckner D, Gordon LK, et al. Colonic bacteria express an ulcerative colitis pANCA-related protein epitope. Infect Immun 2000; 68:1542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/25/27034/abstract/88\">",
"      Granito A, Zauli D, Muratori P, et al. Anti-Saccharomyces cerevisiae and perinuclear anti-neutrophil cytoplasmic antibodies in coeliac disease before and after gluten-free diet. Aliment Pharmacol Ther 2005; 21:881.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5879 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-217.16.9.173-D52E307D49-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_25_27034=[""].join("\n");
var outline_f26_25_27034=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H184210419\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Symptoms suggesting colitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Other gastrointestinal symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11172431\">",
"      Growth failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1351752\">",
"      Extraintestinal manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H184210643\">",
"      Laboratory features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20369433\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11172589\">",
"      Diagnostic approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8243939\">",
"      Stool testing for enteric pathogens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13111353\">",
"      Endoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13111361\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23926440\">",
"      Other modalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9479602\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11173222\">",
"      Rectal bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11173229\">",
"      Growth failure and diarrhea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11173236\">",
"      Abdominal pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11173243\">",
"      Extraintestinal symptoms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9481834\">",
"      DIFFERENTIATION BETWEEN CROHN'S DISEASE AND ULCERATIVE COLITIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9480154\">",
"      Features of CD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9480161\">",
"      Features of UC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9480168\">",
"      Antibody testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      LOCALIZATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5879\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5879|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?24/33/25107\" title=\"algorithm 1\">",
"      Crohns vs UC",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5879|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?20/18/20768\" title=\"diagnostic image 1\">",
"      Crohns UGI children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5879|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/14/11502\" title=\"figure 1\">",
"      Age at onset of IBD in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5879|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/46/8943\" title=\"picture 1\">",
"      Erythema nodosum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/48/26383\" title=\"picture 2\">",
"      Nodular episcleritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/26/8615\" title=\"picture 3\">",
"      Crohns granuloma Light",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/56/3983\" title=\"picture 4A\">",
"      Aphthous lesions Crohns Endosc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/19/4400\" title=\"picture 4B\">",
"      Linear ulcers Crohns Endosc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/50/31520\" title=\"picture 4C\">",
"      Patchy lesions Crohns Endosc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?43/47/44786\" title=\"picture 5\">",
"      Continuous lesions UC Endosc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/40/42627\" title=\"picture 6\">",
"      UC cecal patch",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5879|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/2/11309\" title=\"table 1\">",
"      Evaluation of child IBD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/32/28173\" title=\"table 2\">",
"      Extraintestinal manifest IBD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/50/41772\" title=\"table 3\">",
"      Compare UC Crohns",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/55/43897?source=related_link\">",
"      Approach to the adult with chronic diarrhea in developed countries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/44/25289?source=related_link\">",
"      Arthritis associated with gastrointestinal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/20/11593?source=related_link\">",
"      Causes of acute abdominal pain in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/49/40729?source=related_link\">",
"      Clinical manifestations and diagnosis of Henoch-Sch&ouml;nlein purpura (IgA vasculitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/3/37946?source=related_link\">",
"      Clinical manifestations and diagnosis of celiac disease in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/31/25078?source=related_link\">",
"      Clinical manifestations and diagnosis of familial Mediterranean fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/63/22521?source=related_link\">",
"      Clinical manifestations and diagnosis of primary sclerosing cholangitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/7/24693?source=related_link\">",
"      Clinical manifestations of Crohn's disease in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/0/20490?source=related_link\">",
"      Clinical manifestations, diagnosis and prognosis of Crohn's disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/5/14426?source=related_link\">",
"      Clostridium difficile infection in children: Treatment and prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/25/40342?source=related_link\">",
"      Colorectal cancer and primary sclerosing cholangitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/17/7450?source=related_link\">",
"      Definition, epidemiology, and risk factors in inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/52/29513?source=related_link\">",
"      Diagnostic approach to lower gastrointestinal bleeding in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14089?source=related_link\">",
"      Endoscopic diagnosis of inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/13/3288?source=related_link\">",
"      Epidemiology and environmental factors in inflammatory bowel disease in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/32/33289?source=related_link\">",
"      Evaluation and diagnosis of hematogenous osteomyelitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/17/1306?source=related_link\">",
"      Evaluation of the child and adolescent with chronic abdominal pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/46/2794?source=related_link\">",
"      Growth failure and poor weight gain in children with inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/31/22006?source=related_link\">",
"      Hepatobiliary manifestations of inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/48/27401?source=related_link\">",
"      Immune and microbial mechanisms in the pathogenesis of inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/54/30569?source=related_link\">",
"      Metabolic bone disease in inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/47/41722?source=related_link\">",
"      Overview of the management of Crohn's disease in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?28/55/29554?source=related_link\">",
"      Patient information: Crohn&rsquo;s disease in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/33/38418?source=related_link\">",
"      Patient information: Ulcerative colitis in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/22/29034?source=related_link\">",
"      Pulmonary complications of inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/17/21785?source=related_link\">",
"      Radiation-related risks of imaging studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41350?source=related_link\">",
"      Skin and eye manifestations of inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/25/39319?source=related_link\">",
"      The role of imaging tests in the evaluation of anal abscesses and fistulas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/8/41097?source=related_link\">",
"      Treatment of primary sclerosing cholangitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/34/4650?source=related_link\">",
"      Treatment of ulcerative colitis in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17178?source=related_link\">",
"      Wireless video capsule endoscopy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_25_27035="Survival after nutrition and hydration cessation";
var content_f26_25_27035=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F61932&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F61932&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Survival duration after the decision to forgo artificial nutrition and hydration",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Duration",
"       </td>",
"       <td class=\"subtitle1\">",
"        Absolute number",
"       </td>",
"       <td class=\"subtitle1\">",
"        Percent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Cumulative percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0 to 2 days",
"       </td>",
"       <td>",
"        50",
"       </td>",
"       <td>",
"        28",
"       </td>",
"       <td>",
"        28",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3 to 7 days",
"       </td>",
"       <td>",
"        56",
"       </td>",
"       <td>",
"        31",
"       </td>",
"       <td>",
"        59",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1 to 2 weeks",
"       </td>",
"       <td>",
"        28",
"       </td>",
"       <td>",
"        16",
"       </td>",
"       <td>",
"        75",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2 to 6 weeks",
"       </td>",
"       <td>",
"        17",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        85",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Greater than 6 weeks",
"       </td>",
"       <td>",
"        27",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        100",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     <p>",
"      &nbsp;",
"     </p>",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Pasman, HR, Onwuteaka-Philipsen, BD, Kriegsman, DM, et al. Discomfort in nursing home patients with severe dementia in whom artificial nutrition and hydration is forgone. Arch Intern Med 2005; 165:1729.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_25_27035=[""].join("\n");
var outline_f26_25_27035=null;
var title_f26_25_27036="Prevalence of substance abuse in pregnancy";
var content_f26_25_27036=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F62478&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F62478&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Percent of past month substance use among women aged 15 to 44",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Substance",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Pregnant",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Not pregnant",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        2009-2010",
"       </td>",
"       <td class=\"subtitle2\">",
"        2007-2008",
"       </td>",
"       <td class=\"subtitle2\">",
"        2009-2010",
"       </td>",
"       <td class=\"subtitle2\">",
"        2007-2008",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Alcohol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Any use",
"       </td>",
"       <td>",
"        10.8",
"       </td>",
"       <td>",
"        10.6",
"       </td>",
"       <td>",
"        54.7",
"       </td>",
"       <td>",
"        54.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Binge drinking*",
"       </td>",
"       <td>",
"        3.7",
"       </td>",
"       <td>",
"        4.5",
"       </td>",
"       <td>",
"        24.6",
"       </td>",
"       <td>",
"        24.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Heavy use&bull;",
"       </td>",
"       <td>",
"        1.0",
"       </td>",
"       <td>",
"        0.8",
"       </td>",
"       <td>",
"        5.4",
"       </td>",
"       <td>",
"        5.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Illicit drugs",
"        </strong>",
"        &Delta;",
"       </td>",
"       <td>",
"        4.4",
"       </td>",
"       <td>",
"        5.1",
"       </td>",
"       <td>",
"        10.9",
"       </td>",
"       <td>",
"        28.6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Cigarettes",
"        </strong>",
"       </td>",
"       <td>",
"        16.3",
"       </td>",
"       <td>",
"        16.4",
"       </td>",
"       <td>",
"        26.7",
"       </td>",
"       <td>",
"        27.3",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Defined as 5 or more drinks on the same occasion (at the same time or within a couple of hours of each other) on at least one day in the past 30. Please note that the National Institute on Alcohol Abuse and Alcoholism has defined binge drinking for women as 4 or more drinks on the same occasion, so these numbers are likely to be under-estimates.",
"     <br>",
"      &bull; Heavy alcohol use is defined as drinking 5 or more drinks on the same occasion on each of 5 or more days in the past 30 days; heavy alcohol users are also binge alcohol drinkers. Again, these definitions are underestimates of binge drinking women according to the NIAAA definition.",
"      <br>",
"       &Delta; Illicit drugs include marijuana/hashish, cocaine (including crack), heroin, hallucinogens, inhalants, or prescription type psychotherapeutics used non-medically.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     <p>",
"      Reproduced from: Substance Abuse and Mental Health Services Administration. Results from the 2010 National Survey on Drug Use and Health: Summary of National Findings. NSDH Series H-41, HHS Publication No (SMA) 11-4658. Substance Abuse and Mental Health Services Administration, Rockville MD 2011.",
"     </p>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_25_27036=[""].join("\n");
var outline_f26_25_27036=null;
var title_f26_25_27037="Endoscopic ureterocele decompression";
var content_f26_25_27037=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/PEDS/88334/Endo_ureteroce_decomp_video.mp4?title=Endoscopic+ureterocele+decompression\" style=\"width:368px;height:224px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Endoscopic ureterocele decompression of a right sided ureterocele with drainage of frank purulent material",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 313px; height: 227px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_25_27037=[""].join("\n");
var outline_f26_25_27037=null;
var title_f26_25_27038="Ixodes pacificus";
var content_f26_25_27038=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F60501&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F60501&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    An adult female Ixodes pacificus (western blacklegged tick)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 179px; height: 178px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Champman, AS, Bakken, JS, Folk, SM, et al. Diagnosis and management of tickborne rickettsial diseases: Rocky Mountain Spotted Fever, Ehrlichoioses, and Anaplasmosis-United States: A practical guide for physicians and other health-care and public health professionals. MMWR Recomm Rep 2006; 55(RR-4):1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_25_27038=[""].join("\n");
var outline_f26_25_27038=null;
var title_f26_25_27039="Risk factors acute hepatitis C";
var content_f26_25_27039=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F74500&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F74500&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sources of infection for persons with hepatitis C",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 407px; height: 233px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Nosocomial; health-care work; perinatal.",
"    </div>",
"    <div class=\"reference\">",
"     Centers for Disease Control and Prevention.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_25_27039=[""].join("\n");
var outline_f26_25_27039=null;
          